In	ADP	O	O
brain	NOUN	O	O
membranes	NOUN	O	O
from	ADP	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
clonidine	NOUN	O	I-Entity
,	PUNCT	O	O
10(-8	NUM	O	O
)	PUNCT	O	O
to	ADP	O	O
10(-5	NUM	O	O
)	PUNCT	O	O

M	PROPN	O	O
,	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
influence	VERB	O	O
stereoselective	ADJ	O	O
binding	NOUN	O	O
of	ADP	O	O
[	PUNCT	O	B-Entity
3H]-naloxone	NUM	O	I-Entity
(	PUNCT	O	O
8	NUM	O	O
nM	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
naloxone	NOUN	O	I-Entity
,	PUNCT	O	O
10(-8	NUM	O	O
)	PUNCT	O	O
to	ADP	O	O
10(-4	NUM	O	O
)	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
in	ADP	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
adrenoceptor	NOUN	O	O
stimulation	NOUN	O	O
involve	VERB	O	O
activation	NOUN	O	O
of	ADP	O	O
opiate	NOUN	O	O
receptors	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
no	DET	O	O
apparent	ADJ	O	O
associated	ADJ	O	O
conditions	NOUN	O	O
which	ADJ	O	O
might	VERB	O	O
have	VERB	O	O
predisposed	VERB	O	O
him	PRON	O	O
to	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
bradyarrhythmias	NOUN	O	I-Entity
;	PUNCT	O	O
and	CCONJ	O	O
,	PUNCT	O	O
thus	ADV	O	O
,	PUNCT	O	O
this	DET	O	O
probably	ADV	O	O
represented	VERB	O	O
a	DET	O	O
true	ADJ	O	O
idiosyncrasy	NOUN	O	O
to	ADP	O	O
lidocaine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
infusion	NOUN	O	O
was	VERB	O	O
discontinued	VERB	O	O
either	CCONJ	O	O
when	ADV	O	O
there	ADV	O	O
was	VERB	O	O
no	DET	O	O
muscular	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
tetanic	ADJ	O	I-Entity
stimulation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ulnar	ADJ	O	O
nerve	NOUN	O	O
or	CCONJ	O	O
when	ADV	O	O
Sch	PROPN	O	I-Entity
120	NUM	O	O
mg	NUM	O	O
was	VERB	O	O
exceeded	VERB	O	O
.	PUNCT	O	O

-DOCSTART- (603022)

Galanthamine	PROPN	O	B-Entity
hydrobromide	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
anticholinesterase	NOUN	O	O
drug	NOUN	O	O
capable	ADJ	O	O
of	ADP	O	O
penetrating	VERB	O	O
the	DET	O	O
blood	NOUN	O	O
-	PUNCT	O	O
brain	NOUN	O	O
barrier	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
in	ADP	O	O
a	DET	O	O
patient	ADJ	O	O
demonstrating	VERB	O	O
central	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
scopolamine	NOUN	O	I-Entity
(	PUNCT	O	O
hyoscine	NOUN	O	I-Entity
)	PUNCT	O	O

overdosage	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
longer	ADV	O	O
acting	VERB	O	O
than	ADP	O	O
physostigmine	NOUN	O	I-Entity
and	CCONJ	O	O
is	VERB	O	O
used	VERB	O	O
in	ADP	O	O
anaesthesia	NOUN	O	O
to	PART	O	O
reverse	VERB	O	O
the	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
depolarizing	VERB	O	O
neuromuscular	ADJ	O	O
block	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
studies	NOUN	O	O
into	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
necessary	ADJ	O	O
to	ADP	O	O
combating	VERB	O	O
scopolamine	NOUN	O	I-Entity
intoxication	NOUN	O	O
are	VERB	O	O
indicated	VERB	O	O
.	PUNCT	O	O

Newborn	ADJ	O	O
female	ADJ	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
fed	VERB	O	O
a	DET	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
containing	VERB	O	O
diet	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
mmol	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
then	ADV	O	O
randomized	ADJ	O	O
to	ADP	O	O
normal	ADJ	O	O
diet	NOUN	O	O
,	PUNCT	O	O
HP	PROPN	O	O
diet	NOUN	O	O
(	PUNCT	O	O
40	NUM	O	O
vs.	X	O	O
19%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
NX	NOUN	O	O
or	CCONJ	O	O
HP+NX	NOUN	O	O
for	ADP	O	O
another	DET	O	O
8	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Corresponding	VERB	O	O
non	ADV	O	O
-	PUNCT	O	O
lithium	NOUN	O	I-Entity
pretreated	ADJ	O	O
groups	NOUN	O	O
were	VERB	O	O
generated	VERB	O	O
.	PUNCT	O	O

Consequently	ADV	O	O
,	PUNCT	O	O
lithium	NOUN	O	I-Entity
pretreatment	NOUN	O	O
caused	VERB	O	O
a	DET	O	O
fall	NOUN	O	O
in	ADP	O	O
filtration	NOUN	O	O
fraction	NOUN	O	O
and	CCONJ	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
fractional	ADJ	O	O
Li	PROPN	O	I-Entity
excretion	NOUN	O	O
.	PUNCT	O	O

HP	PROPN	O	O
failed	VERB	O	O
to	PART	O	O
accentuante	VERB	O	O
progression	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
fact	NOUN	O	O
tended	VERB	O	O
to	PART	O	O
increase	VERB	O	O
GFR	PROPN	O	O
and	CCONJ	O	O
decrease	VERB	O	O
plasma	NOUN	O	O
creatinine	NOUN	O	I-Entity
levels	NOUN	O	O
in	ADP	O	O
lithium	NOUN	O	I-Entity
pretreated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Fusidic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
orally	ADV	O	O
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
500	NUM	O	O
mg	NUM	O	O
t.d.s	NUM	O	O
.	PUNCT	O	O

Sulpiride	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
tardive	ADJ	O	B-Entity
dystonia	NOUN	O	I-Entity
.	PUNCT	O	O

Sulpiride	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
selective	ADJ	O	O
D2-receptor	NOUN	O	O
antagonist	NOUN	O	O
with	ADP	O	O
antipsychotic	ADJ	O	O
and	CCONJ	O	O
antidepressant	ADJ	O	I-Entity
properties	NOUN	O	O
.	PUNCT	O	O


Ocular	PROPN	O	B-Entity
and	CCONJ	O	I-Entity
auditory	ADJ	O	I-Entity
toxicity	NOUN	O	I-Entity
in	ADP	O	O
hemodialyzed	ADJ	O	O
patients	NOUN	O	O
receiving	VERB	O	O
desferrioxamine	NOUN	O	I-Entity
.	PUNCT	O	O

During	ADP	O	O
an	DET	O	O
18-month	ADJ	O	O
period	NOUN	O	O
of	ADP	O	O
study	NOUN	O	O
41	NUM	O	O
hemodialyzed	VERB	O	O
patients	NOUN	O	O
receiving	VERB	O	O
desferrioxamine	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
-	SYM	O	O
40	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
BW/3	ADP	O	O
times	NOUN	O	O
weekly	ADV	O	O
)	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
time	NOUN	O	O
were	VERB	O	O
monitored	VERB	O	O
for	ADP	O	O
detection	NOUN	O	O
of	ADP	O	O
audiovisual	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Myasthenia	PROPN	O	B-Entity
gravis	NOUN	O	I-Entity
presenting	VERB	O	O
as	ADP	O	O
weakness	NOUN	O	O
after	ADP	O	O
magnesium	NOUN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
serum	NOUN	O	O
magnesium	NOUN	O	I-Entity
concentration	NOUN	O	O
was	VERB	O	O
3.0	NUM	O	O
mEq	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
usually	ADV	O	O
well	ADV	O	O
tolerated	VERB	O	O
.	PUNCT	O	O

administration	NOUN	O	O
does	VERB	O	O
not	ADV	O	O
contribute	VERB	O	O
to	ADP	O	O
bladder	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
not	ADV	O	O
consistent	ADJ	O	O
with	ADP	O	O
a	DET	O	O
CNS	PROPN	O	O
origin	NOUN	O	O
of	ADP	O	O
migraine	ADJ	O	I-Entity
attack	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (2572625)

Clotiazepam	PROPN	O	I-Entity
withdrawal	NOUN	O	O
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
prompt	ADJ	O	O
recovery	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (2632720)

In	ADP	O	O
patient	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
plasma	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
deoxycorticosterone	NOUN	O	I-Entity
and	CCONJ	O	O
11-deoxycortisol	NUM	O	I-Entity
were	VERB	O	O
elevated	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
fibrin	NOUN	O	O
in	ADP	O	O
the	DET	O	O
kidneys	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
considerably	ADV	O	O
lower	ADJ	O	O
than	ADP	O	O
in	ADP	O	O
animals	NOUN	O	O
which	ADJ	O	O
received	VERB	O	O
thrombin	NOUN	O	O
and	CCONJ	O	O
AMCA	PROPN	O	I-Entity
alone	ADV	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
Captopril	PROPN	O	I-Entity
on	ADP	O	O
the	DET	O	O
lungs	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
attributable	ADJ	O	O
to	ADP	O	O
a	DET	O	O
vasodilatory	NOUN	O	O
effect	NOUN	O	O
due	ADP	O	O
to	ADP	O	O
a	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
circulating	NOUN	O	O
level	NOUN	O	O
of	ADP	O	O
Angiotension	PROPN	O	B-Entity
II	PROPN	O	I-Entity
and	CCONJ	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
prostacyclin	PROPN	O	I-Entity
(	PUNCT	O	O
secondary	ADJ	O	O
to	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
bradykinin	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O


A	DET	O	O
randomized	ADJ	O	O
comparison	NOUN	O	O
of	ADP	O	O
labetalol	NOUN	O	I-Entity
and	CCONJ	O	O
nitroprusside	NOUN	O	I-Entity
for	ADP	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

Arterial	ADJ	O	O
PO2	PROPN	O	I-Entity
decreased	VERB	O	O
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
labetalol	NOUN	O	I-Entity
offers	VERB	O	O
advantages	NOUN	O	O
over	ADP	O	O
nitroprusside	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (2924746)

Chronic	ADJ	O	O
carbamazepine	NOUN	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
:	PUNCT	O	O
efficacy	NOUN	O	O
,	PUNCT	O	O
toxicity	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
effect	NOUN	O	O
on	ADP	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
tissue	NOUN	O	O
folate	ADJ	O	I-Entity
concentrations	NOUN	O	O
.	PUNCT	O	O

Seizures	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
hexafluorodiethyl	NOUN	O	B-Entity
ether	NOUN	O	I-Entity
(	PUNCT	O	O
HFDE	PROPN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
also	ADV	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
more	ADV	O	O
sensitive	ADJ	O	O
measure	NOUN	O	O
of	ADP	O	O
protection	NOUN	O	O
by	ADP	O	O
CBZ	PROPN	O	I-Entity
than	ADP	O	O
seizures	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
maximal	ADJ	O	O
electroshock	NOUN	O	O
(	PUNCT	O	O
MES	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
six	NUM	O	O
conscious	ADJ	O	O
,	PUNCT	O	O
trained	VERB	O	O
dogs	NOUN	O	O
,	PUNCT	O	O
maintained	VERB	O	O
on	ADP	O	O
a	DET	O	O
normal	ADJ	O	O
sodium	NOUN	O	I-Entity
intake	NOUN	O	O
of	ADP	O	O
2	NUM	O	O
to	ADP	O	O
4	NUM	O	O
mEq	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
,	PUNCT	O	O
sympathetic	ADJ	O	O
activity	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
as	ADP	O	O
the	DET	O	O
release	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
norepinephrine	NOUN	O	I-Entity
and	CCONJ	O	O
epinephrine	NOUN	O	I-Entity
during	ADP	O	O
15-minute	ADJ	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
first	ADJ	O	O
day	NOUN	O	O
of	ADP	O	O
the	DET	O	O
schedule	NOUN	O	O
,	PUNCT	O	O
moderate	ADJ	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
Methotrexate	PROPN	O	I-Entity
,	PUNCT	O	O
Etoposide	PROPN	O	I-Entity
and	CCONJ	O	O
Cyclophosphamide	PROPN	O	I-Entity
were	VERB	O	O
administered	VERB	O	O
.	PUNCT	O	O


The	DET	O	O
relationship	NOUN	O	O
of	ADP	O	O
arthritis	NOUN	O	I-Entity
and	CCONJ	O	O
sexual	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
was	VERB	O	O
investigated	VERB	O	O
among	ADP	O	O
169	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
,	PUNCT	O	O
osteoarthritis	NOUN	O	I-Entity
and	CCONJ	O	O
spondyloarthropathy	NOUN	O	I-Entity
,	PUNCT	O	O
130	NUM	O	O
of	ADP	O	O
whom	NOUN	O	O
were	VERB	O	O
pair	NOUN	O	O
-	PUNCT	O	O
matched	VERB	O	O
to	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O


The	DET	O	O
pentose	ADJ	O	B-Entity
phosphate	NOUN	O	I-Entity
shunt	NOUN	O	O
activity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dapsone	NOUN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
AE	PROPN	O	O
RBCs	PROPN	O	O
was	VERB	O	O
increased	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
normal	ADJ	O	O
RBCs	NOUN	O	O
.	PUNCT	O	O


Three	NUM	O	O
months	NOUN	O	O
later	ADV	O	O
the	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
exposed	VERB	O	O
to	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
metoprolol	NOUN	O	I-Entity
,	PUNCT	O	O
diltiazem	NOUN	O	I-Entity
,	PUNCT	O	O
propafenone	NOUN	O	I-Entity
(	PUNCT	O	O
since	ADP	O	O
he	PRON	O	O
had	VERB	O	O
received	VERB	O	O
this	DET	O	O
drug	NOUN	O	O
in	ADP	O	O
the	DET	O	O
past	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
sparteine	NOUN	O	I-Entity
(	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
probe	NOUN	O	O
for	ADP	O	O
the	DET	O	O
debrisoquine	NOUN	O	I-Entity
/	PUNCT	O	O
sparteine	ADJ	O	I-Entity
type	NOUN	O	O
polymorphism	NOUN	O	O
of	ADP	O	O
oxidative	ADJ	O	O
drug	NOUN	O	O
metabolism	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Triazolam	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
brief	ADJ	O	O
episodes	NOUN	O	O
of	ADP	O	O
secondary	ADJ	O	O
mania	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
depressed	ADJ	O	I-Entity
patient	NOUN	O	O
.	PUNCT	O	O

Large	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
triazolam	NOUN	O	I-Entity
repeatedly	ADV	O	O
induced	VERB	O	O
brief	ADJ	O	O
episodes	NOUN	O	O
of	ADP	O	O
mania	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
depressed	ADJ	O	I-Entity
elderly	ADJ	O	O
woman	NOUN	O	O
.	PUNCT	O	O


The	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
rigidity	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
assumed	VERB	O	O
to	PART	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
an	DET	O	O
action	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
,	PUNCT	O	O
can	VERB	O	O
be	VERB	O	O
antagonized	VERB	O	O
by	ADP	O	O
another	DET	O	O
process	NOUN	O	O
leading	VERB	O	O
to	ADP	O	O
dopaminergic	ADJ	O	O
activation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
.	PUNCT	O	O

Recurrent	ADJ	O	O
reversible	ADJ	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
from	ADP	O	O
amphotericin	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
cryptogenic	ADJ	O	O
cirrhosis	NOUN	O	I-Entity
and	CCONJ	O	O
disseminated	VERB	O	O
sporotrichosis	NOUN	O	I-Entity
developed	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
immediately	ADV	O	O
following	VERB	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
amphotericin	NOUN	O	B-Entity
B	PROPN	O	I-Entity
on	ADP	O	O
four	NUM	O	O
separate	ADJ	O	O
occasions	NOUN	O	O
.	PUNCT	O	O

Review	NOUN	O	O
of	ADP	O	O
this	DET	O	O
and	CCONJ	O	O
previously	ADV	O	O
reported	VERB	O	O
cases	NOUN	O	O
indicates	VERB	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
early	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
pneumonitis	NOUN	O	I-Entity
,	PUNCT	O	O
immediate	ADJ	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
prompt	VERB	O	O
but	CCONJ	O	O
continued	VERB	O	O
steroid	NOUN	O	I-Entity
therapy	NOUN	O	O
to	PART	O	O
ensure	VERB	O	O
full	ADJ	O	O
recovery	NOUN	O	O
.	PUNCT	O	O

Prompt	ADJ	O	O
restoration	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
followed	VERB	O	O
drug	NOUN	O	O
withdrawal	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
re	ADP	O	O
-	PUNCT	O	O
exposure	NOUN	O	O
to	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
indomethacin	NOUN	O	I-Entity
caused	VERB	O	O
recurrence	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
reversible	ADJ	O	O
oliguria	NOUN	O	I-Entity
.	PUNCT	O	O

administration	NOUN	O	O
of	ADP	O	O
flunitrazepam	NOUN	O	I-Entity
in	ADP	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

Flunitrazepam	PROPN	O	I-Entity
0.5	NUM	O	O
,	PUNCT	O	O
1.0	NUM	O	O
or	CCONJ	O	O
2.0	NUM	O	O
mg	PRON	O	O
was	VERB	O	O
given	VERB	O	O
by	ADP	O	O
the	DET	O	O
oral	ADJ	O	O
or	CCONJ	O	O
i.m	ADJ	O	O
.	PUNCT	O	O

-DOCSTART- (6229975)

After	ADP	O	O
re	ADV	O	O
-	PUNCT	O	O
infarction	NOUN	O	I-Entity
,	PUNCT	O	O
heart	NOUN	O	O
size	NOUN	O	O
increased	VERB	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
remained	VERB	O	O
unchanged	ADJ	O	O
in	ADP	O	O
the	DET	O	O
timolol	NOUN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (6286738)

IU	PROPN	O	O
vitamin	NOUN	O	B-Entity
D3	NOUN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
prolonged	ADJ	O	O
hypercalcemia	NOUN	O	I-Entity
,	PUNCT	O	O
hyperphosphatemia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
large	ADJ	O	O
increases	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
D3	PROPN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
metabolites	NOUN	O	O
in	ADP	O	O
the	DET	O	O
blood	NOUN	O	O
plasma	NOUN	O	O
of	ADP	O	O
nonlactating	VERB	O	O
nonpregnant	NOUN	O	O
and	CCONJ	O	O
pregnant	ADJ	O	O
Jersey	PROPN	O	O
cows	NOUN	O	O
.	PUNCT	O	O

Isoniazid	PROPN	O	I-Entity
was	VERB	O	O
the	DET	O	O
most	ADV	O	O
frequent	ADJ	O	O
agent	NOUN	O	O
in	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
6-week	NUM	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
parallel	ADJ	O	O
treatment	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
dothiepin	NOUN	O	I-Entity
and	CCONJ	O	O
amitriptyline	NOUN	O	I-Entity
were	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
33	NUM	O	O
depressed	ADJ	O	I-Entity
outpatients	NOUN	O	O
.	PUNCT	O	O

Dothiepin	PROPN	O	I-Entity
also	ADV	O	O
produced	VERB	O	O
fewer	ADJ	O	O
CNS	PROPN	O	O
and	CCONJ	O	O
cardiovascular	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Accumulation	NOUN	O	O
of	ADP	O	O
drugs	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
reflected	VERB	O	O
in	ADP	O	O
prolonged	VERB	O	O
behavioral	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
.	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
on	ADP	O	O
N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
epithelial	ADJ	O	O
proliferation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
urinary	ADJ	O	O
bladder	NOUN	O	O
and	CCONJ	O	O
forestomach	NOUN	O	O
of	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
co	NOUN	O	O
-	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
with	ADP	O	O
N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide	PROPN	O	I-Entity
(	PUNCT	O	O
FANFT	PROPN	O	I-Entity
)	PUNCT	O	O
to	ADP	O	O
rats	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
reduced	VERB	O	O
incidence	NOUN	O	O
of	ADP	O	O
FANFT	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
bladder	NOUN	O	B-Entity
carcinomas	NOUN	O	I-Entity
but	CCONJ	O	O
a	DET	O	O
concomitant	ADJ	O	O
induction	NOUN	O	O
of	ADP	O	O
forestomach	NOUN	O	B-Entity
tumors	NOUN	O	I-Entity
.	PUNCT	O	O

An	DET	O	O
autoradiographic	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
on	ADP	O	O
male	ADJ	O	O
F-344	PROPN	O	O
rats	NOUN	O	O
fed	VERB	O	O
diet	NOUN	O	O
containing	VERB	O	O
FANFT	PROPN	O	I-Entity
at	ADP	O	O
a	DET	O	O
level	NOUN	O	O
of	ADP	O	O
0.2%	NUM	O	O
and/or	CCONJ	O	O
aspirin	NOUN	O	I-Entity
at	ADP	O	O
a	DET	O	O
level	NOUN	O	O
of	ADP	O	O
0.5%	NUM	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
increased	VERB	O	O
cell	NOUN	O	O
proliferation	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
FANFT	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
forestomach	NOUN	O	O
and	CCONJ	O	O
bladder	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (6888657)

Pituitary	ADJ	O	B-Entity
tumors	NOUN	O	I-Entity
were	VERB	O	O
induced	VERB	O	O
in	ADP	O	O
F344	PROPN	O	O
female	ADJ	O	O
rats	NOUN	O	O
by	ADP	O	O
chronic	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
diethylstilbestrol	NOUN	O	I-Entity
(	PUNCT	O	O
DES	PROPN	O	I-Entity
,	PUNCT	O	O
8	NUM	O	O
-	SYM	O	O
10	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
implanted	VERB	O	O
subcutaneously	ADV	O	O
in	ADP	O	O
silastic	ADJ	O	O
capsules	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
cell	NOUN	O	O
populations	NOUN	O	O
were	VERB	O	O
examined	VERB	O	O
regarding	VERB	O	O
total	ADJ	O	O
cell	NOUN	O	O
recovery	NOUN	O	O
correlated	VERB	O	O
with	ADP	O	O
gland	NOUN	O	O
weight	NOUN	O	O
,	PUNCT	O	O
intracellular	ADJ	O	O
prolactin	NOUN	O	O
(	PUNCT	O	O
PRL	PROPN	O	O
)	PUNCT	O	O
content	NOUN	O	O
and	CCONJ	O	O
subsequent	ADJ	O	O
release	NOUN	O	O
in	ADP	O	O
primary	ADJ	O	O
culture	NOUN	O	O
,	PUNCT	O	O
immunocytochemical	ADJ	O	O
PRL	PROPN	O	O
staining	NOUN	O	O
,	PUNCT	O	O
density	NOUN	O	O
and/or	CCONJ	O	O
size	NOUN	O	O
alterations	NOUN	O	O
via	ADP	O	O
separation	NOUN	O	O
on	ADP	O	O
Ficoll	PROPN	O	O
-	PUNCT	O	O
Hypaque	PROPN	O	O
and	CCONJ	O	O
by	ADP	O	O
unit	NOUN	O	O
gravity	NOUN	O	O
sedimentation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cell	NOUN	O	O
cycle	NOUN	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
after	ADP	O	O
acriflavine	ADJ	O	I-Entity
DNA	PROPN	O	O
staining	NOUN	O	O
,	PUNCT	O	O
by	ADP	O	O
laser	NOUN	O	O
flow	NOUN	O	O
cytometry	NOUN	O	O
.	PUNCT	O	O

Triamterene	PROPN	O	I-Entity
nephrolithiasis	NOUN	O	I-Entity
complicating	VERB	O	O
dyazide	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Metabolic	ADJ	O	O
involvement	NOUN	O	O
in	ADP	O	O
adriamycin	ADJ	O	I-Entity
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
possible	ADJ	O	O
involvement	NOUN	O	O
of	ADP	O	O
energy	NOUN	O	O
metabolism	NOUN	O	O
was	VERB	O	O
suggested	VERB	O	O
previously	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
the	DET	O	O
adenylate	ADJ	O	O
energy	NOUN	O	O
charge	NOUN	O	O
and	CCONJ	O	O
phosphorylcreatine	NOUN	O	I-Entity
mole	NOUN	O	O
fraction	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
in	ADP	O	O
the	DET	O	O
adriamycin	ADV	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
cells	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
adriamycin	ADJ	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
cells	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
adenosine	NOUN	O	I-Entity
increased	VERB	O	O
the	DET	O	O
adenylate	NOUN	O	O
charge	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
concomitant	ADJ	O	O
with	ADP	O	O
this	DET	O	O
inrcease	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
cells	NOUN	O	O
'	PART	O	O
functional	ADJ	O	O
integrity	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
percentage	NOUN	O	O
of	ADP	O	O
beating	VERB	O	O
cells	NOUN	O	O
and	CCONJ	O	O
rate	NOUN	O	O
of	ADP	O	O
contractions	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
maintained	VERB	O	O
.	PUNCT	O	O

-DOCSTART- (7444978)


Other	ADJ	O	O
possible	ADJ	O	O
causes	NOUN	O	O
of	ADP	O	O
rapidly	ADV	O	O
progressive	ADJ	O	O
glomerulonephritis	NOUN	O	I-Entity
were	VERB	O	O
investigated	VERB	O	O
and	CCONJ	O	O
ruled	VERB	O	O
out	PART	O	O
.	PUNCT	O	O

Proteinuria	PROPN	O	I-Entity
was	VERB	O	O
evident	ADJ	O	O
at	ADP	O	O
day	NOUN	O	O
5	NUM	O	O
,	PUNCT	O	O
peaked	VERB	O	O
at	ADP	O	O
day	NOUN	O	O
7	NUM	O	O
and	CCONJ	O	O
persisted	VERB	O	O
to	ADP	O	O
day	NOUN	O	O
27	NUM	O	O
.	PUNCT	O	O


Clomipramine	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
sleep	NOUN	O	B-Entity
disturbance	NOUN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
impair	VERB	O	O
its	ADJ	O	O
prolactin	NOUN	O	O
-	PUNCT	O	O
releasing	VERB	O	O
action	NOUN	O	O
.	PUNCT	O	O

10%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
it	PRON	O	O
can	VERB	O	O
be	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
the	DET	O	O
observed	ADJ	O	O
sleep	NOUN	O	B-Entity
disturbance	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
interfere	VERB	O	O
with	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
action	NOUN	O	O
per	ADP	O	O
se	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
first	ADJ	O	O
day	NOUN	O	O
of	ADP	O	O
hospitalization	NOUN	O	O
(	PUNCT	O	O
while	ADP	O	O
intubated	ADJ	O	O
)	PUNCT	O	O
,	PUNCT	O	O
intravenous	ADJ	O	O
metoprolol	NOUN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
severe	ADJ	O	O
angioedema	NOUN	O	I-Entity
.	PUNCT	O	O

Coniine	PROPN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
alkaloid	NOUN	O	O
from	ADP	O	O
Conium	PROPN	O	O
maculatum	NOUN	O	O
(	PUNCT	O	O
poison	NOUN	O	O
hemlock	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
be	VERB	O	O
teratogenic	ADJ	O	O
in	ADP	O	O
livestock	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
compounds	NOUN	O	O
caused	VERB	O	O
deformations	NOUN	O	I-Entity
and	CCONJ	O	O
lethality	NOUN	O	O
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
manner	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8302922)

To	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
prostaglandin	NOUN	O	B-Entity
E1	PROPN	O	I-Entity
(	PUNCT	O	O
PGE1	PROPN	O	I-Entity
)	PUNCT	O	O
or	CCONJ	O	O
trimethaphan	NOUN	O	I-Entity
(	PUNCT	O	O
TMP	PROPN	O	I-Entity
)	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
on	ADP	O	O
epidural	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
(	PUNCT	O	O
EBF	PROPN	O	O
)	PUNCT	O	O
during	ADP	O	O
spinal	ADJ	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
EBF	PROPN	O	O
was	VERB	O	O
measured	VERB	O	O
using	VERB	O	O
the	DET	O	O
heat	NOUN	O	O
clearance	NOUN	O	O
method	NOUN	O	O
in	ADP	O	O
30	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
underwent	VERB	O	O
postero	NOUN	O	O
-	PUNCT	O	O
lateral	ADJ	O	O
interbody	NOUN	O	O
fusion	NOUN	O	O
under	ADP	O	O
isoflurane	NOUN	O	I-Entity
anaesthesia	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
hypotensive	ADJ	O	I-Entity
drug	NOUN	O	O
was	VERB	O	O
discontinued	VERB	O	O
at	ADP	O	O
the	DET	O	O
completion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
operative	ADJ	O	O
procedure	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
starting	VERB	O	O
PGE1	PROPN	O	I-Entity
or	CCONJ	O	O
TMP	PROPN	O	I-Entity
,	PUNCT	O	O
MAP	PROPN	O	O
and	CCONJ	O	O
rate	NOUN	O	O
pressure	NOUN	O	O
product	NOUN	O	O
(	PUNCT	O	O
RPP	PROPN	O	O
)	PUNCT	O	O
decreased	VERB	O	O
significantly	ADV	O	O
compared	VERB	O	O
with	ADP	O	O
preinfusion	NOUN	O	O
values	NOUN	O	O

EBFF	PROPN	O	O
did	VERB	O	O
not	ADV	O	O
change	VERB	O	O
during	ADP	O	O
PGE1	NOUN	O	I-Entity
infusion	NOUN	O	O
whereas	ADP	O	O
in	ADP	O	O
the	DET	O	O
TMP	PROPN	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
EBF	PROPN	O	O
decreased	VERB	O	O
significantly	ADV	O	O
at	ADP	O	O
30	NUM	O	O
and	CCONJ	O	O
60	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
the	DET	O	O
start	NOUN	O	O
of	ADP	O	O
TMP	PROPN	O	I-Entity
(	PUNCT	O	O
preinfusion	NOUN	O	O
:	PUNCT	O	O
45.9	NUM	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
PGE1	PROPN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
preferable	ADJ	O	O
to	PART	O	O
TMP	PROPN	O	I-Entity
for	ADP	O	O
hypotensive	ADJ	O	I-Entity
anaesthesia	NOUN	O	O
in	ADP	O	O
spinal	ADJ	O	O
surgery	NOUN	O	O
because	ADP	O	O
TMP	PROPN	O	I-Entity
decreased	VERB	O	O
EBF	PROPN	O	O
.	PUNCT	O	O

-DOCSTART- (8410052)

Focal	ADJ	O	O
injury	NOUN	O	B-Entity
in	ADP	O	I-Entity
the	DET	O	I-Entity
cortex	NOUN	O	I-Entity
was	VERB	O	O
produced	VERB	O	O
by	ADP	O	O
infusion	NOUN	O	O
of	ADP	O	O
lactate	NOUN	O	I-Entity
at	ADP	O	O
acid	NOUN	O	O
pH	NOUN	O	O
or	CCONJ	O	O
by	ADP	O	O
stab	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
needle	NOUN	O	O
insertion	NOUN	O	O
.	PUNCT	O	O

Depression	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
major	ADJ	O	O
clinical	ADJ	O	O
feature	NOUN	O	O
of	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
increased	VERB	O	O
amount	NOUN	O	O
of	ADP	O	O
motor	NOUN	O	B-Entity
disability	NOUN	O	I-Entity
in	ADP	O	O
four	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
idiopathic	ADJ	O	B-Entity
Parkinson	PROPN	O	I-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
after	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
the	DET	O	O
antidepressant	NOUN	O	I-Entity
fluoxetine	NOUN	O	I-Entity
.	PUNCT	O	O


An	DET	O	O
80-yr	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
developed	VERB	O	O
acute	ADJ	O	O
hepatitis	NOUN	O	I-Entity
shortly	ADV	O	O
after	ADP	O	O
ingesting	VERB	O	O
oral	ADJ	O	O
ceftriaxone	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
transaminases	NOUN	O	O
gradually	ADV	O	O
returned	VERB	O	O
to	ADP	O	O
baseline	NOUN	O	O
after	ADP	O	O
withholding	VERB	O	O
the	DET	O	O
beta	NOUN	O	B-Entity
lactam	NOUN	O	I-Entity
antibiotic	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
gradual	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
bilirubin	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
hemoglobin	NOUN	O	O
concentration	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
an	DET	O	O
autoimmune	ADJ	O	B-Entity
hemolytic	NOUN	O	I-Entity
anemia	NOUN	O	I-Entity
and	CCONJ	O	O
erythroblastocytopenia	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
prevalence	NOUN	O	O
of	ADP	O	O
nonsmall	NOUN	O	B-Entity
cell	NOUN	O	I-Entity
lung	NOUN	O	I-Entity
carcinoma	NOUN	O	I-Entity
(	PUNCT	O	O
NSCLC	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
high	ADJ	O	O
among	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
few	ADJ	O	O
data	NOUN	O	O
are	VERB	O	O
available	ADJ	O	O
regarding	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
chemotherapy	NOUN	O	O
in	ADP	O	O
this	DET	O	O
group	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Recent	ADJ	O	O
reports	NOUN	O	O
indicate	VERB	O	O
that	DET	O	O
single	ADJ	O	O
agent	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
vinorelbine	NOUN	O	I-Entity
(	PUNCT	O	O
VNB	PROPN	O	I-Entity
)	PUNCT	O	O
or	CCONJ	O	O
gemcitabine	NOUN	O	I-Entity
(	PUNCT	O	O
GEM	PROPN	O	I-Entity
)	PUNCT	O	O
may	VERB	O	O
obtain	VERB	O	O
a	DET	O	O
response	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
20	NUM	O	O
-	PUNCT	O	O
30%	NUM	O	O
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
acceptable	ADJ	O	O
toxicity	NOUN	O	I-Entity
and	CCONJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
.	PUNCT	O	O

<	X	O	O
70	NUM	O	O
years	NOUN	O	O
but	CCONJ	O	O
who	NOUN	O	O
had	VERB	O	O
some	DET	O	O
contraindication	NOUN	O	O
to	ADP	O	O
receiving	VERB	O	O
cisplatin	NOUN	O	I-Entity
.	PUNCT	O	O

Treatment	PROPN	O	O
was	VERB	O	O
comprised	VERB	O	O
of	ADP	O	O
VNB	PROPN	O	I-Entity
,	PUNCT	O	O
25	NUM	O	O
mg	CCONJ	O	O
/	SYM	O	O
m(2	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
plus	CCONJ	O	O
GEM	PROPN	O	I-Entity
,	PUNCT	O	O
1000	NUM	O	O
mg	CCONJ	O	O
/	SYM	O	O
m(2	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
both	DET	O	O
on	ADP	O	O
Days	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
8	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
15	NUM	O	O
every	DET	O	O
28	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Six	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
12%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
World	PROPN	O	O
Health	PROPN	O	O
Organization	PROPN	O	O
Grade	PROPN	O	O
3	NUM	O	O
-	SYM	O	O
4	NUM	O	O
neutropenia	NOUN	O	I-Entity
,	PUNCT	O	O
2	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
4%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
Grade	PROPN	O	O
3	NUM	O	O
-	SYM	O	O
4	NUM	O	O
thrombocytopenia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
2	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
4%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
Grade	NOUN	O	O
3	NUM	O	O
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
GEM	PROPN	O	I-Entity
and	CCONJ	O	O
VNB	PROPN	O	I-Entity
is	VERB	O	O
moderately	ADV	O	O
active	ADJ	O	O
and	CCONJ	O	O
well	ADV	O	O
tolerated	VERB	O	O
except	ADP	O	O
in	ADP	O	O
patients	NOUN	O	O
age	NOUN	O	O
>	X	O	O
/=	SYM	O	O
75	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
age	NOUN	O	O
group	NOUN	O	O
had	VERB	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
myelosuppression	NOUN	O	I-Entity
.	PUNCT	O	O

Warfarin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
artery	NOUN	O	B-Entity
calcification	NOUN	O	I-Entity
is	VERB	O	O
accelerated	VERB	O	O
by	ADP	O	O
growth	NOUN	O	O
and	CCONJ	O	O
vitamin	NOUN	O	B-Entity
D.	PROPN	O	I-Entity

Treatment	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
with	ADP	O	O
Warfarin	PROPN	O	I-Entity
caused	VERB	O	O
massive	ADJ	O	O
focal	ADJ	O	O
calcification	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
artery	NOUN	O	I-Entity
media	NOUN	O	O
in	ADP	O	O
20-day	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
rats	NOUN	O	O
and	CCONJ	O	O
less	ADV	O	O
extensive	ADJ	O	O
focal	ADJ	O	O
calcification	NOUN	O	I-Entity
in	ADP	O	O
42-day	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
explanation	NOUN	O	O
for	ADP	O	O
the	DET	O	O
association	NOUN	O	O
between	ADP	O	O
artery	NOUN	O	B-Entity
calcification	NOUN	O	I-Entity
and	CCONJ	O	O
growth	NOUN	O	O
status	NOUN	O	O
can	VERB	O	O
not	ADV	O	O
be	VERB	O	O
determined	VERB	O	O
from	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
higher	ADJ	O	O
serum	NOUN	O	O
phosphate	NOUN	O	I-Entity
and	CCONJ	O	O
susceptibility	NOUN	O	O
to	ADP	O	O
artery	NOUN	O	B-Entity
calcification	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
30%	NUM	O	O
higher	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
phosphate	NOUN	O	I-Entity
in	ADP	O	O
young	ADJ	O	O
,	PUNCT	O	O
ad	NOUN	O	O
libitum	NOUN	O	O
-	PUNCT	O	O
fed	VERB	O	O
rats	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
either	DET	O	O
of	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
that	ADJ	O	O
was	VERB	O	O
resistant	ADJ	O	O
to	ADP	O	O
Warfarin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
artery	NOUN	O	B-Entity
calcification	NOUN	O	I-Entity
,	PUNCT	O	O
ie	X	O	O
,	PUNCT	O	O
the	DET	O	O
10-month	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
rats	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
restricted	VERB	O	O
-	PUNCT	O	O
diet	NOUN	O	O
,	PUNCT	O	O
growth	NOUN	O	O
-	PUNCT	O	O
inhibited	VERB	O	O
young	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
observation	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
increased	VERB	O	O
susceptibility	NOUN	O	O
to	ADP	O	O
Warfarin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
artery	NOUN	O	B-Entity
calcification	NOUN	O	I-Entity
could	VERB	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
higher	ADJ	O	O
serum	NOUN	O	O
phosphate	NOUN	O	I-Entity
levels	NOUN	O	O
.	PUNCT	O	O

High	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
D	PROPN	O	I-Entity
are	VERB	O	O
known	VERB	O	O
to	PART	O	O
cause	VERB	O	O
calcification	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
artery	NOUN	O	I-Entity
media	NOUN	O	O
in	ADP	O	O
as	ADV	O	O
little	ADJ	O	O
as	ADP	O	O
3	NUM	O	O
to	PART	O	O
4	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
synergy	NOUN	O	O
between	ADP	O	O
these	DET	O	O
2	NUM	O	O
treatments	NOUN	O	O
and	CCONJ	O	O
found	VERB	O	O
that	ADP	O	O
concurrent	ADJ	O	O
Warfarin	PROPN	O	I-Entity
administration	NOUN	O	O
dramatically	ADV	O	O
increased	VERB	O	O
the	DET	O	O
extent	NOUN	O	O
of	ADP	O	O
calcification	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
media	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
D	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
at	ADP	O	O
3	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O


Concerns	NOUN	O	O
about	ADP	O	O
possible	ADJ	O	O
risks	NOUN	O	O
of	ADP	O	O
switching	VERB	O	O
to	ADP	O	O
mania	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
antidepressants	NOUN	O	I-Entity
continue	VERB	O	O
to	PART	O	O
interfere	VERB	O	O
with	ADP	O	O
the	DET	O	O
establishment	NOUN	O	O
of	ADP	O	O
an	DET	O	O
optimal	ADJ	O	O
treatment	NOUN	O	O
paradigm	NOUN	O	O
for	ADP	O	O
bipolar	ADJ	O	B-Entity
depression	NOUN	O	I-Entity
.	PUNCT	O	O

Switches	NOUN	O	O
to	ADP	O	O
hypomania	VERB	O	I-Entity
or	CCONJ	O	O
mania	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
27%	NUM	O	O
of	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
12	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
24%	NUM	O	O
of	ADP	O	O
the	DET	O	O
subgroup	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
SSRIs	PROPN	O	I-Entity
[	PUNCT	O	O
8/33	NUM	O	O
]	PUNCT	O	O
)	PUNCT	O	O
;	PUNCT	O	O
16%	NUM	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
7	NUM	O	O
)	PUNCT	O	O
experienced	VERB	O	O
manic	ADJ	O	I-Entity
episodes	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
11%	NUM	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
5	NUM	O	O
)	PUNCT	O	O
experienced	VERB	O	O
hypomanic	ADJ	O	I-Entity
episodes	NOUN	O	O
.	PUNCT	O	O

Sex	NOUN	O	O
,	PUNCT	O	O
age	NOUN	O	O
,	PUNCT	O	O
diagnosis	NOUN	O	O
(	PUNCT	O	O
bipolar	NOUN	O	B-Entity
I	PRON	O	I-Entity
vs.	VERB	O	O
bipolar	ADJ	O	B-Entity
II	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
additional	ADJ	O	O
treatment	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
switching	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (11752354)

We	PRON	O	O
investigated	VERB	O	O
this	DET	O	O
association	NOUN	O	O
,	PUNCT	O	O
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
type	NOUN	O	O
of	ADP	O	O
progestagen	NOUN	O	I-Entity
included	VERB	O	O
in	ADP	O	O
third	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
(	PUNCT	O	O
i.e.	X	O	O
,	PUNCT	O	O
desogestrel	NOUN	O	I-Entity
or	CCONJ	O	O
gestodene	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
second	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
(	PUNCT	O	O
i.e.	X	O	O
,	PUNCT	O	O
levonorgestrel	PUNCT	O	I-Entity
)	PUNCT	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity

Effects	NOUN	O	O
of	ADP	O	O
5-HT1B	NUM	O	O
receptor	NOUN	O	O
ligands	NOUN	O	O
microinjected	VERB	O	O
into	ADP	O	O
the	DET	O	O
accumbal	ADJ	O	O
shell	NOUN	O	O
or	CCONJ	O	O
core	NOUN	O	O
on	ADP	O	O
the	DET	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
locomotor	NOUN	O	B-Entity
hyperactivity	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
injected	VERB	O	O
into	ADP	O	O
the	DET	O	O
accumbens	NOUN	O	O
shell	NOUN	O	O
(	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
the	DET	O	O
core	NOUN	O	O
)	PUNCT	O	O
before	ADP	O	O
cocaine	NOUN	O	I-Entity
,	PUNCT	O	O
CP	PROPN	O	B-Entity
93129	NUM	O	I-Entity
(	PUNCT	O	O
0.1	NUM	O	O
-	SYM	O	O
10	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
side	NOUN	O	O
)	PUNCT	O	O
enhanced	VERB	O	O
the	DET	O	O
locomotor	NOUN	O	O
response	NOUN	O	O
to	ADP	O	O
cocaine	NOUN	O	I-Entity
;	PUNCT	O	O
the	DET	O	O
maximum	ADJ	O	O
effect	NOUN	O	O
being	VERB	O	O
observed	VERB	O	O
after	ADP	O	O
10	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
side	NOUN	O	O
of	ADP	O	O
the	DET	O	O
agonist	NOUN	O	O
.	PUNCT	O	O

CASE	NOUN	O	O
SUMMARIES	NOUN	O	O
:	PUNCT	O	O
Two	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
prolonged	ADJ	O	O
cholestatic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
after	ADP	O	O
receiving	VERB	O	O
ticlopidine	NOUN	O	I-Entity
following	VERB	O	O
percutaneous	ADJ	O	O
coronary	ADJ	O	O
angioplasty	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
complete	ADJ	O	O
remission	NOUN	O	O
during	ADP	O	O
the	DET	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Cholestatic	PROPN	O	B-Entity
hepatitis	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
ticlopidine	NOUN	O	I-Entity
that	ADJ	O	O
may	VERB	O	O
be	VERB	O	O
immune	ADJ	O	O
mediated	VERB	O	O
.	PUNCT	O	O


Epithelial	ADJ	O	O
sodium	NOUN	O	I-Entity
channel	NOUN	O	O
(	PUNCT	O	O
ENaC	PROPN	O	O
)	PUNCT	O	O
subunit	NOUN	O	O
mRNA	NOUN	O	O
and	CCONJ	O	O
protein	NOUN	O	O
expression	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
experimental	ADJ	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
,	PUNCT	O	O
urinary	ADJ	O	O
sodium	NOUN	O	I-Entity
excretion	NOUN	O	O
is	VERB	O	O
decreased	VERB	O	O
during	ADP	O	O
the	DET	O	O
early	ADJ	O	O
phase	NOUN	O	O
of	ADP	O	O
the	DET	O	O
disease	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
examined	VERB	O	O
the	DET	O	O
abundance	NOUN	O	O
of	ADP	O	O
ENaC	PROPN	O	O
subunit	NOUN	O	O
mRNAs	PROPN	O	O
and	CCONJ	O	O
proteins	NOUN	O	O
in	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
(	PUNCT	O	O
PAN)-induced	VERB	O	I-Entity
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
time	NOUN	O	O
courses	NOUN	O	O
of	ADP	O	O
urinary	ADJ	O	O
sodium	NOUN	O	I-Entity
excretion	NOUN	O	O
,	PUNCT	O	O
plasma	NOUN	O	O
aldosterone	NOUN	O	I-Entity
concentration	NOUN	O	O
and	CCONJ	O	O
proteinuria	NOUN	O	I-Entity
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
male	ADJ	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
either	DET	O	O
PAN	PROPN	O	I-Entity
or	CCONJ	O	O
vehicle	NOUN	O	O
.	PUNCT	O	O

Sodium	ADJ	O	I-Entity
retention	NOUN	O	O
occurred	VERB	O	O
on	ADP	O	O
days	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
after	ADP	O	O
PAN	PROPN	O	I-Entity
injection	NOUN	O	O
.	PUNCT	O	O

NO	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
migraine	ADJ	O	I-Entity
attack	NOUN	O	O
:	PUNCT	O	O
strong	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
plasma	NOUN	O	O
calcitonin	NOUN	O	B-Entity
gene	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
related	VERB	O	I-Entity
peptide	NOUN	O	I-Entity
(	PUNCT	O	O
CGRP	PROPN	O	I-Entity
)	PUNCT	O	O
concentration	NOUN	O	O
and	CCONJ	O	O
negative	ADJ	O	O
correlation	NOUN	O	O
with	ADP	O	O
platelet	NOUN	O	O
serotonin	NOUN	O	I-Entity
release	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
those	DET	O	O
subjects	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
no	DET	O	O
migraine	ADJ	O	I-Entity
attack	NOUN	O	O
(	PUNCT	O	O
11	NUM	O	O
subjects	NOUN	O	O
)	PUNCT	O	O
a	DET	O	O
similar	ADJ	O	O
time	NOUN	O	O
schedule	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
.	PUNCT	O	O

Plasma	PROPN	O	O
CGRP	PROPN	O	I-Entity
concentration	NOUN	O	O
increased	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
P<0.01	PROPN	O	O
)	PUNCT	O	O
during	ADP	O	O
the	DET	O	O
migraine	ADJ	O	I-Entity
attack	NOUN	O	O
and	CCONJ	O	O
returned	VERB	O	O
to	ADP	O	O
baseline	NOUN	O	O
after	ADP	O	O
the	DET	O	O
cessation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
migraine	NOUN	O	I-Entity
.	PUNCT	O	O

Behavioral	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
urotensin	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
II	PROPN	O	I-Entity
centrally	ADV	O	O
administered	VERB	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
graded	VERB	O	O
doses	NOUN	O	O
of	ADP	O	O
U	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
II	PROPN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
-	SYM	O	O
10,000	NUM	O	O
ng	NOUN	O	O
/	SYM	O	O
mouse	NOUN	O	O
)	PUNCT	O	O
provoked	VERB	O	O
:	PUNCT	O	O
(	PUNCT	O	O
1	PUNCT	O	O
)	PUNCT	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
head	NOUN	O	O
dips	NOUN	O	O
in	ADP	O	O
the	DET	O	O
hole	NOUN	O	O
-	PUNCT	O	O
board	NOUN	O	O
test	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
2	PUNCT	O	O
)	PUNCT	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
entries	NOUN	O	O
in	ADP	O	O
the	DET	O	O
white	ADJ	O	O
chamber	NOUN	O	O
in	ADP	O	O
the	DET	O	O
black	ADJ	O	O
-	PUNCT	O	O
and	CCONJ	O	O
-	PUNCT	O	O
white	ADJ	O	O
compartment	NOUN	O	O
test	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
entries	NOUN	O	O
in	ADP	O	O
the	DET	O	O
central	ADJ	O	O
platform	NOUN	O	O
and	CCONJ	O	O
open	ADJ	O	O
arms	NOUN	O	O
in	ADP	O	O
the	DET	O	O
plus	NOUN	O	O
-	PUNCT	O	O
maze	NOUN	O	O
test	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
3	PUNCT	O	O
)	PUNCT	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
immobility	NOUN	O	O
in	ADP	O	O
the	DET	O	O
forced	VERB	O	O
-	PUNCT	O	O
swimming	NOUN	O	O
test	NOUN	O	O
and	CCONJ	O	O
tail	NOUN	O	O
suspension	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

Intracerebroventricular	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
U	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
II	PROPN	O	I-Entity
also	ADV	O	O
caused	VERB	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
:	PUNCT	O	O
food	NOUN	O	O
intake	NOUN	O	O
at	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
100	NUM	O	O
and	CCONJ	O	O
1,000	NUM	O	O
ng	NOUN	O	O
/	SYM	O	O
mouse	NOUN	O	O
,	PUNCT	O	O
water	NOUN	O	O
intake	NOUN	O	O
at	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
100	NUM	O	O
-	SYM	O	O
10,000	NUM	O	O
ng	NOUN	O	O
/	SYM	O	O
mouse	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
horizontal	ADJ	O	O
locomotion	NOUN	O	O
activity	NOUN	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
10,000	NUM	O	O
ng	PROPN	O	O
/	SYM	O	O
mouse	NOUN	O	O
.	PUNCT	O	O

Recurrent	PROPN	O	O
dysphonia	NOUN	O	I-Entity
and	CCONJ	O	O
acitretin	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
woman	NOUN	O	O
complaining	VERB	O	O
of	ADP	O	O
dysphonia	NOUN	O	I-Entity
while	ADP	O	O
she	PRON	O	O
was	VERB	O	O
treated	VERB	O	O
by	ADP	O	O
acitretin	NOUN	O	I-Entity
.	PUNCT	O	O

Abnormal	ADJ	O	O
brain	NOUN	O	O
responses	NOUN	O	O
to	ADP	O	O
somatosensory	ADJ	O	O
stimuli	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
found	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hyperalgesia	NOUN	O	I-Entity
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
in	ADP	O	O
normal	ADJ	O	O
subjects	NOUN	O	O
during	ADP	O	O
experimental	ADJ	O	O
central	ADJ	O	O
sensitization	NOUN	O	O
.	PUNCT	O	O

Using	VERB	O	O
functional	ADJ	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	NOUN	O	O
(	PUNCT	O	O
fMRI	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
normal	ADJ	O	O
volunteers	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
studied	VERB	O	O
the	DET	O	O
gabapentin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
modulation	NOUN	O	O
of	ADP	O	O
brain	NOUN	O	O
activity	NOUN	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
nociceptive	ADJ	O	O
mechanical	ADJ	O	O
stimulation	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	O
skin	NOUN	O	O
and	CCONJ	O	O
capsaicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
secondary	ADJ	O	B-Entity
hyperalgesia	NOUN	O	I-Entity
.	PUNCT	O	O

Reported	VERB	O	O
medications	NOUN	O	O
included	VERB	O	O
bumetanide	NOUN	O	I-Entity
,	PUNCT	O	O
pravastatin	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
paroxetine	NOUN	O	I-Entity
.	PUNCT	O	O

Upon	ADP	O	O
additional	ADJ	O	O
retrospective	ADJ	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
was	VERB	O	O
noted	VERB	O	O
that	ADP	O	O
bumetanide	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
loop	NOUN	O	B-Entity
diuretic	NOUN	O	I-Entity
that	ADJ	O	O
may	VERB	O	O
cause	VERB	O	O
significant	ADJ	O	O
hypocalcemia	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
careful	ADJ	O	O
screening	NOUN	O	O
for	ADP	O	O
medications	NOUN	O	O
and	CCONJ	O	O
underlying	ADJ	O	O
conditions	NOUN	O	O
predisposing	VERB	O	O
to	ADP	O	O
hypocalcemia	NOUN	O	I-Entity
is	VERB	O	O
recommended	VERB	O	O
to	PART	O	O
help	VERB	O	O
prevent	VERB	O	O
severe	ADJ	O	O
reactions	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
citrate	VERB	O	I-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Laboratory	PROPN	O	O
measurement	NOUN	O	O
of	ADP	O	O
pre	NOUN	O	O
-	PUNCT	O	O
procedure	NOUN	O	O
serum	NOUN	O	O
calcium	NOUN	O	I-Entity
levels	NOUN	O	O
in	ADP	O	O
selected	VERB	O	O
donors	NOUN	O	O
may	VERB	O	O
identify	VERB	O	O
cases	NOUN	O	O
requiring	VERB	O	O
heightened	VERB	O	O
vigilance	NOUN	O	O
.	PUNCT	O	O

Proteinuria	PROPN	O	I-Entity
after	ADP	O	O
conversion	NOUN	O	O
to	ADP	O	O
sirolimus	VERB	O	I-Entity
in	ADP	O	O
renal	ADJ	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
retrospectively	ADV	O	O
examined	VERB	O	O
the	DET	O	O
records	NOUN	O	O
of	ADP	O	O
25	NUM	O	O
renal	ADJ	O	O
transplant	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
who	NOUN	O	O
developed	VERB	O	O
or	CCONJ	O	O
displayed	VERB	O	O
increased	VERB	O	O
proteinuria	NOUN	O	I-Entity
after	ADP	O	O
SRL	PROPN	O	I-Entity
conversion	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	ADJ	O	O
cohort	NOUN	O	O
(	PUNCT	O	O
14	NUM	O	O
men	NOUN	O	O
,	PUNCT	O	O
11	NUM	O	O
women	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
SRL	PROPN	O	I-Entity
as	ADP	O	O
conversion	NOUN	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
due	ADJ	O	O
to	ADP	O	O
chronic	ADJ	O	B-Entity
allograft	NOUN	O	I-Entity
nephropathy	NOUN	O	I-Entity
(	PUNCT	O	O
CAN	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
15	NUM	O	O
)	PUNCT	O	O

SRL	PROPN	O	I-Entity
was	VERB	O	O
started	VERB	O	O
at	ADP	O	O
a	DET	O	O
mean	NOUN	O	O
of	ADP	O	O
78	NUM	O	O
+	NOUN	O	O
/-	PUNCT	O	O

Mean	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	PART	O	O
on	ADP	O	O
SRL	PROPN	O	I-Entity
therapy	NOUN	O	O
was	VERB	O	O
20	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Before	ADP	O	O
conversion	NOUN	O	O
8	NUM	O	O
(	PUNCT	O	O
32%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
had	VERB	O	O
no	DET	O	O
proteinuria	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
afterwards	ADV	O	O
all	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
proteinuria	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
28%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
proteinuria	ADV	O	I-Entity
remained	VERB	O	O
unchanged	ADJ	O	O
,	PUNCT	O	O
whereas	ADP	O	O
it	PRON	O	O
increased	VERB	O	O
in	ADP	O	O
68%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Five	NUM	O	O
patients	NOUN	O	O
displayed	VERB	O	O
CAN	PROPN	O	I-Entity
and	CCONJ	O	O
Kaposi	PROPN	O	B-Entity
's	PART	O	I-Entity
sarcoma	NOUN	O	I-Entity
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
conversion	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
for	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
have	VERB	O	O
not	ADV	O	O
developed	VERB	O	O
advanced	ADJ	O	O
CAN	PROPN	O	I-Entity
and	CCONJ	O	O
proteinuria	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cystitis	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
,	PUNCT	O	O
detrusor	NOUN	O	O
function	NOUN	O	O
is	VERB	O	O
impaired	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
expression	NOUN	O	O
and	CCONJ	O	O
effects	NOUN	O	O
of	ADP	O	O
muscarinic	NOUN	O	O
receptors	NOUN	O	O
altered	VERB	O	O
.	PUNCT	O	O

Associations	NOUN	O	O
between	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
benzodiazepines	NOUN	O	I-Entity
or	CCONJ	O	O
related	VERB	O	O
drugs	NOUN	O	O
and	CCONJ	O	O
health	NOUN	O	O
,	PUNCT	O	O
physical	ADJ	O	O
abilities	NOUN	O	O
and	CCONJ	O	O
cognitive	ADJ	O	O
function	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
randomised	ADJ	O	O
clinical	ADJ	O	O
study	NOUN	O	O
in	ADP	O	O
the	DET	O	O
elderly	ADJ	O	O
.	PUNCT	O	O

Of	ADP	O	O
these	DET	O	O
,	PUNCT	O	O
nearly	ADV	O	O
half	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
78	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
used	VERB	O	O
BZDs	NOUN	O	I-Entity
/	SYM	O	O
RDs	ADV	O	O
before	ADP	O	O
admission	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
remainder	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
86	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
non	ADJ	O	O
-	PUNCT	O	O
users	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
or	CCONJ	O	O
three	NUM	O	O
BZDs	NOUN	O	I-Entity
/	SYM	O	O
RDs	NOUN	O	O
were	VERB	O	O
concomitantly	ADV	O	O
taken	VERB	O	O
by	ADP	O	O
26%	NUM	O	O
of	ADP	O	O
users	NOUN	O	O
(	PUNCT	O	O
n	VERB	O	O
=	SYM	O	O
20	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
adjustment	NOUN	O	O
for	ADP	O	O
these	DET	O	O
variables	NOUN	O	O
as	ADP	O	O
confounders	NOUN	O	O
,	PUNCT	O	O
use	NOUN	O	O
of	ADP	O	O
BZDs	PROPN	O	I-Entity
/	SYM	O	O
RDs	PROPN	O	O
was	VERB	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
cognitive	ADJ	O	O
function	NOUN	O	O
as	ADP	O	O
measured	VERB	O	O
by	ADP	O	O
the	DET	O	O
MMSE	PROPN	O	O
.	PUNCT	O	O


A	DET	O	O
49-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
was	VERB	O	O
transferred	VERB	O	O
to	ADP	O	O
our	ADJ	O	O
department	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
quadriparesis	NOUN	O	I-Entity
,	PUNCT	O	O
lancinating	VERB	O	O
pain	NOUN	O	I-Entity
,	PUNCT	O	O
sensory	ADJ	O	B-Entity
loss	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
paresthesia	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
distal	ADJ	O	O
limbs	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
month	NOUN	O	O
previously	ADV	O	O
,	PUNCT	O	O
she	PRON	O	O
had	VERB	O	O
taken	VERB	O	O
a	DET	O	O
single	ADJ	O	O
high	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
disulfiram	NOUN	O	I-Entity
(	PUNCT	O	O
130	NUM	O	O
tablets	NOUN	O	O
of	ADP	O	O
ALCOHOL	PROPN	O	I-Entity
STOP	PROPN	O	O
TAB	PROPN	O	O
,	PUNCT	O	O
Shin	PROPN	O	O
-	PUNCT	O	O
Poong	PROPN	O	O
Pharm	PROPN	O	O
.	PUNCT	O	O

A	DET	O	O
nerve	NOUN	O	O
conduction	NOUN	O	O
study	NOUN	O	O
was	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
severe	ADJ	O	O
sensorimotor	NOUN	O	O
axonal	ADJ	O	O
polyneuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (18208574)

;	PUNCT	O	O
the	DET	O	O
assay	NOUN	O	O
utilizes	VERB	O	O
reaction	NOUN	O	O
inhibition	NOUN	O	O
characteristics	NOUN	O	O
of	ADP	O	O
a	DET	O	O
high	ADJ	O	O
heparin	NOUN	O	I-Entity
concentration	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
diagnosis	NOUN	O	O
there	ADV	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
OD	NOUN	O	O
between	ADP	O	O
HIT	PROPN	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
thrombosis	NOUN	O	I-Entity
and	CCONJ	O	O
those	DET	O	O
with	ADP	O	O
isolated	ADJ	O	O
-	PUNCT	O	O
HIT	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
OD	PROPN	O	O
was	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
thrombosis	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
48	NUM	O	O
,	PUNCT	O	O
1.34	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

The	DET	O	O
Receiver	PROPN	O	O
Operative	PROPN	O	O
Characteristic	PROPN	O	O
Curve	PROPN	O	O
showed	VERB	O	O
that	ADP	O	O
OD	PROPN	O	O
>	SYM	O	O
1.27	NUM	O	O
in	ADP	O	O
the	DET	O	O
isolated	ADJ	O	O
-	PUNCT	O	O
HIT	PROPN	O	I-Entity
group	NOUN	O	O
had	VERB	O	O
a	DET	O	O
significantly	ADV	O	O
higher	ADJ	O	O
chance	NOUN	O	O
of	ADP	O	O
developing	VERB	O	O
thrombosis	NOUN	O	I-Entity
by	ADP	O	O
day	NOUN	O	O
30	NUM	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Higher	ADJ	O	O
OD	PROPN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
significant	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
subsequent	ADJ	O	O
thrombosis	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
isolated	ADJ	O	O
-	PUNCT	O	O
HIT	PROPN	O	I-Entity
;	PUNCT	O	O
percent	NOUN	O	O
inhibition	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
was	VERB	O	O
not	ADV	O	O
predictive	ADJ	O	O
.	PUNCT	O	O


Extra	PROPN	O	O
caution	NOUN	O	O
is	VERB	O	O
warranted	VERB	O	O
in	ADP	O	O
treating	VERB	O	O
infertility	NOUN	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
CC	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
patients	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
well	ADJ	O	O
informed	VERB	O	O
of	ADP	O	O
this	DET	O	O
side	NOUN	O	O
effect	NOUN	O	O
before	ADP	O	O
commencement	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Eight	NUM	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
inhaled	VERB	O	O
nicotine	NOUN	O	I-Entity
in	ADP	O	O
darkness	NOUN	O	O
during	ADP	O	O
a	DET	O	O
functional	ADJ	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	NOUN	O	O
(	PUNCT	O	O
fMRI	PROPN	O	O
)	PUNCT	O	O
experiment	NOUN	O	O
;	PUNCT	O	O
eye	NOUN	O	O
movements	NOUN	O	O
were	VERB	O	O
registered	VERB	O	O
using	VERB	O	O
video	NOUN	O	O
-	PUNCT	O	O
oculography	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (18619688)

RESULTS	NOUN	O	O
:	PUNCT	O	O
3MA	NUM	O	I-Entity
significantly	ADV	O	O
improved	VERB	O	O
cardiac	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
reduced	ADJ	O	O
mitochondrial	ADJ	O	O
injury	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
adriamycin	ADV	O	I-Entity
induced	VERB	O	O
the	DET	O	O
formation	NOUN	O	O
of	ADP	O	O
autophagic	ADJ	O	O
vacuoles	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
3MA	NUM	O	I-Entity
strongly	ADV	O	O
downregulated	VERB	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
beclin	NOUN	O	O
1	NUM	O	O
in	ADP	O	O
adriamycin	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
failing	VERB	O	O
heart	NOUN	O	O
and	CCONJ	O	O
inhibited	VERB	O	O
the	DET	O	O
formation	NOUN	O	O
of	ADP	O	O
autophagic	ADJ	O	O
vacuoles	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Autophagic	PROPN	O	O
cardiomyocyte	NOUN	O	O
death	NOUN	O	I-Entity
plays	VERB	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
adriamycin	ADV	O	I-Entity
.	PUNCT	O	O

Confusion	NOUN	O	I-Entity
is	VERB	O	O
an	DET	O	O
adverse	ADJ	O	O
drug	NOUN	O	O
reaction	NOUN	O	O
frequently	ADV	O	O
observed	VERB	O	O
with	ADP	O	O
valproic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
both	DET	O	O
ecstasy	NOUN	O	I-Entity
and	CCONJ	O	O
cannabis	ADJ	O	I-Entity
groups	NOUN	O	O
brain	NOUN	O	O
activation	NOUN	O	O
was	VERB	O	O
decreased	VERB	O	O
in	ADP	O	O
the	DET	O	O
right	ADJ	O	O
medial	ADJ	O	O
frontal	NOUN	O	O
gyrus	NOUN	O	O
,	PUNCT	O	O
left	VERB	O	O
parahippocampal	ADJ	O	O
gyrus	NOUN	O	O
,	PUNCT	O	O
left	VERB	O	O
dorsal	NOUN	O	O
cingulate	ADJ	O	O
gyrus	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
left	VERB	O	O
caudate	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
elucidated	VERB	O	O
ecstasy	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
deficits	NOUN	O	O
,	PUNCT	O	O
only	ADV	O	O
some	DET	O	O
of	ADP	O	O
which	ADJ	O	O
might	VERB	O	O
be	VERB	O	O
attributed	VERB	O	O
to	ADP	O	O
cannabis	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
required	VERB	O	O
massive	ADJ	O	O
transfusion	NOUN	O	O
support	NOUN	O	O
(	PUNCT	O	O
55	NUM	O	O
units	NOUN	O	O
of	ADP	O	O
red	ADJ	O	O
blood	NOUN	O	O
cells	NOUN	O	O
,	PUNCT	O	O
42	NUM	O	O
units	NOUN	O	O
of	ADP	O	O
fresh	ADJ	O	O
-	PUNCT	O	O
frozen	ADJ	O	O
plasma	NOUN	O	O
,	PUNCT	O	O
40	NUM	O	O
units	NOUN	O	O
of	ADP	O	O
cryoprecipitate	NOUN	O	O
,	PUNCT	O	O
40	NUM	O	O
units	NOUN	O	O
of	ADP	O	O
platelets	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
three	NUM	O	O
doses	NOUN	O	O
of	ADP	O	O
recombinant	NOUN	O	O
Factor	PROPN	O	O
VIIa	PROPN	O	O
)	PUNCT	O	O
for	ADP	O	O
severe	ADJ	O	O
intraoperative	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
postoperative	ADJ	O	I-Entity
bleeding	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
report	NOUN	O	O
to	PART	O	O
measure	VERB	O	O
plasma	NOUN	O	O
argatroban	ADJ	O	I-Entity
concentration	NOUN	O	O
in	ADP	O	O
the	DET	O	O
context	NOUN	O	O
of	ADP	O	O
CPB	PROPN	O	O
and	CCONJ	O	O
extended	VERB	O	O
coagulopathy	NOUN	O	I-Entity
.	PUNCT	O	O

Another	DET	O	O
15	NUM	O	O
(	PUNCT	O	O
1.2%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
ATT	PROPN	O	O
and	CCONJ	O	O
simultaneous	ADJ	O	O
hepatitis	NOUN	O	B-Entity
virus	NOUN	O	I-Entity
infection	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
44	NUM	O	O
(	PUNCT	O	O
62.8%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
,	PUNCT	O	O
ATT	PROPN	O	O
was	VERB	O	O
prescribed	VERB	O	O
empirically	ADV	O	O
without	ADP	O	O
definitive	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
tuberculosis	NOUN	O	I-Entity
.	PUNCT	O	O

ATT	PROPN	O	O
-	PUNCT	O	O
ALF	PROPN	O	I-Entity
patients	NOUN	O	O
were	VERB	O	O
younger	ADJ	O	O
(	PUNCT	O	O
32.87	NUM	O	O
[	PUNCT	O	O
+	SYM	O	O
/-15.8	PROPN	O	O
]	PUNCT	O	O
years	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
49	NUM	O	O
(	PUNCT	O	O
70%	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
them	PRON	O	O
were	VERB	O	O
women	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
presentation	NOUN	O	O
,	PUNCT	O	O
advanced	ADJ	O	O
encephalopathy	ADJ	O	I-Entity
and	CCONJ	O	O
cerebral	ADJ	O	B-Entity
edema	NOUN	O	I-Entity
were	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
51	NUM	O	O
(	PUNCT	O	O
76%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
29	NUM	O	O
(	PUNCT	O	O
41.4%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Gastrointestinal	ADJ	O	B-Entity
bleed	NOUN	O	I-Entity
,	PUNCT	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
infection	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
were	VERB	O	O
documented	VERB	O	O
in	ADP	O	O
seven	NUM	O	O
(	PUNCT	O	O
10%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
five	NUM	O	O
(	PUNCT	O	O
7.1%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
26	NUM	O	O
(	PUNCT	O	O
37.1%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
seven	NUM	O	O
(	PUNCT	O	O
10%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
mortality	NOUN	O	O
rate	NOUN	O	O
among	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
ATT	PROPN	O	O
-	PUNCT	O	O
ALF	PROPN	O	I-Entity
was	VERB	O	O
high	ADJ	O	O
(	PUNCT	O	O
67.1%	NUM	O	O
,	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
47	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
only	ADV	O	O
23	NUM	O	O
(	PUNCT	O	O
32.9%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
recovered	VERB	O	O
with	ADP	O	O
medical	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
ATT	PROPN	O	O
-	PUNCT	O	O
ALF	PROPN	O	I-Entity
constituted	VERB	O	O
5.7%	NUM	O	O
of	ADP	O	O
ALF	NOUN	O	I-Entity
at	ADP	O	O
our	ADJ	O	O
center	NOUN	O	O
and	CCONJ	O	O
had	VERB	O	O
a	DET	O	O
high	ADJ	O	O
mortality	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
analyzed	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
neurological	ADJ	O	B-Entity
complications	NOUN	O	I-Entity
during	ADP	O	O
ALL	DET	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
a	DET	O	O
single	ADJ	O	O
pediatric	ADJ	O	O
institution	NOUN	O	O
,	PUNCT	O	O
focusing	VERB	O	O
on	ADP	O	O
clinical	ADJ	O	O
,	PUNCT	O	O
radiological	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
electrophysiological	ADJ	O	O
findings	NOUN	O	O
.	PUNCT	O	O

Safety	NOUN	O	O
of	ADP	O	O
capecitabine	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
review	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
has	VERB	O	O
shown	VERB	O	O
promising	ADJ	O	O
results	NOUN	O	O
alone	ADV	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
other	ADJ	O	O
chemotherapeutic	ADJ	O	O
agents	NOUN	O	O
in	ADP	O	O
colorectal	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
breast	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
pancreaticobiliary	ADJ	O	I-Entity
,	PUNCT	O	I-Entity
gastric	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
renal	ADJ	O	I-Entity
cell	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
head	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
neck	NOUN	O	I-Entity
cancers	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
commonly	ADV	O	O
reported	VERB	O	O
toxic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
capecitabine	NOUN	O	I-Entity
are	VERB	O	O
diarrhea	NOUN	O	I-Entity
,	PUNCT	O	O
nausea	NOUN	O	I-Entity
,	PUNCT	O	O
vomiting	VERB	O	I-Entity
,	PUNCT	O	O
stomatitis	NOUN	O	I-Entity
and	CCONJ	O	O
hand	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
foot	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

Capecitabine	PROPN	O	I-Entity
has	VERB	O	O
a	DET	O	O
well	ADV	O	O
-	PUNCT	O	O
established	VERB	O	O
safety	NOUN	O	O
profile	NOUN	O	O
and	CCONJ	O	O
can	VERB	O	O
be	VERB	O	O
given	VERB	O	O
safely	ADV	O	O
to	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	ADJ	O	O
age	NOUN	O	O
,	PUNCT	O	O
hepatic	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
renal	ADJ	O	I-Entity
dysfunctions	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (20882060)

Electrophysiological	ADJ	O	O
recordings	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
microinjection	NOUN	O	O
of	ADP	O	O
neurotensin	NOUN	O	I-Entity
induced	VERB	O	O
excitation	NOUN	O	O
of	ADP	O	O
pallidal	NOUN	O	O
neurons	NOUN	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
systemic	ADJ	O	O
haloperidol	NOUN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
neurotensin	NOUN	O	B-Entity
type-1	ADJ	O	I-Entity
receptor	NOUN	O	I-Entity
antagonist	NOUN	O	I-Entity
SR48692	NOUN	O	I-Entity
blocked	VERB	O	O
both	CCONJ	O	O
the	DET	O	O
behavioral	ADJ	O	O
and	CCONJ	O	O
the	DET	O	O
electrophysiological	ADJ	O	O
effects	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
neurotensin	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
high	ADJ	O	O
prevalence	NOUN	O	O
of	ADP	O	O
depression	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
preponderance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
hypertensive	ADJ	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
accounted	VERB	O	O
for	ADP	O	O
by	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
depressions	NOUN	O	I-Entity
occurring	VERB	O	O
in	ADP	O	O
methyl	NOUN	O	B-Entity
dopa	NOUN	O	I-Entity
treated	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
psychiatric	ADJ	O	I-Entity
histories	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (322550)

These	DET	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
nitroprusside	ADJ	O	I-Entity
infusion	NOUN	O	O
rates	NOUN	O	O
that	ADJ	O	O
decrease	VERB	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
by	ADP	O	O
40	NUM	O	O
-	SYM	O	O
50	NUM	O	O
per	NOUN	O	O
cent	NOUN	O	O
do	VERB	O	O
not	ADV	O	O
change	VERB	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
or	CCONJ	O	O
QS	PROPN	O	O
/	SYM	O	O
QT	PROPN	O	O
.	PUNCT	O	O


However	ADV	O	O
,	PUNCT	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	PROPN	O	I-Entity
restored	VERB	O	O
the	DET	O	O
bradycardia	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
norepinephrine	NOUN	O	I-Entity
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
decreasing	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

decreased	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
decreased	VERB	O	O
the	DET	O	O
reflex	NOUN	O	O
bradycardia	NOUN	O	I-Entity
to	ADP	O	O
norepinephrine	NOUN	O	I-Entity
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
effects	NOUN	O	O
are	VERB	O	O
mediated	VERB	O	O
through	ADP	O	O
dopamine	NOUN	O	I-Entity
rather	ADV	O	O
than	ADP	O	O
norepinephrine	NOUN	O	I-Entity
and	CCONJ	O	O
do	VERB	O	O
not	ADV	O	O
require	VERB	O	O
the	DET	O	O
carotid	ADJ	O	O
sinus	NOUN	O	O
baroreceptors	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
certain	ADJ	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
experimental	ADJ	O	O
findings	NOUN	O	O
support	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADJ	O	O
spasm	NOUN	O	I-Entity
involves	VERB	O	O
the	DET	O	O
epicardial	ADJ	O	O
,	PUNCT	O	O
medium	NOUN	O	O
-	PUNCT	O	O
size	NOUN	O	O
vessels	NOUN	O	O
,	PUNCT	O	O
other	ADJ	O	O
data	NOUN	O	O
suggest	VERB	O	O
intramural	ADJ	O	O
vasoconstriction	NOUN	O	O
.	PUNCT	O	O

Diffuse	ADP	O	O
intramural	ADJ	O	O
vasoconstriction	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
consistent	ADJ	O	O
with	ADP	O	O
reports	NOUN	O	O
of	ADP	O	O
segmental	NOUN	O	O
,	PUNCT	O	O
discrete	ADJ	O	O
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
bronchodilator	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
ipratropium	NOUN	O	B-Entity
bromide	NOUN	O	I-Entity
aerosol	NOUN	O	O
(	PUNCT	O	O
36	NUM	O	O
micrograms	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
short	ADJ	O	O
-	PUNCT	O	O
acting	VERB	O	O
theophylline	NOUN	O	I-Entity
tablets	NOUN	O	O
(	PUNCT	O	O
dose	NOUN	O	O
titrated	VERB	O	O
to	PART	O	O
produce	VERB	O	O
serum	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
-	SYM	O	O
20	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
mL	PROPN	O	O
)	PUNCT	O	O
were	VERB	O	O
compared	VERB	O	O
in	ADP	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	NOUN	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
crossover	ADJ	O	O
study	NOUN	O	O
in	ADP	O	O
21	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
stable	ADJ	O	O
,	PUNCT	O	O
chronic	ADJ	O	B-Entity
obstructive	ADJ	O	I-Entity
pulmonary	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Mean	ADJ	O	O
peak	NOUN	O	O
forced	VERB	O	O
expiratory	NOUN	O	O
volume	NOUN	O	O
in	ADP	O	O
1	NUM	O	O
second	NOUN	O	O
(	PUNCT	O	O
FEV1	PROPN	O	O
)	PUNCT	O	O
increases	VERB	O	O
over	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
attaining	VERB	O	O
at	ADP	O	O
least	ADJ	O	O
a	DET	O	O
15%	NUM	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
FEV1	PROPN	O	O
(	PUNCT	O	O
responders	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
31%	NUM	O	O
and	CCONJ	O	O
90%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
for	ADP	O	O
ipratropium	NOUN	O	I-Entity
and	CCONJ	O	O
17%	NUM	O	O
and	CCONJ	O	O
50%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
for	ADP	O	O
theophylline	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
average	ADJ	O	O
FEV1	PROPN	O	O
increases	NOUN	O	O
during	ADP	O	O
the	DET	O	O
6-hour	NUM	O	O
observation	NOUN	O	O
period	NOUN	O	O
were	VERB	O	O
18%	NUM	O	O
for	ADP	O	O
ipratropium	NOUN	O	I-Entity
and	CCONJ	O	O
8%	NUM	O	O
for	ADP	O	O
theophylline	NOUN	O	I-Entity
.	PUNCT	O	O


Thermal	ADJ	O	O
enhancement	NOUN	O	O
ratios	NOUN	O	O
estimated	VERB	O	O
for	ADP	O	O
"	PUNCT	O	O
acute	ADJ	O	O
"	PUNCT	O	O
hematological	ADJ	O	O
changes	NOUN	O	O
were	VERB	O	O
1.3	NUM	O	O
,	PUNCT	O	O
whereas	ADP	O	O
those	DET	O	O
estimated	VERB	O	O
for	ADP	O	O
"	PUNCT	O	O
late	ADJ	O	O
"	PUNCT	O	O
damage	NOUN	O	O
(	PUNCT	O	O
based	VERB	O	O
on	ADP	O	O
morphological	ADJ	O	O
cardiac	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
renal	ADJ	O	I-Entity
lesions	NOUN	O	I-Entity
)	PUNCT	O	O
varied	VERB	O	O
between	ADP	O	O
2.4	NUM	O	O
and	CCONJ	O	O
4.3	NUM	O	O
.	PUNCT	O	O

-DOCSTART- (2304736)

-DOCSTART- (2549018)

(	PUNCT	O	O
5	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
stroke	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
intracranial	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
exceeds	VERB	O	O
that	ADP	O	O
of	ADP	O	O
cerebral	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
type	NOUN	O	B-Entity
II	NUM	O	I-Entity
diabetes	NOUN	O	I-Entity
mellitus	NOUN	O	I-Entity
developed	VERB	O	O
an	DET	O	O
acute	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
like	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
soon	ADV	O	O
after	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
glyburide	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Glyburide	PROPN	O	I-Entity
can	VERB	O	O
produce	VERB	O	O
an	DET	O	O
acute	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
like	ADJ	O	I-Entity
illness	NOUN	O	I-Entity
in	ADP	O	O
some	DET	O	O
persons	NOUN	O	O
.	PUNCT	O	O


Intense	ADJ	O	O
vasospasm	NOUN	O	I-Entity
with	ADP	O	O
threatened	VERB	O	O
gangrene	NOUN	O	I-Entity
arose	VERB	O	O
in	ADP	O	O
the	DET	O	O
arm	NOUN	O	O
used	VERB	O	O
for	ADP	O	O
the	DET	O	O
infusion	NOUN	O	O
.	PUNCT	O	O

Controlled	VERB	O	O
hypotension	NOUN	O	I-Entity
to	ADP	O	O
an	DET	O	O
average	ADJ	O	O
MAP	PROPN	O	O
of	ADP	O	O
50	NUM	O	O
-	SYM	O	O
55	NUM	O	O
mm	NOUN	O	O
Hg	PROPN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
increasing	VERB	O	O
the	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
isoflurane	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
maintained	VERB	O	O
at	ADP	O	O
an	DET	O	O
inspired	ADJ	O	O
concentration	NOUN	O	O
of	ADP	O	O
2.2	NUM	O	O
+	NOUN	O	O
/-	PUNCT	O	O

Three	NUM	O	O
infants	NOUN	O	O
,	PUNCT	O	O
born	VERB	O	O
of	ADP	O	O
two	NUM	O	O
mothers	NOUN	O	O
with	ADP	O	O
inflammatory	ADJ	O	B-Entity
bowel	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
who	NOUN	O	O
received	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
sulphasalazine	NOUN	O	I-Entity
throughout	ADP	O	O
pregnancy	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
found	VERB	O	O
to	PART	O	O
have	VERB	O	O
major	ADJ	O	O
congenital	ADJ	O	B-Entity
anomalies	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
singleton	NOUN	O	O
pregnancy	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
mother	NOUN	O	O
had	VERB	O	O
ulcerative	ADJ	O	B-Entity
colitis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
infant	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
male	NOUN	O	O
,	PUNCT	O	O
had	VERB	O	O
coarctation	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
aorta	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
ventricular	ADJ	O	B-Entity
septal	ADJ	O	I-Entity
defect	NOUN	O	I-Entity
.	PUNCT	O	O

Despite	ADP	O	O
reports	NOUN	O	O
to	ADP	O	O
the	DET	O	O
contrary	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
sulphasalazine	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
teratogenic	ADJ	O	O
.	PUNCT	O	O

Small-	PUNCT	O	O
and	CCONJ	O	O
medium	NOUN	O	O
-	PUNCT	O	O
sized	ADJ	O	O
hepatic	ADJ	O	O
veins	NOUN	O	O
were	VERB	O	O
blocked	VERB	O	O
by	ADP	O	O
thrombosis	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
is	VERB	O	O
presented	VERB	O	O
of	ADP	O	O
a	DET	O	O
reversible	ADJ	O	O
intra	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
Hisian	PROPN	O	I-Entity
block	NOUN	O	I-Entity
occurring	VERB	O	O
under	ADP	O	O
amiodarone	NOUN	O	I-Entity
treatment	NOUN	O	O
for	ADP	O	O
atrial	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
without	ADP	O	O
clear	ADJ	O	O
intraventricular	ADJ	O	B-Entity
conduction	NOUN	O	I-Entity
abnormalities	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
busulfan	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hemorrhage	NOUN	O	B-Entity
cystitis	NOUN	O	I-Entity
is	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
similarity	NOUN	O	O
between	ADP	O	O
the	DET	O	O
histologic	ADJ	O	O
appearances	NOUN	O	O
of	ADP	O	O
busulfan	NOUN	O	I-Entity
cystitis	NOUN	O	I-Entity
and	CCONJ	O	O
both	DET	O	O
radiation	NOUN	O	O
and	CCONJ	O	O
cyclophosphamide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cystitis	NOUN	O	I-Entity
is	VERB	O	O
discussed	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
world	NOUN	O	O
literature	NOUN	O	O
reviewed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
role	NOUN	O	O
of	ADP	O	O
the	DET	O	O
renin	NOUN	O	O
--	PUNCT	O	O
angiotensin	NOUN	O	I-Entity
system	NOUN	O	O
in	ADP	O	O
the	DET	O	O
maintenance	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
during	ADP	O	O
halothane	NOUN	O	I-Entity
anesthesia	NOUN	O	O
and	CCONJ	O	O
sodium	NOUN	O	B-Entity
nitroprusside	NOUN	O	I-Entity
(	PUNCT	O	O
SNP)-induced	PROPN	O	I-Entity
hypotension	NOUN	O	I-Entity
was	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
demonstrates	VERB	O	O
the	DET	O	O
participation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
renin	NOUN	O	O
--	PUNCT	O	O
angiotensin	NOUN	O	I-Entity
system	NOUN	O	O
in	ADP	O	O
antagonizing	VERB	O	O
the	DET	O	O
combined	VERB	O	O
hypotensive	ADJ	O	I-Entity
effects	NOUN	O	O
of	ADP	O	O
halothane	NOUN	O	I-Entity
and	CCONJ	O	O
SNP	PROPN	O	I-Entity
.	PUNCT	O	O

Only	ADV	O	O
2	NUM	O	O
patients	NOUN	O	O
of	ADP	O	O
our	ADJ	O	O
retrospective	ADJ	O	O
study	NOUN	O	O
experienced	VERB	O	O
a	DET	O	O
mild	ADJ	O	O
or	CCONJ	O	O
severe	ADJ	O	O
neutropenia	NOUN	O	I-Entity
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Toxic	PROPN	O	B-Entity
hepatitis	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
potential	ADJ	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
antithyroid	ADJ	O	O
drugs	NOUN	O	O
which	ADJ	O	O
warrants	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
for	ADP	O	O
haematological	ADJ	O	O
disturbances	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
pre	NOUN	O	O
-	PUNCT	O	O
therapeutic	ADJ	O	O
determination	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
careful	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
of	ADP	O	O
relevant	ADJ	O	O
biological	ADJ	O	O
markers	NOUN	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
hepatotoxicity	NOUN	O	I-Entity
may	VERB	O	O
not	ADV	O	O
be	VERB	O	O
restricted	VERB	O	O
to	ADP	O	O
one	NUM	O	O
class	NOUN	O	O
of	ADP	O	O
antithyroid	ADJ	O	O
agents	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (7858459)

Acute	PROPN	O	O
confusion	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
a	DET	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
infusion	NOUN	O	O
of	ADP	O	O
5-fluorouracil	NUM	O	I-Entity
and	CCONJ	O	O
folinic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O

He	PRON	O	O
developed	VERB	O	O
acute	ADJ	O	O
neurologic	ADJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
mental	ADJ	O	O
confusion	NOUN	O	I-Entity
,	PUNCT	O	O
disorientation	NOUN	O	I-Entity
and	CCONJ	O	O
irritability	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
then	ADV	O	O
lapsed	VERB	O	O
into	ADP	O	O
a	DET	O	O
deep	ADJ	O	O
coma	NOUN	O	I-Entity
,	PUNCT	O	O
lasting	VERB	O	O
for	ADP	O	O
approximately	ADV	O	O
40	NUM	O	O
hours	NOUN	O	O
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
dose	NOUN	O	O
(	PUNCT	O	O
day	NOUN	O	O
2	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
5-fluorouracil	NUM	O	I-Entity
and	CCONJ	O	O
folinic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
infusion	NOUN	O	O
.	PUNCT	O	O

High	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
5-fluorouracil	PROPN	O	I-Entity
/	SYM	O	O
folinic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
infusion	NOUN	O	O
therapy	NOUN	O	O
has	VERB	O	O
recently	ADV	O	O
become	VERB	O	O
a	DET	O	O
popular	ADJ	O	O
regimen	NOUN	O	O
for	ADP	O	O
various	ADJ	O	O
cancers	NOUN	O	I-Entity
.	PUNCT	O	O

Carbamazepine	NOUN	O	I-Entity
was	VERB	O	O
switched	VERB	O	O
to	ADP	O	O
its	ADJ	O	O
10-keto	NUM	O	O
analogue	NOUN	O	O
oxcarbazepine	NOUN	O	I-Entity
among	ADP	O	O
six	NUM	O	O
difficult	ADJ	O	O
-	PUNCT	O	O
to	PART	O	O
-	PUNCT	O	O
treat	VERB	O	O
schizophrenic	ADJ	O	I-Entity
or	CCONJ	O	O
organic	ADJ	O	B-Entity
psychotic	ADJ	O	I-Entity
patients	NOUN	O	O
using	VERB	O	O
concomitantly	ADV	O	O
haloperidol	NOUN	O	I-Entity
,	PUNCT	O	O
chlorpromazine	NOUN	O	I-Entity
or	CCONJ	O	O
clozapine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7919560)

Erythema	PROPN	O	B-Entity
multiforme	NOUN	O	I-Entity
and	CCONJ	O	O
hypersensitivity	NOUN	O	B-Entity
myocarditis	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
ampicillin	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
erythema	NOUN	O	B-Entity
multiforme	NOUN	O	I-Entity
and	CCONJ	O	O
hypersensitivity	NOUN	O	B-Entity
myocarditis	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
ampicillin	NOUN	O	I-Entity
.	PUNCT	O	O

Hypersensitivity	PROPN	O	B-Entity
myocarditis	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
and	CCONJ	O	O
dangerous	ADJ	O	O
manifestation	NOUN	O	O
of	ADP	O	O
allergy	NOUN	O	I-Entity
to	ADP	O	O
penicillins	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
large	ADJ	O	O
group	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
suspected	VERB	O	O
allergic	ADJ	O	B-Entity
reactions	NOUN	O	I-Entity
to	ADP	O	O
beta	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
lactam	NOUN	O	I-Entity
antibiotics	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

When	ADV	O	O
both	DET	O	O
skin	NOUN	O	O
test	NOUN	O	O
and	CCONJ	O	O
RAST	PROPN	O	O
for	ADP	O	O
BPO	PROPN	O	I-Entity
were	VERB	O	O
negative	ADJ	O	O
,	PUNCT	O	O
single	ADJ	O	O
-	PUNCT	O	O
blind	NOUN	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
challenge	NOUN	O	O
tests	NOUN	O	O
were	VERB	O	O
done	VERB	O	O
to	PART	O	O
ensure	VERB	O	O
tolerance	NOUN	O	O
of	ADP	O	O
PG	PROPN	O	I-Entity
or	CCONJ	O	O
sensitivity	NOUN	O	O
to	PART	O	O
AX	PROPN	O	I-Entity
.	PUNCT	O	O

None	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sera	NOUN	O	O
with	ADP	O	O
negative	ADJ	O	O
RAST	PROPN	O	O
for	ADP	O	O
AX	PROPN	O	I-Entity
were	VERB	O	O
positive	ADJ	O	O
to	ADP	O	O
BPO	PROPN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
the	DET	O	O
largest	ADJ	O	O
group	NOUN	O	O
of	ADP	O	O
AX	PROPN	O	I-Entity
-	PUNCT	O	O
allergic	ADJ	O	I-Entity
patients	NOUN	O	O
who	NOUN	O	O
have	VERB	O	O
tolerated	VERB	O	O
PG	PROPN	O	I-Entity
reported	VERB	O	O
so	ADV	O	O
far	ADV	O	O
.	PUNCT	O	O

Diagnosis	NOUN	O	O
of	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
achieved	VERB	O	O
only	ADV	O	O
if	ADP	O	O
specific	ADJ	O	O
AX	PROPN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
reagents	NOUN	O	O
are	VERB	O	O
employed	VERB	O	O
.	PUNCT	O	O

Atracurium	NOUN	O	B-Entity
besylate	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
short	ADJ	O	O
-	PUNCT	O	O
acting	VERB	O	O
benzylisoquinolinium	NOUN	O	I-Entity
NMBA	PROPN	O	O
that	ADJ	O	O
is	VERB	O	O
eliminated	VERB	O	O
independently	ADV	O	O
of	ADP	O	O
renal	NOUN	O	O
or	CCONJ	O	O
hepatic	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
has	VERB	O	O
also	ADV	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
persistent	ADJ	O	O
paralysis	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
only	ADV	O	O
when	ADV	O	O
used	VERB	O	O
with	ADP	O	O
corticosteroids	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
apparent	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
risk	NOUN	O	O
may	VERB	O	O
not	ADV	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
differences	NOUN	O	O
in	ADP	O	O
nephrotoxic	ADJ	O	I-Entity
potential	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drugs	NOUN	O	O
themselves	PRON	O	O
.	PUNCT	O	O

The	DET	O	O
nephrotoxic	ADJ	O	I-Entity
action	NOUN	O	O
of	ADP	O	O
anticancer	NOUN	O	O
drugs	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
nitrogranulogen	NOUN	O	I-Entity
(	PUNCT	O	O
NG	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
methotrexate	NOUN	O	I-Entity
(	PUNCT	O	O
MTX	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
5-fluorouracil	NOUN	O	I-Entity
(	PUNCT	O	O
5-FU	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
cyclophosphamide	NOUN	O	I-Entity
(	PUNCT	O	O

After	ADP	O	O
drug	NOUN	O	O
administration	NOUN	O	O
,	PUNCT	O	O
creatinine	ADJ	O	I-Entity
concentrations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
urine	NOUN	O	O
of	ADP	O	O
the	DET	O	O
rats	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
creatinine	NOUN	O	I-Entity
clearance	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
MTX	PROPN	O	I-Entity
administration	NOUN	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0228	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
plasma	NOUN	O	O
creatinine	NOUN	O	I-Entity
concentration	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
decrease	NOUN	O	O
in	ADP	O	O
creatinine	NOUN	O	I-Entity
clearance	NOUN	O	O
was	VERB	O	O
noted	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Lithium	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
cognitive	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
functional	ADJ	O	I-Entity
deficits	NOUN	O	I-Entity
reduced	VERB	O	O
by	ADP	O	O
a	DET	O	O
switch	NOUN	O	O
to	ADP	O	O
divalproex	VERB	O	B-Entity
sodium	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
series	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
much	ADJ	O	O
has	VERB	O	O
been	VERB	O	O
written	VERB	O	O
about	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
the	DET	O	O
more	ADV	O	O
common	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
polyuria	NOUN	O	I-Entity
and	CCONJ	O	O
tremor	NOUN	O	I-Entity
,	PUNCT	O	O
more	ADV	O	O
subtle	ADJ	O	O
lithium	ADJ	O	I-Entity
side	NOUN	O	O
effects	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
cognitive	ADJ	O	B-Entity
deficits	NOUN	O	I-Entity
,	PUNCT	O	O
loss	NOUN	O	B-Entity
of	ADP	O	I-Entity
creativity	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
functional	ADJ	O	B-Entity
impairments	NOUN	O	I-Entity
remain	VERB	O	O
understudied	ADJ	O	O
.	PUNCT	O	O

-DOCSTART- (9390208)

Combination	NOUN	O	O
chemotherapy	NOUN	O	O
with	ADP	O	O
mitoxantrone	NOUN	O	I-Entity
,	PUNCT	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
5-fluorouracil	NOUN	O	I-Entity
(	PUNCT	O	O
5-FU	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
leucovorin	NOUN	O	I-Entity
(	PUNCT	O	O
MFL	PROPN	O	B-Entity
regimen	NOUN	O	I-Entity
)	PUNCT	O	O
had	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
as	ADP	O	O
an	DET	O	O
effective	ADJ	O	O
and	CCONJ	O	O
well	ADV	O	O
tolerated	VERB	O	O
regimen	NOUN	O	O
.	PUNCT	O	O

Major	ADJ	O	O
toxicities	NOUN	O	I-Entity
were	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
leukopenia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
MFL	PROPN	O	B-Entity
regimen	NOUN	O	I-Entity
achieves	VERB	O	O
little	ADJ	O	O
palliative	ADJ	O	O
benefit	NOUN	O	O
and	CCONJ	O	O
induces	VERB	O	O
severe	ADJ	O	O
toxicity	NOUN	O	I-Entity
at	ADP	O	O
a	DET	O	O
fairly	ADV	O	O
high	ADJ	O	O
rate	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
arginine	NOUN	O	B-Entity
vasopressin	NOUN	O	I-Entity
(	PUNCT	O	O
AVP	PROPN	O	I-Entity
)	PUNCT	O	O
gene	NOUN	O	O
in	ADP	O	O
the	DET	O	O
paraventricular	NOUN	O	O
(	PUNCT	O	O
PVN	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
supraoptic	ADJ	O	O
nuclei	NOUN	O	O
(	PUNCT	O	O
SON	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
lithium	NOUN	O	I-Entity
(	PUNCT	O	O
Li)-induced	PROPN	O	I-Entity
polyuria	NOUN	O	I-Entity
,	PUNCT	O	O
using	VERB	O	O
in	ADP	O	O
situ	NOUN	O	O
hybridization	NOUN	O	O
histochemistry	NOUN	O	O
and	CCONJ	O	O
radioimmunoassay	NOUN	O	O
.	PUNCT	O	O

Apart	ADV	O	O
from	ADP	O	O
the	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
level	NOUN	O	O
of	ADP	O	O
consciousness	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
were	VERB	O	O
no	DET	O	O
signs	NOUN	O	O
of	ADP	O	O
motor	NOUN	O	O
neurone	NOUN	O	O
damage	NOUN	O	O
or	CCONJ	O	O
of	ADP	O	O
any	DET	O	O
of	ADP	O	O
the	DET	O	O
other	ADJ	O	O
known	VERB	O	O
predisposing	NOUN	O	O
conditions	NOUN	O	O
for	ADP	O	O
hyperkalaemia	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
suxamethonium	NOUN	O	I-Entity
.	PUNCT	O	O

An	DET	O	O
unusual	ADJ	O	O
toxic	ADJ	O	O
reaction	NOUN	O	O
to	ADP	O	O
axillary	ADJ	O	O
block	NOUN	O	O
by	ADP	O	O
mepivacaine	NOUN	O	I-Entity
with	ADP	O	O
adrenaline	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
intravenous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
labetalol	NOUN	O	I-Entity
,	PUNCT	O	O
metoprolol	NOUN	O	I-Entity
and	CCONJ	O	O
midazolam	NOUN	O	I-Entity
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
condition	NOUN	O	O
improved	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
15	NUM	O	O
min	NOUN	O	O
later	ADV	O	O
he	PRON	O	O
woke	VERB	O	O
up	PART	O	O
.	PUNCT	O	O

The	DET	O	O
block	NOUN	O	O
was	VERB	O	O
successful	ADJ	O	O
and	CCONJ	O	O
surgery	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
as	ADP	O	O
scheduled	VERB	O	O
despite	ADP	O	O
persisting	VERB	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (9855119)

The	DET	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
levels	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
mild	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
chronic	ADJ	O	O
FK506	NOUN	O	I-Entity
nephropathy	ADJ	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
included	VERB	O	O
7	NUM	O	O
episode	NOUN	O	O
biopsies	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
statistically	ADV	O	O
higher	ADJ	O	O
than	ADP	O	O
those	DET	O	O
in	ADP	O	O
the	DET	O	O
minimum	NOUN	O	O
-	PUNCT	O	O
type	NOUN	O	O
chronic	ADJ	O	O
FK506-nephropathy	NOUN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
PG-9	PROPN	O	I-Entity
(	PUNCT	O	O
3alpha	NUM	O	B-Entity
-	PUNCT	O	I-Entity
tropyl	NOUN	O	I-Entity
2-(p	NUM	O	I-Entity
-	PUNCT	O	I-Entity
bromophenyl)propionate	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
acetylcholine	NOUN	O	I-Entity
releaser	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
memory	NOUN	O	O
processes	NOUN	O	O
and	CCONJ	O	O
nerve	NOUN	O	O
growth	NOUN	O	O
factor	NOUN	O	O
(	PUNCT	O	O
NGF	PROPN	O	O
)	PUNCT	O	O
synthesis	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
mouse	NOUN	O	O
passive	ADJ	O	O
-	PUNCT	O	O
avoidance	NOUN	O	O
test	NOUN	O	O
,	PUNCT	O	O
PG-9	PROPN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
-	SYM	O	O
30	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
administered	VERB	O	O
20	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
the	DET	O	O
training	NOUN	O	O
session	NOUN	O	O
,	PUNCT	O	O
prevented	VERB	O	O
amnesia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
both	DET	O	O
the	DET	O	O
non	ADJ	O	O
selective	ADJ	O	O
antimuscarinic	ADJ	O	O
drug	NOUN	O	O
scopolamine	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
M1-selective	ADJ	O	O
antagonist	NOUN	O	O
S-(-)-ET-126	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
same	ADJ	O	O
experimental	ADJ	O	O
conditions	NOUN	O	O
,	PUNCT	O	O
PG-9	PROPN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
-	SYM	O	O
20	NUM	O	O
microg	NOUN	O	O
per	ADP	O	O
mouse	NOUN	O	O
,	PUNCT	O	O
i.c.v	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
was	VERB	O	O
also	ADV	O	O
able	ADJ	O	O
to	PART	O	O
prevent	VERB	O	O
antimuscarine	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
amnesia	NOUN	O	I-Entity
,	PUNCT	O	O
demonstrating	VERB	O	O
a	DET	O	O
central	ADJ	O	O
localization	NOUN	O	O
of	ADP	O	O
the	DET	O	O
activity	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10457883)

A	DET	O	O
respiratory	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
with	ADP	O	O
severe	ADJ	O	O
desaturation	NOUN	O	I-Entity
and	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
occurred	VERB	O	O
.	PUNCT	O	O

-DOCSTART- (10739826)

The	DET	O	O
adjusted	ADJ	O	O
rate	NOUN	O	O
ratio	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
for	ADP	O	O
repeat	NOUN	O	O
users	NOUN	O	O
of	ADP	O	O
third	ADJ	O	O
generation	NOUN	O	O
OC	PROPN	O	I-Entity
was	VERB	O	O
0.6	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI:0.3	NUM	O	O
-	PUNCT	O	O
1.2	NUM	O	O
)	PUNCT	O	O
relative	ADJ	O	O
to	PART	O	O
repeat	VERB	O	O
users	NOUN	O	O
of	ADP	O	O
second	ADJ	O	O
generation	NOUN	O	O
pills	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
it	PRON	O	O
was	VERB	O	O
1.3	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI:0.7	NUM	O	O
-	PUNCT	O	O
2.4	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
switchers	NOUN	O	O
from	ADP	O	O
second	ADJ	O	O
to	ADP	O	O
third	ADJ	O	O
generation	NOUN	O	O
pills	NOUN	O	O
relative	ADJ	O	O
to	ADP	O	O
switchers	NOUN	O	O
from	ADP	O	O
third	ADJ	O	O
to	ADP	O	O
second	ADJ	O	O
generation	NOUN	O	O
pills	NOUN	O	O
.	PUNCT	O	O

once	ADV	O	O
daily	ADV	O	O
)	PUNCT	O	O
aggressive	ADJ	O	B-Entity
behavior	NOUN	O	I-Entity
of	ADP	O	O
adult	NOUN	O	O
male	ADJ	O	O
and	CCONJ	O	O
female	ADJ	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
obtained	VERB	O	O
from	ADP	O	O
the	DET	O	O
same	ADJ	O	O
breeder	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
two	NUM	O	O
consecutive	ADJ	O	O
sets	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
female	ADJ	O	O
rats	NOUN	O	O
,	PUNCT	O	O
only	ADV	O	O
a	DET	O	O
weak	ADJ	O	O
tendency	NOUN	O	O
toward	ADP	O	O
aggressiveness	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
.	PUNCT	O	O

Although	ADP	O	O
urinary	ADJ	O	B-Entity
incontinence	NOUN	O	I-Entity
is	VERB	O	O
listed	VERB	O	O
as	ADP	O	O
one	NUM	O	O
side	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
these	DET	O	O
drugs	NOUN	O	O
in	ADP	O	O
their	ADJ	O	O
package	NOUN	O	O
inserts	NOUN	O	O
there	ADV	O	O
is	VERB	O	O
only	ADV	O	O
one	NUM	O	O
report	NOUN	O	O
in	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
.	PUNCT	O	O


Hypotension	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
initiation	NOUN	O	O
of	ADP	O	O
tizanidine	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
an	DET	O	O
angiotensin	NOUN	O	I-Entity
converting	VERB	O	O
enzyme	NOUN	O	O
inhibitor	NOUN	O	O
for	ADP	O	O
chronic	ADJ	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

Adults	NOUN	O	O
chronically	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
angiotensin	NOUN	O	I-Entity
converting	VERB	O	O
enzyme	NOUN	O	O
inhibitors	NOUN	O	O
may	VERB	O	O
have	VERB	O	O
a	DET	O	O
limited	VERB	O	O
ability	NOUN	O	O
to	PART	O	O
respond	VERB	O	O
to	ADP	O	O
hypotension	NOUN	O	I-Entity
when	ADV	O	O
the	DET	O	O
sympathetic	ADJ	O	O
response	NOUN	O	O
is	VERB	O	O
simultaneously	ADV	O	O
blocked	VERB	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
An	DET	O	O
association	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
found	VERB	O	O
between	ADP	O	O
transplant	NOUN	O	B-Entity
glomerulopathy	NOUN	O	I-Entity
(	PUNCT	O	O
TG	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
reduplication	NOUN	O	O
of	ADP	O	O
peritubular	ADJ	O	O
capillary	ADJ	O	O
basement	NOUN	O	O
membranes	NOUN	O	O
(	PUNCT	O	O
PTCR	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
found	VERB	O	O
PTCR	PROPN	O	O
in	ADP	O	O
14	NUM	O	O
of	ADP	O	O
15	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
TG	PROPN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
7	NUM	O	O
transplant	NOUN	O	O
biopsy	NOUN	O	O
specimens	NOUN	O	O
without	ADP	O	O
TG	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
13	NUM	O	O
of	ADP	O	O
143	NUM	O	O
native	ADJ	O	O
kidney	NOUN	O	O
biopsy	NOUN	O	O
specimens	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
suggest	VERB	O	O
that	ADP	O	O
repeated	VERB	O	O
endothelial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
,	PUNCT	O	O
including	VERB	O	O
immunologic	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
,	PUNCT	O	O
may	VERB	O	O
be	VERB	O	O
the	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
this	DET	O	O
lesion	NOUN	O	O
both	CCONJ	O	O
in	ADP	O	O
allografts	NOUN	O	O
and	CCONJ	O	O
native	ADJ	O	O
kidneys	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
three	NUM	O	O
compounds	NOUN	O	O
vary	VERB	O	O
in	ADP	O	O
their	ADJ	O	O
affinities	NOUN	O	O
for	ADP	O	O
sigma2	NOUN	O	O
receptors	NOUN	O	O
and	CCONJ	O	O
exhibit	NOUN	O	O
negligible	ADJ	O	O
affinities	NOUN	O	O
for	ADP	O	O
dopamine	NOUN	O	I-Entity
,	PUNCT	O	O
opioid	ADJ	O	O
,	PUNCT	O	O
GABA(A	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
NMDA	PROPN	O	I-Entity
receptors	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
to	ADP	O	O
the	DET	O	O
protection	NOUN	O	O
provided	VERB	O	O
by	ADP	O	O
the	DET	O	O
putative	ADJ	O	O
antagonists	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
well	ADV	O	O
-	PUNCT	O	O
characterized	VERB	O	O
sigma	NOUN	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
di	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
o	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
tolylguanidine	NOUN	O	I-Entity
(	PUNCT	O	O
DTG	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
novel	NOUN	O	O
sigma	NOUN	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
BD1031	NOUN	O	I-Entity
(	PUNCT	O	O
3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane	NOUN	O	I-Entity
)	PUNCT	O	O
each	DET	O	O
worsened	VERB	O	O
the	DET	O	O
behavioral	ADJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
cocaine	NOUN	O	I-Entity
.	PUNCT	O	O

To	PART	O	O
further	ADV	O	O
validate	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
the	DET	O	O
anti	ADJ	O	O
-	PUNCT	O	O
cocaine	NOUN	O	I-Entity
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
novel	NOUN	O	O
ligands	NOUN	O	O
involved	VERB	O	O
antagonism	NOUN	O	O
of	ADP	O	O
sigma	NOUN	O	O
receptors	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
antisense	NOUN	O	O
oligodeoxynucleotide	NOUN	O	I-Entity
against	ADP	O	O
sigma1	NOUN	O	O
receptors	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
shown	VERB	O	O
to	ADP	O	O
significantly	ADV	O	O
attenuate	VERB	O	O
the	DET	O	O
convulsive	ADJ	O	I-Entity
and	CCONJ	O	O
locomotor	NOUN	O	O
stimulatory	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
.	PUNCT	O	O

Four	NUM	O	O
compounds	NOUN	O	O
known	VERB	O	O
to	PART	O	O
increase	VERB	O	O
QT	PROPN	O	O
interval	NOUN	O	O
and	CCONJ	O	O
cause	VERB	O	O
TDP	PROPN	O	I-Entity
were	VERB	O	O
investigated	VERB	O	O
:	PUNCT	O	O
terfenadine	NOUN	O	I-Entity
,	PUNCT	O	O
terodiline	NOUN	O	I-Entity
,	PUNCT	O	O
cisapride	NOUN	O	I-Entity
and	CCONJ	O	O
E4031	PROPN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
the	DET	O	O
free	ADJ	O	O
ED50	PROPN	O	O
in	ADP	O	O
plasma	NOUN	O	O
for	ADP	O	O
terfenadine	NOUN	O	I-Entity
(	PUNCT	O	O
1.9	NUM	O	O
nM	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
terodiline	NOUN	O	I-Entity
(	PUNCT	O	O
76	NUM	O	O
nM	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
cisapride	NOUN	O	I-Entity
(	PUNCT	O	O
11	NUM	O	O
nM	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
E4031	PROPN	O	I-Entity
(	PUNCT	O	O
1.9	NUM	O	O
nM	NOUN	O	O
)	PUNCT	O	O
closely	ADV	O	O
correlate	VERB	O	O
with	ADP	O	O
the	DET	O	O
free	ADJ	O	O
concentration	NOUN	O	O
in	ADP	O	O
man	NOUN	O	O
causing	VERB	O	O
QT	PROPN	O	O
effects	NOUN	O	O
.	PUNCT	O	O


Histological	ADJ	O	O
and	CCONJ	O	O
immunohistochemical	ADJ	O	O
investigations	NOUN	O	O
(	PUNCT	O	O
HE	PROPN	O	O
-	PUNCT	O	O
LFB	PROPN	O	O
,	PUNCT	O	O
CD-68	PROPN	O	O
,	PUNCT	O	O
Neurofilament	PROPN	O	O
)	PUNCT	O	O
revealed	VERB	O	O
degeneration	NOUN	O	B-Entity
of	ADP	O	I-Entity
myelin	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
axons	NOUN	O	I-Entity
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
pseudocystic	ADJ	O	B-Entity
transformation	NOUN	O	I-Entity
in	ADP	O	O
areas	NOUN	O	O
exposed	VERB	O	O
to	ADP	O	O
vincristine	NOUN	O	I-Entity
,	PUNCT	O	O
accompanied	VERB	O	O
by	ADP	O	O
secondary	ADJ	O	O
changes	NOUN	O	O
with	ADP	O	O
numerous	ADJ	O	O
prominent	ADJ	O	O
macrophages	NOUN	O	O
.	PUNCT	O	O


In	ADP	O	O
the	DET	O	O
bolus	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
26.0%	NUM	O	O
(	PUNCT	O	O
13/50	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
akathisia	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
32.7%	NUM	O	O
(	PUNCT	O	O
16/49	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
infusion	NOUN	O	O
group	NOUN	O	O

Potassium	NOUN	O	I-Entity
was	VERB	O	O
applied	VERB	O	O
by	ADP	O	O
reverse	ADJ	O	O
dialysis	NOUN	O	O
twice	ADV	O	O
,	PUNCT	O	O
separated	VERB	O	O
by	ADP	O	O
75	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

Sensitivity	NOUN	O	O
to	ADP	O	O
several	ADJ	O	O
convulsion	NOUN	O	I-Entity
endpoints	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
nicotine	NOUN	O	I-Entity
,	PUNCT	O	O
carbachol	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
neostigmine	NOUN	O	I-Entity
were	VERB	O	O
significantly	ADV	O	O
greater	ADJ	O	O
in	ADP	O	O
WSR	PROPN	O	O
versus	ADP	O	O
WSP	PROPN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
hippocampal	ADJ	O	O
ACh	PROPN	O	I-Entity
was	VERB	O	O
measured	VERB	O	O
during	ADP	O	O
testing	NOUN	O	O
for	ADP	O	O
handling	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
,	PUNCT	O	O
extracellular	ADJ	O	O
ACh	PROPN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
elevated	ADJ	O	O
(	PUNCT	O	O
192%	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
WSP	PROPN	O	O
mice	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
was	VERB	O	O
nonsignificantly	ADV	O	O
elevated	ADJ	O	O
(	PUNCT	O	O
59%	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
WSR	PROPN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
differences	NOUN	O	O
in	ADP	O	O
cholinergic	ADJ	O	O
activity	NOUN	O	O
and	CCONJ	O	O
postsynaptic	ADJ	O	O
sensitivity	NOUN	O	O
to	PART	O	O
cholinergic	VERB	O	O
convulsants	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
ethanol	NOUN	O	I-Entity
withdrawal	NOUN	O	O
severity	NOUN	O	O
and	CCONJ	O	O
implicate	VERB	O	O
cholinergic	ADJ	O	O
mechanisms	NOUN	O	O
in	ADP	O	O
alcohol	NOUN	O	I-Entity
withdrawal	NOUN	O	O
.	PUNCT	O	O

Using	VERB	O	O
the	DET	O	O
General	PROPN	O	O
Practice	PROPN	O	O
Research	PROPN	O	O
Database	PROPN	O	O
we	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
cohort	NOUN	O	O
analysis	NOUN	O	O
and	CCONJ	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
study	NOUN	O	O
nested	VERB	O	O
within	ADP	O	O
a	DET	O	O
population	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
aged	VERB	O	O
between	ADP	O	O
15	NUM	O	O
and	CCONJ	O	O
39	NUM	O	O
years	NOUN	O	O
with	ADP	O	O
acne	NOUN	O	I-Entity
,	PUNCT	O	O
hirsutism	NOUN	O	I-Entity
or	CCONJ	O	O
PCOS	PROPN	O	I-Entity
to	PART	O	O
estimate	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
CPA	PROPN	O	I-Entity
/	SYM	O	O
EE	PROPN	O	I-Entity
.	PUNCT	O	O

Using	VERB	O	O
as	ADP	O	O
the	DET	O	O
reference	NOUN	O	O
group	NOUN	O	O
women	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
using	VERB	O	O
oral	ADJ	O	O
contraception	NOUN	O	O
,	PUNCT	O	O
had	VERB	O	O
no	DET	O	O
recent	ADJ	O	O
pregnancy	NOUN	O	O
or	CCONJ	O	O
menopausal	NOUN	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
analysis	NOUN	O	O
gave	VERB	O	O
an	DET	O	O
adjusted	ADJ	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
(	PUNCT	O	O
OR(adj	PROPN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
of	ADP	O	O
7.44	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
3.67	NUM	O	O
-	SYM	O	O
15.08	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
CPA	PROPN	O	I-Entity
/	SYM	O	O
EE	PROPN	O	I-Entity
use	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
an	DET	O	O
OR(adj	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
2.58	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
1.60	NUM	O	O
-	SYM	O	O
4.18	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
conventional	ADJ	O	O
COCs	NOUN	O	O
.	PUNCT	O	O

:	PUNCT	O	O
We	PRON	O	O
have	VERB	O	O
demonstrated	VERB	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
CPA	PROPN	O	I-Entity
/	SYM	O	O
EE	PROPN	O	I-Entity
in	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
acne	NOUN	O	I-Entity
,	PUNCT	O	O
hirsutism	NOUN	O	I-Entity
or	CCONJ	O	O
PCOS	PROPN	O	I-Entity
although	ADP	O	O
residual	ADJ	O	O
confounding	NOUN	O	O
by	ADP	O	O
indication	NOUN	O	O
can	VERB	O	O
not	ADV	O	O
be	VERB	O	O
excluded	VERB	O	O
.	PUNCT	O	O

Acromegaly	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
endocrine	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
chronic	ADJ	O	O
excessive	ADJ	O	O
growth	NOUN	O	O
hormone	NOUN	O	O
secretion	NOUN	O	O
from	ADP	O	O
the	DET	O	O
anterior	ADJ	O	O
pituitary	ADJ	O	O
gland	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
determine	VERB	O	O
the	DET	O	O
onset	NOUN	O	O
and	CCONJ	O	O
extent	NOUN	O	O
of	ADP	O	O
combined	VERB	O	O
androgen	NOUN	O	O
blockade	NOUN	O	O
(	PUNCT	O	O
CAB)-induced	VERB	O	O
anemia	NOUN	O	I-Entity
in	ADP	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
without	ADP	O	O
bone	NOUN	O	O
involvement	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
CAB	PROPN	O	O
[	PUNCT	O	O
leuprolide	NOUN	O	B-Entity
acetate	NOUN	O	I-Entity
(	PUNCT	O	O
LHRH	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
A	PROPN	O	I-Entity
)	PUNCT	O	O
3.75	NUM	O	O
mg	NUM	O	O
,	PUNCT	O	O
intramuscularly	ADV	O	O
,	PUNCT	O	O
every	DET	O	O
28	NUM	O	O
days	NOUN	O	O
plus	CCONJ	O	O
250	NUM	O	O
mg	NUM	O	O
flutamide	NOUN	O	I-Entity
,	PUNCT	O	O
tid	NOUN	O	O
,	PUNCT	O	O
per	ADP	O	O
Os	NOUN	O	O
]	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
evaluated	VERB	O	O
for	ADP	O	O
anemia	NOUN	O	I-Entity
by	ADP	O	O
physical	ADJ	O	O
examination	NOUN	O	O
and	CCONJ	O	O
laboratory	NOUN	O	O
tests	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
4	NUM	O	O
subsequent	ADJ	O	O
intervals	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
months	NOUN	O	O
post	NOUN	O	O
-	PUNCT	O	O
CAB	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
CAB	PROPN	O	O
-	PUNCT	O	O
induced	VERB	O	O
anemia	NOUN	O	I-Entity
was	VERB	O	O
normochromic	ADJ	O	O
and	CCONJ	O	O
normocytic	ADJ	O	O
.	PUNCT	O	O

At	ADP	O	O
six	NUM	O	O
months	NOUN	O	O
post	NOUN	O	O
-	PUNCT	O	O
CAB	PROPN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
anemia	NOUN	O	I-Entity
had	VERB	O	O
a	DET	O	O
Hb	PROPN	O	O
mean	ADJ	O	O
value	NOUN	O	O
of	ADP	O	O
10.2	NUM	O	O
+	NOUN	O	O
/-	PUNCT	O	O


-DOCSTART- (14657095)

Risks	NOUN	O	O
of	ADP	O	O
the	DET	O	O
consumption	NOUN	O	O
of	ADP	O	O
beverages	NOUN	O	O
containing	VERB	O	O
quinine	NOUN	O	I-Entity
.	PUNCT	O	O

When	ADV	O	O
CPA	PROPN	O	I-Entity
,	PUNCT	O	O
diazepam	NOUN	O	I-Entity
or	CCONJ	O	O
2PAM	NOUN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
immediately	ADV	O	O
after	ADP	O	O
DFP	PROPN	O	I-Entity
-	PUNCT	O	O
atropine	NOUN	O	I-Entity
,	PUNCT	O	O
these	DET	O	O
treatments	NOUN	O	O
prevented	VERB	O	O
,	PUNCT	O	O
delayed	VERB	O	O
or	CCONJ	O	O
shortened	VERB	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
serious	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
poisoning	NOUN	O	I-Entity
.	PUNCT	O	O


Estrogen	NOUN	O	O
replacement	NOUN	O	O
(	PUNCT	O	O
17beta	NUM	O	B-Entity
-	PUNCT	O	I-Entity
estradiol	NOUN	O	I-Entity
subcutaneous	ADJ	O	O
pellet	NOUN	O	O
,	PUNCT	O	O
14.2	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
,	PUNCT	O	O
12	NUM	O	O
wk	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
Ovx	PROPN	O	O
rats	NOUN	O	O
restored	VERB	O	O
the	DET	O	O
hemodynamic	NOUN	O	O
and	CCONJ	O	O
locomotor	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methyldopa	NOUN	O	I-Entity
to	ADP	O	O
sham	VERB	O	O
-	PUNCT	O	O
operated	VERB	O	O
levels	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
estrogen	NOUN	O	I-Entity
downregulates	NOUN	O	O
alpha2-	X	O	O
but	CCONJ	O	O
not	ADV	O	O
I1-receptor	NUM	O	O
-	PUNCT	O	O
mediated	VERB	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
highlight	VERB	O	O
a	DET	O	O
role	NOUN	O	O
for	ADP	O	O
the	DET	O	O
cardiac	ADJ	O	O
autonomic	NOUN	O	O
control	NOUN	O	O
in	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methyldopa	NOUN	O	I-Entity
-	PUNCT	O	O
estrogen	NOUN	O	I-Entity
interaction	NOUN	O	O
.	PUNCT	O	O

Cardioprotective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
tincture	NOUN	O	B-Entity
of	ADP	O	I-Entity
Crataegus	PROPN	O	I-Entity
on	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Tincture	NOUN	O	B-Entity
of	ADP	O	I-Entity
Crataegus	PROPN	O	I-Entity
(	PUNCT	O	O
TCR	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
alcoholic	ADJ	O	B-Entity
extract	NOUN	O	I-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
berries	NOUN	O	I-Entity
of	ADP	O	I-Entity
hawthorn	NOUN	O	I-Entity
(	PUNCT	O	O
Crataegus	PROPN	O	B-Entity
oxycantha	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
is	VERB	O	O
used	VERB	O	O
in	ADP	O	O
herbal	ADJ	O	O
and	CCONJ	O	O
homeopathic	ADJ	O	O
medicine	NOUN	O	O
.	PUNCT	O	O

Pretreatment	NOUN	O	O
of	ADP	O	O
TCR	PROPN	O	I-Entity
,	PUNCT	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
0.5	NUM	O	O
mL/100	PROPN	O	O
g	INTJ	O	O
bodyweight	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
,	PUNCT	O	O
orally	ADV	O	O
for	ADP	O	O
30	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
prevented	VERB	O	O
the	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
lipid	ADJ	O	O
peroxidation	NOUN	O	O
and	CCONJ	O	O
activity	NOUN	O	O
of	ADP	O	O
marker	NOUN	O	O
enzymes	NOUN	O	O
observed	VERB	O	O
in	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
rats	NOUN	O	O
(	PUNCT	O	O
85	NUM	O	O
mg	NUM	O	O
kg(-1	NOUN	O	O
)	PUNCT	O	O
s.	NOUN	O	O
c.	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
days	NOUN	O	O
at	ADP	O	O
an	DET	O	O
interval	NOUN	O	O
of	ADP	O	O
24	NUM	O	O
h	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

-DOCSTART- (15458908)

Safety	NOUN	O	O
and	CCONJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
raloxifene	NOUN	O	I-Entity
:	PUNCT	O	O
multiple	ADJ	O	O
outcomes	NOUN	O	O
of	ADP	O	O
raloxifene	ADJ	O	I-Entity
evaluation	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
examine	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
raloxifene	NOUN	O	I-Entity
on	ADP	O	O
major	ADJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
that	ADJ	O	O
occur	VERB	O	O
with	ADP	O	O
postmenopausal	NOUN	O	O
estrogen	NOUN	O	I-Entity
therapy	NOUN	O	O
or	CCONJ	O	O
tamoxifen	NOUN	O	I-Entity
.	PUNCT	O	O

Women	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
raloxifene	VERB	O	I-Entity
60	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
d	NOUN	O	O
or	CCONJ	O	O
120	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
d	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
support	VERB	O	O
the	DET	O	O
important	ADJ	O	O
potential	NOUN	O	O
of	ADP	O	O
GNC92H2	PROPN	O	I-Entity
as	ADP	O	O
a	DET	O	O
therapeutic	ADJ	O	O
tool	NOUN	O	O
against	ADP	O	O
cocaine	NOUN	O	B-Entity
overdose	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
postulate	VERB	O	O
that	DET	O	O
by	ADP	O	O
virtue	NOUN	O	O
of	ADP	O	O
its	ADJ	O	O
direct	ADJ	O	O
blocking	VERB	O	O
action	NOUN	O	O
on	ADP	O	O
IKr	PROPN	O	O
,	PUNCT	O	O
ketoconazole	NOUN	O	I-Entity
alone	ADV	O	O
may	VERB	O	O
prolong	VERB	O	O
QT	PROPN	O	O
interval	NOUN	O	O
and	CCONJ	O	O
induce	VERB	O	O
TdP.	PROPN	O	I-Entity

This	DET	O	O
calls	VERB	O	O
for	ADP	O	O
attention	NOUN	O	O
when	ADV	O	O
ketoconazole	NOUN	O	I-Entity
is	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
acquired	VERB	O	O
long	ADJ	O	B-Entity
QT	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (16755009)

kg	INTJ	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
diazepam	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O


High	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
testosterone	NOUN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
atherosclerosis	NOUN	O	I-Entity
in	ADP	O	O
postmenopausal	NOUN	O	O
women	NOUN	O	O
.	PUNCT	O	O


Sirolimus	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
proteinuria	NOUN	O	I-Entity
and	CCONJ	O	O
renal	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

Because	ADP	O	O
sirolimus	NOUN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
share	VERB	O	O
the	DET	O	O
vasomotor	NOUN	O	O
renal	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
exhibited	VERB	O	O
by	ADP	O	O
calcineurin	NOUN	O	O
inhibitors	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
has	VERB	O	O
been	VERB	O	O
designated	VERB	O	O
a	DET	O	O
'	PUNCT	O	O
non	ADJ	O	O
-	PUNCT	O	O
nephrotoxic	ADJ	O	I-Entity
drug	NOUN	O	O
'	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
clinical	ADJ	O	O
reports	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
,	PUNCT	O	O
under	ADP	O	O
some	DET	O	O
circumstances	NOUN	O	O
,	PUNCT	O	O
sirolimus	NOUN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
proteinuria	NOUN	O	I-Entity
and	CCONJ	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
sirolimus	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
proteinuria	NOUN	O	I-Entity
are	VERB	O	O
multifactorial	ADJ	O	O
and	CCONJ	O	O
may	VERB	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
glomerular	ADJ	O	O
capillary	ADJ	O	O
pressure	NOUN	O	O
following	VERB	O	O
calcineurin	NOUN	O	O
inhibitor	NOUN	O	O
withdrawal	NOUN	O	O
.	PUNCT	O	O

Statins	NOUN	O	I-Entity
can	VERB	O	O
cause	VERB	O	O
a	DET	O	O
necrotizing	NOUN	O	O
myopathy	NOUN	O	I-Entity
and	CCONJ	O	O
hyperCKaemia	NOUN	O	I-Entity
which	ADJ	O	O
is	VERB	O	O
reversible	ADJ	O	O
on	ADP	O	O
cessation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
had	VERB	O	O
myofibre	ADJ	O	O
necrosis	NOUN	O	I-Entity
but	CCONJ	O	O
only	ADV	O	O
3	NUM	O	O
had	VERB	O	O
an	DET	O	O
inflammatory	ADJ	O	O
infiltrate	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
observations	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
statins	NOUN	O	I-Entity
may	VERB	O	O
initiate	VERB	O	O
an	DET	O	O
immune	ADJ	O	O
-	PUNCT	O	O
mediated	VERB	O	O
myopathy	NOUN	O	I-Entity
that	ADJ	O	O
persists	VERB	O	O
after	ADP	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
and	CCONJ	O	O
responds	VERB	O	O
to	ADP	O	O
immunosuppressive	VERB	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Direct	ADJ	O	O
inhibition	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
hyperpolarization	NOUN	O	O
-	PUNCT	O	O
activated	VERB	O	O
cyclic	ADJ	O	B-Entity
nucleotide	ADV	O	I-Entity
-	PUNCT	O	O
gated	ADJ	O	O
pacemaker	NOUN	O	O
channels	NOUN	O	O
by	ADP	O	O
clonidine	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
neonatal	ADJ	O	O
screening	NOUN	O	O
for	ADP	O	O
hearing	VERB	O	B-Entity
impairment	NOUN	O	I-Entity
and	CCONJ	O	O
involved	VERB	O	O
both	DET	O	O
ears	NOUN	O	O
of	ADP	O	O
200	NUM	O	O
newborns	NOUN	O	O
.	PUNCT	O	O

Further	ADJ	O	O
studies	NOUN	O	O
are	VERB	O	O
needed	VERB	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
establish	VERB	O	O
a	DET	O	O
potential	ADJ	O	O
negative	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
maternal	ADJ	O	O
smoking	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
neonate	NOUN	O	O
's	PART	O	O
hearing	NOUN	O	O
acuity	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17400887)

Terbutaline	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
beta2-adrenoceptor	NOUN	O	O
agonist	NOUN	O	O
used	VERB	O	O
to	PART	O	O
arrest	VERB	O	O
preterm	NOUN	O	B-Entity
labor	NOUN	O	I-Entity
,	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
concordance	NOUN	O	O
for	ADP	O	O
autism	NOUN	O	I-Entity
in	ADP	O	O
dizygotic	ADJ	O	O
twins	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
behavioral	ADJ	O	O
tests	NOUN	O	O
,	PUNCT	O	O
animals	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
terbutaline	NOUN	O	I-Entity
on	ADP	O	O
PN	PROPN	O	O
2	NUM	O	O
to	ADP	O	O
5	NUM	O	O
showed	VERB	O	O
consistent	ADJ	O	O
patterns	NOUN	O	O
of	ADP	O	O
hyper	ADJ	O	O
-	PUNCT	O	O
reactivity	NOUN	O	O
to	PART	O	O
novelty	NOUN	O	O
and	CCONJ	O	O
aversive	ADJ	O	O
stimuli	NOUN	O	O
when	ADV	O	O
assessed	VERB	O	O
in	ADP	O	O
a	DET	O	O
novel	NOUN	O	O
open	ADJ	O	O
field	NOUN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
in	ADP	O	O
the	DET	O	O
acoustic	ADJ	O	O
startle	NOUN	O	O
response	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
20-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
male	NOUN	O	O
with	ADP	O	O
schizophrenia	NOUN	O	I-Entity
developed	VERB	O	O
a	DET	O	O
sudden	ADJ	O	O
onset	NOUN	O	O
of	ADP	O	O
myocarditis	NOUN	O	I-Entity
after	ADP	O	O
commencement	NOUN	O	O
of	ADP	O	O
clozapine	NOUN	O	I-Entity
.	PUNCT	O	O


BACKGROUND	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
report	VERB	O	O
on	ADP	O	O
the	DET	O	O
manifestation	NOUN	O	O
of	ADP	O	O
a	DET	O	O
levetiracetam	NOUN	O	I-Entity
(	PUNCT	O	O
LEV)-induced	VERB	O	I-Entity
encephalopathy	NOUN	O	I-Entity
.	PUNCT	O	O


:	PUNCT	O	O
In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
evaluated	VERB	O	O
the	DET	O	O
performance	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
beta	NOUN	O	O
-	PUNCT	O	O
hydroxylase	NOUN	O	O
knockout	NOUN	O	O
(	PUNCT	O	O
Dbh	PROPN	O	O
-/-	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
lack	VERB	O	O
norepinephrine	NOUN	O	I-Entity
(	PUNCT	O	O
NE	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
elevated	ADJ	O	O
plus	CCONJ	O	O
maze	NOUN	O	O
(	PUNCT	O	O
EPM	PROPN	O	O
)	PUNCT	O	O
to	PART	O	O
examine	VERB	O	O
the	DET	O	O
contribution	NOUN	O	O
of	ADP	O	O
noradrenergic	ADJ	O	O
signaling	VERB	O	O
to	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
anxiety	NOUN	O	I-Entity
.	PUNCT	O	O

Cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
anxiety	NOUN	O	I-Entity
was	VERB	O	O
also	ADV	O	O
attenuated	VERB	O	O
in	ADP	O	O
Dbh	PROPN	O	O
+	SYM	O	O
/-	PUNCT	O	O

mice	NOUN	O	O
following	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
disulfiram	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
dopamine	NOUN	O	I-Entity
beta	NOUN	O	O
-	PUNCT	O	O
hydroxylase	NOUN	O	O
(	PUNCT	O	O
DBH	PROPN	O	O
)	PUNCT	O	O
inhibitor	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
experiments	NOUN	O	O
using	VERB	O	O
specific	ADJ	O	O
adrenergic	ADJ	O	O
antagonists	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
found	VERB	O	O
that	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
the	DET	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenergic	ADJ	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
propranolol	NOUN	O	I-Entity
blocked	VERB	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
anxiety	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
behavior	NOUN	O	O
in	ADP	O	O
Dbh	PROPN	O	O
+	SYM	O	O
/-	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
more	ADJ	O	O
incidents	NOUN	O	O
of	ADP	O	O
bradycardia	NOUN	O	I-Entity
in	ADP	O	O
subjects	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
clonidine	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
those	DET	O	O
not	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
clonidine	NOUN	O	I-Entity
(	PUNCT	O	O
17.5%	NUM	O	O
versus	ADP	O	O
3.4%	NUM	O	O
;	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.02	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
no	DET	O	O
other	ADJ	O	O
significant	ADJ	O	O
group	NOUN	O	O
differences	NOUN	O	O
regarding	VERB	O	O
electrocardiogram	NOUN	O	O
and	CCONJ	O	O
other	ADJ	O	O
cardiovascular	ADJ	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18996674)

Intracavernous	ADJ	O	O
epinephrine	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
minimally	ADV	O	O
invasive	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
priapism	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
department	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
45-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
admitted	VERB	O	O
frequent	ADJ	O	O
cocaine	NOUN	O	I-Entity
user	NOUN	O	O
,	PUNCT	O	O
presented	VERB	O	O
to	ADP	O	O
the	DET	O	O
Emergency	PROPN	O	O
Department	PROPN	O	O
(	PUNCT	O	O
ED	PROPN	O	O
)	PUNCT	O	O
on	ADP	O	O
two	NUM	O	O
separate	ADJ	O	O
occasions	NOUN	O	O
with	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
priapism	NOUN	O	I-Entity
after	ADP	O	O
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
indicate	VERB	O	O
the	DET	O	O
synergistic	ADJ	O	O
protective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
green	ADJ	O	B-Entity
tea	NOUN	O	I-Entity
and	CCONJ	O	O
vitamin	NOUN	O	B-Entity
E	NOUN	O	I-Entity
during	ADP	O	O
ISO	PROPN	O	I-Entity
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Development	NOUN	O	O
of	ADP	O	O
ocular	ADJ	O	B-Entity
myasthenia	NOUN	O	I-Entity
during	ADP	O	O
pegylated	ADJ	O	B-Entity
interferon	NOUN	O	I-Entity
and	CCONJ	O	O
ribavirin	NOUN	O	I-Entity
treatment	NOUN	O	O
for	ADP	O	O
chronic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
C.	PROPN	O	I-Entity

A	DET	O	O
63-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
male	ADJ	O	O
experienced	ADJ	O	O
sudden	ADJ	O	O
diplopia	NOUN	O	I-Entity
after	ADP	O	O
9	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
pegylated	ADJ	O	B-Entity
interferon	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
IFN	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
alpha-2b	X	O	I-Entity
and	CCONJ	O	O
ribavirin	VERB	O	I-Entity
for	ADP	O	O
chronic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
C	PROPN	O	I-Entity
(	PUNCT	O	O
CHC	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Ophthalmologic	ADJ	O	O
examinations	NOUN	O	O
showed	VERB	O	O
ptosis	NOUN	O	B-Entity
on	ADP	O	I-Entity
the	DET	O	I-Entity
right	ADJ	O	I-Entity
upper	ADJ	O	I-Entity
lid	NOUN	O	I-Entity
and	CCONJ	O	O
restricted	VERB	O	B-Entity
right	ADJ	O	I-Entity
eye	NOUN	O	I-Entity
movement	NOUN	O	I-Entity
without	ADP	O	O
any	DET	O	O
other	ADJ	O	O
neurological	ADJ	O	O
signs	NOUN	O	O
.	PUNCT	O	O


blocked	VERB	O	O
hyperactivity	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
the	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
competitive	ADJ	O	O
NMDA	PROPN	O	I-Entity
receptor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
MK-801	PROPN	O	I-Entity
and	CCONJ	O	O
partially	ADV	O	O
reversed	VERB	O	O
spontaneous	ADJ	O	O
hyperactivity	NOUN	O	I-Entity
of	ADP	O	O
NMDA	PROPN	O	I-Entity
Nr1(neo-/-	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
unlike	ADP	O	O
these	DET	O	O
latter	ADJ	O	O
,	PUNCT	O	O
SSR103800	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
produce	VERB	O	O
catalepsy	NOUN	O	I-Entity
(	PUNCT	O	O
retention	NOUN	O	O
on	ADP	O	O
the	DET	O	O
bar	NOUN	O	O
test	NOUN	O	O
)	PUNCT	O	O
up	ADV	O	O
to	ADP	O	O
30	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
p.o	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (19957053)

Current	ADJ	O	O
animal	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
obsessive	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
compulsive	ADJ	O	I-Entity
disorder	NOUN	O	I-Entity
(	PUNCT	O	O
OCD	PROPN	O	I-Entity
)	PUNCT	O	O
typically	ADV	O	O
involve	VERB	O	O
acute	ADJ	O	O
,	PUNCT	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
symptom	NOUN	O	O
provocation	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
genetic	ADJ	O	O
association	NOUN	O	O
with	ADP	O	O
stereotypies	NOUN	O	O
or	CCONJ	O	O
anxiety	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (891050)

A	DET	O	O
reproducible	ADJ	O	O
model	NOUN	O	O
for	ADP	O	O
producing	VERB	O	O
diffuse	NOUN	O	O
myocardial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
(	PUNCT	O	O
epinephrine	ADJ	O	I-Entity
infusion	NOUN	O	O
)	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
developed	VERB	O	O
to	PART	O	O
study	VERB	O	O
the	DET	O	O
cardioprotective	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
agents	NOUN	O	O
or	CCONJ	O	O
maneuvers	NOUN	O	O
which	ADJ	O	O
might	VERB	O	O
alter	VERB	O	O
the	DET	O	O
evolution	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

Infusions	NOUN	O	O
of	ADP	O	O
epinephrine	NOUN	O	I-Entity
(	PUNCT	O	O
4	NUM	O	O
mug	NOUN	O	O
per	ADP	O	O
kilogram	NOUN	O	O
per	ADP	O	O
minute	NOUN	O	O
for	ADP	O	O
6	NUM	O	O
hours	NOUN	O	O
)	PUNCT	O	O
increased	VERB	O	O
radiocalcium	NOUN	O	I-Entity
uptakes	NOUN	O	O
into	ADP	O	O
intact	ADJ	O	O
myocardium	NOUN	O	O
and	CCONJ	O	O
each	DET	O	O
of	ADP	O	O
its	ADJ	O	O
subcellular	ADJ	O	O
components	NOUN	O	O
with	ADP	O	O
the	DET	O	O
mitochondrial	ADJ	O	O
fraction	NOUN	O	O
showing	VERB	O	O
the	DET	O	O
most	ADV	O	O
consistent	ADJ	O	O
changes	NOUN	O	O
when	ADV	O	O
compared	VERB	O	O
to	ADP	O	O
saline	NOUN	O	O
-	PUNCT	O	O
infused	VERB	O	O
control	NOUN	O	O
animals	NOUN	O	O
(	PUNCT	O	O
4,957	NUM	O	O
vs.	ADP	O	O
827	NUM	O	O
counts	NOUN	O	O
per	ADP	O	O
minute	NOUN	O	O
per	ADP	O	O
gram	NOUN	O	O
of	ADP	O	O
dried	VERB	O	O
tissue	NOUN	O	O
or	CCONJ	O	O
fraction	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Myocardial	ADJ	O	O
concentrations	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	I-Entity
also	ADV	O	O
increased	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
12.0	NUM	O	O
vs.	NOUN	O	O
5.0	NUM	O	O
mg.per	NOUN	O	O
100	NUM	O	O
Gm	PROPN	O	O
.	PUNCT	O	O

Infusions	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
sufficient	ADJ	O	O
to	PART	O	O
raise	VERB	O	O
serum	NOUN	O	O
calcium	NOUN	O	I-Entity
concentrations	NOUN	O	O
2	NUM	O	O
mEq	PROPN	O	O
.	PUNCT	O	O

per	ADP	O	O
liter	NOUN	O	O
failed	VERB	O	O
to	PART	O	O
increase	VERB	O	O
calcium	NOUN	O	I-Entity
influx	NOUN	O	O
into	ADP	O	O
the	DET	O	O
myocardial	ADJ	O	O
cell	NOUN	O	O
.	PUNCT	O	O

Depression	NOUN	O	I-Entity
and	CCONJ	O	O
sexual	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
related	VERB	O	O
to	ADP	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
topical	ADJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blockers	NOUN	O	O
.	PUNCT	O	O

Long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
of	ADP	O	O
ifosfamide	ADJ	O	I-Entity
renal	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
in	ADP	O	O
children	NOUN	O	O
treated	VERB	O	O
for	ADP	O	O
malignant	ADJ	O	B-Entity
mesenchymal	ADJ	O	I-Entity
tumors	NOUN	O	I-Entity
:	PUNCT	O	O
an	DET	O	O
International	PROPN	O	O
Society	PROPN	O	O
of	ADP	O	O
Pediatric	PROPN	O	O
Oncology	PROPN	O	O
report	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
common	ADJ	O	O
primary	ADJ	O	O
tumor	NOUN	O	I-Entity
site	NOUN	O	O
was	VERB	O	O
the	DET	O	O
head	NOUN	O	O
and	CCONJ	O	O
neck	NOUN	O	O
.	PUNCT	O	O

Renal	ADJ	O	O
function	NOUN	O	O
was	VERB	O	O
investigated	VERB	O	O
by	ADP	O	O
measuring	VERB	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
urinary	ADJ	O	O
electrolytes	NOUN	O	O
,	PUNCT	O	O
glucosuria	NOUN	O	I-Entity
,	PUNCT	O	O
proteinuria	NOUN	O	I-Entity
,	PUNCT	O	O
aminoaciduria	NOUN	O	I-Entity
,	PUNCT	O	O
urinary	ADJ	O	O
pH	NOUN	O	O
,	PUNCT	O	O
osmolarity	NOUN	O	O
,	PUNCT	O	O
creatinine	NOUN	O	I-Entity
clearance	NOUN	O	O
,	PUNCT	O	O
phosphate	ADJ	O	I-Entity
tubular	ADJ	O	O
reabsorption	NOUN	O	O
,	PUNCT	O	O
beta	NOUN	O	O
2	NUM	O	O
microglobulinuria	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
lysozymuria	NOUN	O	O
.	PUNCT	O	O

the	DET	O	O
first	ADJ	O	O
included	VERB	O	O
four	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
5%	NUM	O	O
of	ADP	O	O
the	DET	O	O
total	ADJ	O	O
population	NOUN	O	O
)	PUNCT	O	O
who	NOUN	O	O
developed	VERB	O	O
major	ADJ	O	O
toxicity	NOUN	O	I-Entity
resulting	VERB	O	O
in	ADP	O	O
Fanconi	PROPN	O	B-Entity
's	PART	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
TDFS	PROPN	O	I-Entity
)	PUNCT	O	O
;	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
second	ADJ	O	O
group	NOUN	O	O
included	VERB	O	O
five	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
elevated	ADJ	O	O
beta	NOUN	O	O
2	NUM	O	O
microglobulinuria	NOUN	O	O
and	CCONJ	O	O
low	ADJ	O	O
phosphate	NOUN	O	I-Entity
reabsorption	NOUN	O	O
.	PUNCT	O	O

Severe	ADJ	O	O
toxicity	NOUN	O	I-Entity
was	VERB	O	O
correlated	VERB	O	O
with	ADP	O	O
the	DET	O	O
higher	ADJ	O	O
cumulative	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
60	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
m2	NOUN	O	O
of	ADP	O	O
ifosfamide	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
younger	ADJ	O	O
age	NOUN	O	O
(	PUNCT	O	O
less	ADJ	O	O
than	ADP	O	O
2	NUM	O	O
1/2	NUM	O	O
years	NOUN	O	O
old	ADJ	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
predominance	NOUN	O	O
of	ADP	O	O
vesicoprostatic	ADJ	O	O
tumor	NOUN	O	I-Entity
involvement	NOUN	O	O
.	PUNCT	O	O


Previous	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
repeated	VERB	O	O
exposure	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
to	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
or	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
environment	NOUN	O	O
is	VERB	O	O
necessary	ADJ	O	O
to	PART	O	O
observe	VERB	O	O
nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
locomotor	NOUN	O	O
stimulation	NOUN	O	O
.	PUNCT	O	O

Nicotine	NOUN	O	I-Entity
(	PUNCT	O	O
1.0	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
caused	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	B-Entity
in	ADP	O	I-Entity
locomotor	NOUN	O	I-Entity
activity	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
that	ADJ	O	O
were	VERB	O	O
habituated	VERB	O	O
to	ADP	O	O
the	DET	O	O
test	NOUN	O	O
environment	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
had	VERB	O	O
only	ADV	O	O
a	DET	O	O
weak	ADJ	O	O
and	CCONJ	O	O
delayed	ADJ	O	O
stimulant	NOUN	O	O
action	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
that	ADJ	O	O
were	VERB	O	O
unfamiliar	ADJ	O	O
with	ADP	O	O
the	DET	O	O
test	NOUN	O	O
environment	NOUN	O	O
.	PUNCT	O	O

Nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
was	VERB	O	O
blocked	VERB	O	O
by	ADP	O	O
the	DET	O	O
selective	ADJ	O	O
D1	NOUN	O	O
antagonist	NOUN	O	O
SCH	PROPN	O	B-Entity
23390	NUM	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
selective	ADJ	O	O
D2	NOUN	O	O
antagonist	NOUN	O	O
raclopride	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
D1/D2	PROPN	O	O
antagonist	NOUN	O	O
fluphenazine	NOUN	O	I-Entity
.	PUNCT	O	O

Neuropsychiatric	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
after	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
mefloquine	NOUN	O	I-Entity
.	PUNCT	O	O

Reactions	NOUN	O	O
consisted	VERB	O	O
mainly	ADV	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
acute	ADJ	O	O
psychoses	NOUN	O	I-Entity
,	PUNCT	O	O
anxiety	NOUN	O	B-Entity
neurosis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
major	ADJ	O	O
disturbances	NOUN	O	B-Entity
of	ADP	O	I-Entity
sleep	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
wake	NOUN	O	I-Entity
rhythm	NOUN	O	I-Entity
.	PUNCT	O	O

Twenty	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
asked	VERB	O	O
to	PART	O	O
quantify	VERB	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	I-Entity
after	ADP	O	O
receiving	VERB	O	O
standard	ADJ	O	O
lidocaine	NOUN	O	I-Entity
in	ADP	O	O
one	NUM	O	O
femoral	ADJ	O	O
area	NOUN	O	O
and	CCONJ	O	O
buffered	VERB	O	O
lidocaine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
opposite	ADJ	O	O
femoral	ADJ	O	O
area	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
pH	PROPN	O	O
adjustment	NOUN	O	O
of	ADP	O	O
standard	ADJ	O	O
lidocaine	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
accomplished	VERB	O	O
easily	ADV	O	O
in	ADP	O	O
the	DET	O	O
catheterization	NOUN	O	O
laboratory	NOUN	O	O
before	ADP	O	O
injection	NOUN	O	O
and	CCONJ	O	O
results	NOUN	O	O
in	ADP	O	O
a	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pain	NOUN	O	I-Entity
occurring	VERB	O	O
during	ADP	O	O
the	DET	O	O
infiltration	NOUN	O	O
of	ADP	O	O
tissues	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (2348231)

Dipyridamole	NOUN	O	I-Entity
significantly	ADV	O	O
increased	VERB	O	O
coronary	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
before	ADV	O	O
and	CCONJ	O	O
after	ADP	O	O
7.5	NUM	O	O
or	CCONJ	O	O
15	NUM	O	O
mm	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
pentoxyifylline	NOUN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
inhibit	VERB	O	O
dipyridamole	ADJ	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
coronary	ADJ	O	O
hyperemia	NOUN	O	I-Entity
even	ADV	O	O
at	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
leading	VERB	O	O
causes	NOUN	O	O
of	ADP	O	O
death	NOUN	O	I-Entity
were	VERB	O	O
pneumonia	NOUN	O	I-Entity
and	CCONJ	O	O
bronchitis	NOUN	O	I-Entity
(	PUNCT	O	O
44.1%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
malignant	ADJ	O	O
neoplasms	NOUN	O	I-Entity
(	PUNCT	O	O
11.6%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
heart	NOUN	O	B-Entity
diseases	NOUN	O	I-Entity
(	PUNCT	O	O
4.1%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
cerebral	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
(	PUNCT	O	O
3.7%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
septicaemia	NOUN	O	I-Entity
(	PUNCT	O	O
3.3%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Tolerance	NOUN	O	O
and	CCONJ	O	O
antiviral	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
ribavirin	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Argentine	ADJ	O	B-Entity
hemorrhagic	ADJ	O	I-Entity
fever	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
reversible	ADJ	O	O
anemia	NOUN	O	I-Entity
was	VERB	O	O
the	DET	O	O
only	ADJ	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
observed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
possible	ADJ	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
ribavirin	NOUN	O	I-Entity
during	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
days	NOUN	O	O
of	ADP	O	O
AHF	PROPN	O	I-Entity
is	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O

Angina	PROPN	O	I-Entity
and	CCONJ	O	O
ischemic	ADJ	O	O
electrocardiographic	ADJ	O	O
changes	NOUN	O	O
occurred	VERB	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
dipyridamole	NOUN	O	I-Entity
in	ADP	O	O
four	NUM	O	O
patients	NOUN	O	O
awaiting	VERB	O	O
urgent	ADJ	O	O
myocardial	ADJ	O	O
revascularization	NOUN	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

Epicardial	ADJ	O	O
coronary	ADJ	O	O
collateral	NOUN	O	O
vessels	NOUN	O	O
were	VERB	O	O
demonstrated	VERB	O	O
in	ADP	O	O
all	DET	O	O
four	NUM	O	O
patients	NOUN	O	O
;	PUNCT	O	O
a	DET	O	O
coronary	ADJ	O	O
"	PUNCT	O	O
steal	VERB	O	O
"	PUNCT	O	O
phenomenon	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
the	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dipyridamole	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ischemia	NOUN	O	I-Entity
observed	VERB	O	O
.	PUNCT	O	O

-DOCSTART- (3015567)

Portal	ADJ	O	O
plasma	NOUN	O	O
concentrations	NOUN	O	O
of	ADP	O	O
neither	DET	O	O
arginine	NOUN	O	B-Entity
vasopressin	NOUN	O	I-Entity
nor	CCONJ	O	O
oxytocin	NOUN	O	I-Entity
are	VERB	O	O
significantly	ADV	O	O
altered	VERB	O	O
in	ADP	O	O
this	DET	O	O
paradigm	NOUN	O	O
.	PUNCT	O	O

Resting	VERB	O	O
irCRF	PROPN	O	O
levels	NOUN	O	O
are	VERB	O	O
suppressed	VERB	O	O
only	ADV	O	O
at	ADP	O	O
the	DET	O	O
highest	ADJ	O	O
corticosterone	NOUN	O	I-Entity
infusion	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
resulted	VERB	O	O
in	ADP	O	O
systemic	ADJ	O	O
corticosterone	NOUN	O	I-Entity
levels	NOUN	O	O
of	ADP	O	O
40	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
dl	NOUN	O	O
.	PUNCT	O	O

Ten	NUM	O	O
rats	NOUN	O	O
had	VERB	O	O
arterial	ADJ	O	O
,	PUNCT	O	O
central	ADJ	O	O
venous	ADJ	O	O
(	PUNCT	O	O
CVP	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
subdural	ADJ	O	O
cannulae	NOUN	O	O
inserted	VERB	O	O
under	ADP	O	O
halothane	NOUN	O	I-Entity
anesthesia	NOUN	O	O
.	PUNCT	O	O

Following	VERB	O	O
instrumentation	NOUN	O	O
,	PUNCT	O	O
halothane	NOUN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
and	CCONJ	O	O
alfentanil	NOUN	O	I-Entity
(	PUNCT	O	O
125	NUM	O	O
mu	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
administered	VERB	O	O
iv	NOUN	O	O
during	ADP	O	O
emergence	NOUN	O	O
from	ADP	O	O
halothane	NOUN	O	I-Entity
anesthesia	NOUN	O	O
.	PUNCT	O	O


Adverse	ADJ	O	O
cardiac	ADJ	O	O
effects	NOUN	O	O
during	ADP	O	O
induction	NOUN	O	O
chemotherapy	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
cis	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
platin	NOUN	O	I-Entity
and	CCONJ	O	O
5-fluorouracil	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
common	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
cardiotoxicity	NOUN	O	I-Entity
were	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
,	PUNCT	O	O
ST	PROPN	O	O
-	PUNCT	O	O
T	PROPN	O	O
wave	NOUN	O	O
changes	NOUN	O	O
and	CCONJ	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
patients	NOUN	O	O
on	ADP	O	O
5-FU	NUM	O	I-Entity
treatment	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
under	ADP	O	O
close	ADJ	O	O
supervision	NOUN	O	O
and	CCONJ	O	O
that	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
discontinued	VERB	O	O
if	ADP	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
or	CCONJ	O	O
tachyarrhythmia	NOUN	O	I-Entity
is	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (3503576)

Based	VERB	O	O
on	ADP	O	O
these	DET	O	O
data	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
plan	NOUN	O	O
of	ADP	O	O
management	NOUN	O	O
was	VERB	O	O
developed	VERB	O	O
that	ADJ	O	O
allows	VERB	O	O
effective	ADJ	O	O
yet	ADV	O	O
safe	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
deferoxamine	NOUN	O	I-Entity
.	PUNCT	O	O

With	ADP	O	O
mild	ADJ	O	O
toxicity	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
reduction	NOUN	O	O
to	ADP	O	O
30	NUM	O	O
or	CCONJ	O	O
40	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
per	ADP	O	O
dose	NOUN	O	O
should	VERB	O	O
result	VERB	O	O
in	ADP	O	O
a	DET	O	O
reversal	NOUN	O	O
of	ADP	O	O
the	DET	O	O
abnormal	ADJ	O	O
results	NOUN	O	O
to	ADP	O	O
normal	ADJ	O	O
within	ADP	O	O
four	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
patient	NOUN	O	O
was	VERB	O	O
prematurely	ADV	O	O
discontinued	VERB	O	O
from	ADP	O	O
the	DET	O	O
study	NOUN	O	O
for	ADP	O	O
severe	ADJ	O	O
headache	NOUN	O	I-Entity
and	CCONJ	O	O
abdominal	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (3714122)

These	DET	O	O
data	NOUN	O	O
were	VERB	O	O
correlated	VERB	O	O
with	ADP	O	O
histologically	ADV	O	O
scored	VERB	O	O
cervical	ADJ	O	O
cord	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
separate	ADJ	O	O
group	NOUN	O	O
of	ADP	O	O
similarly	ADV	O	O
dosed	VERB	O	O
rats	NOUN	O	O
sampled	VERB	O	O
14	NUM	O	O
-	SYM	O	O
21	NUM	O	O
days	NOUN	O	O
post	ADV	O	O
-	PUNCT	O	O
exposure	NOUN	O	O
.	PUNCT	O	O

Cerebral	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
with	ADP	O	O
a	DET	O	O
single	ADJ	O	O
oral	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
phenylpropanolamine	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
young	ADJ	O	O
woman	NOUN	O	O
who	NOUN	O	O
suffered	VERB	O	O
a	DET	O	O
cerebral	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
after	ADP	O	O
taking	VERB	O	O
a	DET	O	O
single	ADJ	O	O
oral	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
PPA	PROPN	O	I-Entity
.	PUNCT	O	O

Liver	ADJ	O	O
biopsies	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
undertaken	VERB	O	O
at	ADP	O	O
regular	ADJ	O	O
intervals	NOUN	O	O
if	ADP	O	O
azathioprine	NOUN	O	I-Entity
therapy	NOUN	O	O
is	VERB	O	O
continued	VERB	O	O
so	ADP	O	O
that	ADP	O	O
structural	ADJ	O	O
liver	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
detected	VERB	O	O
at	ADP	O	O
an	DET	O	O
early	ADJ	O	O
and	CCONJ	O	O
reversible	ADJ	O	O
stage	NOUN	O	O
.	PUNCT	O	O

Ebstein	PROPN	O	B-Entity
's	PART	O	I-Entity
anomaly	NOUN	O	I-Entity
:	PUNCT	O	O
evaluation	NOUN	O	O
with	ADP	O	O
cross	NOUN	O	O
-	PUNCT	O	O
sectional	ADJ	O	O
echocardiography	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
other	ADJ	O	O
infant	NOUN	O	O
cross	NOUN	O	O
-	PUNCT	O	O
sectional	ADJ	O	O
echocardiography	NOUN	O	O
provided	VERB	O	O
reassurance	NOUN	O	O
that	ADP	O	O
the	DET	O	O
infant	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
have	VERB	O	O
Ebstein	PROPN	O	B-Entity
's	PART	O	I-Entity
anomaly	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
infarcts	NOUN	O	I-Entity
were	VERB	O	O
confirmed	VERB	O	O
by	ADP	O	O
histological	ADJ	O	O
methods	NOUN	O	O
.	PUNCT	O	O

Elevations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
serum	NOUN	O	O
GOT	PROPN	O	O
and	CCONJ	O	O
GPT	PROPN	O	O
were	VERB	O	O
maximum	ADJ	O	O
in	ADP	O	O
the	DET	O	O
sedentary	ADJ	O	O
-	PUNCT	O	O
isoproterenols	NOUN	O	I-Entity
and	CCONJ	O	O
minimum	NOUN	O	O
in	ADP	O	O
the	DET	O	O
exercise	NOUN	O	O
-	PUNCT	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
polyethylene	NOUN	O	B-Entity
glycol	NOUN	O	I-Entity
400	NUM	O	I-Entity
on	ADP	O	O
adriamycin	ADJ	O	I-Entity
toxicity	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
four	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
recurrent	ADJ	O	O
Grade	PROPN	O	O
I	PRON	O	O
to	ADP	O	O
IV	PROPN	O	O
astrocytomas	NOUN	O	I-Entity
,	PUNCT	O	O
whose	ADJ	O	O
resection	NOUN	O	O
and	CCONJ	O	O
irradiation	NOUN	O	O
therapy	NOUN	O	O
had	VERB	O	O
failed	VERB	O	O
,	PUNCT	O	O
received	VERB	O	O
two	NUM	O	O
to	PART	O	O
eight	NUM	O	O
courses	NOUN	O	O
of	ADP	O	O
intra	NOUN	O	O
-	PUNCT	O	O
arterial	NOUN	O	O
BCNU	PROPN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Sodium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
solution	NOUN	O	O
(	PUNCT	O	O
0.9%	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O

In	ADP	O	O
35	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
ages	NOUN	O	O
20	NUM	O	O
to	PART	O	O
86	NUM	O	O
yr	INTJ	O	O
)	PUNCT	O	O
receiving	VERB	O	O
cimetidine	NOUN	O	I-Entity
therapeutically	ADV	O	O
two	NUM	O	O
serum	NOUN	O	O
samples	NOUN	O	O
and	CCONJ	O	O
all	DET	O	O
urine	NOUN	O	O
formed	VERB	O	O
in	ADP	O	O
the	DET	O	O
interim	ADJ	O	O
were	VERB	O	O
collected	VERB	O	O
for	ADP	O	O
analysis	NOUN	O	O
of	ADP	O	O
cimetidine	NOUN	O	I-Entity
by	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
pressure	NOUN	O	O
liquid	NOUN	O	O
chromatography	NOUN	O	O
and	CCONJ	O	O
for	ADP	O	O
creatinine	NOUN	O	I-Entity
.	PUNCT	O	O

Rc	PROPN	O	O
seemed	VERB	O	O
to	PART	O	O
be	VERB	O	O
independent	ADJ	O	O
of	ADP	O	O
age	NOUN	O	O
and	CCONJ	O	O
decreased	VERB	O	O
with	ADP	O	O
increasing	VERB	O	O
serum	NOUN	O	O
concentration	NOUN	O	O
of	ADP	O	O
cimetidine	NOUN	O	I-Entity
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
secretion	NOUN	O	O
of	ADP	O	O
cimetidine	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
saturable	ADJ	O	O
process	NOUN	O	O
.	PUNCT	O	O

hr	NOUN	O	O
after	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
13	NUM	O	O
patients	NOUN	O	O
without	ADP	O	O
liver	NOUN	O	B-Entity
or	CCONJ	O	I-Entity
kidney	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
who	NOUN	O	O
had	VERB	O	O
cimetidine	NOUN	O	I-Entity
levels	NOUN	O	O
above	ADP	O	O
1.25	NUM	O	O
microgram	NOUN	O	O
/	SYM	O	O
ml	ADV	O	O
.	PUNCT	O	O


Phenobarbitone	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
enlargement	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
liver	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
:	PUNCT	O	O
its	ADJ	O	O
relationship	NOUN	O	O
to	ADP	O	O
carbon	NOUN	O	B-Entity
tetrachloride	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cirrhosis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
amiloride	NOUN	O	I-Entity
on	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
polydipsia	NOUN	O	I-Entity
and	CCONJ	O	O
polyuria	NOUN	O	I-Entity
and	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
lithium	NOUN	O	I-Entity
concentration	NOUN	O	O
in	ADP	O	O
the	DET	O	O
plasma	NOUN	O	O
,	PUNCT	O	O
brain	NOUN	O	O
,	PUNCT	O	O
kidney	NOUN	O	O
,	PUNCT	O	O
thyroid	NOUN	O	O
and	CCONJ	O	O
red	ADJ	O	O
blood	NOUN	O	O
cells	NOUN	O	O
was	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
,	PUNCT	O	O
chronically	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
LiCl	PROPN	O	I-Entity
.	PUNCT	O	O

At	ADP	O	O
12	NUM	O	O
h	NOUN	O	O
,	PUNCT	O	O
all	ADJ	O	O
the	DET	O	O
tissues	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
slight	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
lithium	ADJ	O	I-Entity
levels	NOUN	O	O
.	PUNCT	O	O


Safety	NOUN	O	O
and	CCONJ	O	O
side	NOUN	O	O
-	PUNCT	O	O
effects	NOUN	O	O
of	ADP	O	O
alprazolam	NOUN	O	I-Entity
.	PUNCT	O	O

Controlled	ADJ	O	O
study	NOUN	O	O
in	ADP	O	O
agoraphobia	NOUN	O	I-Entity
with	ADP	O	O
panic	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
.	PUNCT	O	O

Sodium	NOUN	O	B-Entity
bicarbonate	NOUN	O	I-Entity
alleviates	VERB	O	O
penile	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
intracavernous	ADJ	O	O
injections	NOUN	O	O
for	ADP	O	O
erectile	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

papaverine	NOUN	O	I-Entity
,	PUNCT	O	O
100	NUM	O	O
micrograms	NOUN	O	O
.	PUNCT	O	O


In	ADP	O	O
8	NUM	O	O
patients	NOUN	O	O
followed	VERB	O	O
for	ADP	O	O
24	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
gallbladder	NOUN	O	O
contractility	NOUN	O	O
remained	VERB	O	O
depressed	ADJ	O	I-Entity
throughout	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Currently	ADV	O	O
accepted	VERB	O	O
intravitreal	NOUN	O	O
antibiotic	NOUN	O	O
regimens	NOUN	O	O
may	VERB	O	O
cause	VERB	O	O
retinal	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
and	CCONJ	O	O
macular	ADJ	O	O
ischaemia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9284778)

Epidemic	PROPN	O	O
of	ADP	O	O
liver	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
hydrochlorofluorocarbons	NOUN	O	I-Entity
used	VERB	O	O
as	ADP	O	O
ozone	NOUN	O	I-Entity
-	PUNCT	O	O
sparing	VERB	O	O
substitutes	NOUN	O	O
of	ADP	O	O
chlorofluorocarbons	NOUN	O	I-Entity
.	PUNCT	O	O

Limited	ADJ	O	O
studies	NOUN	O	O
in	ADP	O	O
animals	NOUN	O	O
indicate	VERB	O	O
potential	ADJ	O	O
hepatotoxicity	NOUN	O	I-Entity
of	ADP	O	O
some	DET	O	O
of	ADP	O	O
these	DET	O	O
compounds	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
For	ADP	O	O
one	NUM	O	O
severely	ADV	O	O
affected	VERB	O	O
worker	NOUN	O	O
liver	NOUN	O	O
biopsy	NOUN	O	O
and	CCONJ	O	O
immunohistochemical	ADJ	O	O
stainings	NOUN	O	O
for	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
trifluoroacetyl	DET	O	I-Entity
protein	NOUN	O	O
adducts	NOUN	O	O
were	VERB	O	O
done	VERB	O	O
.	PUNCT	O	O

Autoantibodies	NOUN	O	O
against	ADP	O	O
P450	PROPN	O	O
2E1	NUM	O	O
or	CCONJ	O	O
P58	PROPN	O	O
,	PUNCT	O	O
previously	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
halothane	NOUN	O	B-Entity
hepatitis	NOUN	O	I-Entity
,	PUNCT	O	O
were	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
the	DET	O	O
serum	NOUN	O	O
of	ADP	O	O
five	NUM	O	O
affected	VERB	O	O
workers	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (9522143)

The	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
after	ADP	O	O
spinal	ADJ	O	O
anaesthesia	NOUN	O	O
is	VERB	O	O
unknown	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
average	ADJ	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
for	ADP	O	O
speech	NOUN	O	O
frequencies	NOUN	O	O
was	VERB	O	O
about	ADV	O	O
10	NUM	O	O
dB	NOUN	O	O
after	ADP	O	O
prilocaine	NOUN	O	I-Entity
and	CCONJ	O	O
15	NUM	O	O
dB	NOUN	O	O
after	ADP	O	O
bupivacaine	NOUN	O	I-Entity
.	PUNCT	O	O


A	DET	O	O
transient	ADJ	O	O
neurological	ADJ	O	B-Entity
deficit	NOUN	O	I-Entity
following	VERB	O	O
intrathecal	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
1%	NUM	O	O
hyperbaric	ADJ	O	O
bupivacaine	NOUN	O	I-Entity
for	ADP	O	O
unilateral	ADJ	O	O
spinal	ADJ	O	O
anaesthesia	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
plasma	NOUN	O	O
pethidine	NOUN	O	I-Entity
and	CCONJ	O	O
norpethidine	NOUN	O	I-Entity
were	VERB	O	O
elevated	VERB	O	O
in	ADP	O	O
the	DET	O	O
range	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
clinical	ADJ	O	O
manifestations	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
excitation	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
method	NOUN	O	O
allowed	VERB	O	O
frequent	ADJ	O	O
self	NOUN	O	O
-	PUNCT	O	O
dosing	NOUN	O	O
of	ADP	O	O
pethidine	NOUN	O	I-Entity
at	ADP	O	O
short	ADJ	O	O
time	NOUN	O	O
intervals	NOUN	O	O
and	CCONJ	O	O
rapid	ADJ	O	O
accumulation	NOUN	O	O
of	ADP	O	O
pethidine	NOUN	O	I-Entity
and	CCONJ	O	O
norpethidine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
routine	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
pethidine	NOUN	O	I-Entity
via	ADP	O	O
PCA	PROPN	O	O
even	ADV	O	O
for	ADP	O	O
a	DET	O	O
brief	ADJ	O	O
postoperative	ADJ	O	O
analgesia	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
reconsidered	VERB	O	O
.	PUNCT	O	O

Drug	NOUN	O	O
-	PUNCT	O	O
associated	VERB	O	O
acute	ADJ	O	O
-	PUNCT	O	O
onset	NOUN	O	O
vanishing	VERB	O	B-Entity
bile	NOUN	O	I-Entity
duct	NOUN	O	I-Entity
and	CCONJ	O	O
Stevens	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Johnson	PROPN	O	I-Entity
syndromes	VERB	O	I-Entity
in	ADP	O	O
a	DET	O	O
child	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
documents	VERB	O	O
acute	ADJ	O	O
drug	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
vanishing	VERB	O	B-Entity
bile	NOUN	O	I-Entity
duct	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
pediatric	ADJ	O	O
age	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
suggests	VERB	O	O
shared	VERB	O	O
immune	ADJ	O	O
mechanisms	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
both	DET	O	O
Stevens	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Johnson	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
vanishing	VERB	O	B-Entity
bile	ADJ	O	I-Entity
duct	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

High	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
primary	ADJ	O	B-Entity
pulmonary	ADJ	O	I-Entity
hypertension	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
appetite	NOUN	O	B-Entity
suppressants	NOUN	O	I-Entity
in	ADP	O	O
Belgium	PROPN	O	O
.	PUNCT	O	O

Primary	ADJ	O	B-Entity
pulmonary	ADJ	O	I-Entity
hypertension	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
,	PUNCT	O	O
progressive	ADJ	O	O
and	CCONJ	O	O
incurable	ADJ	O	O
disease	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
has	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
intake	NOUN	O	O
of	ADP	O	O
appetite	NOUN	O	B-Entity
suppressant	ADJ	O	I-Entity
drugs	NOUN	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
-	PUNCT	O	O
five	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
primary	ADJ	O	B-Entity
pulmonary	ADJ	O	I-Entity
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
85	NUM	O	O
matched	VERB	O	O
controls	NOUN	O	O
were	VERB	O	O
recruited	VERB	O	O
over	ADP	O	O
32	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
1992	NUM	O	O
-	SYM	O	O
1994	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
Belgium	PROPN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
three	NUM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
previously	ADV	O	O
taken	VERB	O	O
appetite	NOUN	O	B-Entity
suppressants	NOUN	O	I-Entity
,	PUNCT	O	O
mainly	ADV	O	O
fenfluramines	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
only	ADV	O	O
5	NUM	O	O
of	ADP	O	O
the	DET	O	O
controls	NOUN	O	O
(	PUNCT	O	O
66	NUM	O	O
versus	NOUN	O	O
6%	NUM	O	O
,	PUNCT	O	O

Choreatiform	PROPN	O	B-Entity
hyperkinesias	NOUN	O	I-Entity
are	VERB	O	O
known	VERB	O	O
to	PART	O	O
be	VERB	O	O
occasional	ADJ	O	O
movement	NOUN	O	B-Entity
abnormalities	NOUN	O	I-Entity
during	ADP	O	O
intoxications	NOUN	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
but	CCONJ	O	O
not	ADV	O	O
opiates	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
work	NOUN	O	O
evaluates	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
TAM	PROPN	O	I-Entity
on	ADP	O	O
isolated	ADJ	O	O
human	ADJ	O	O
erythrocytes	NOUN	O	O
,	PUNCT	O	O
attempting	VERB	O	O
to	PART	O	O
identify	VERB	O	O
the	DET	O	O
underlying	VERB	O	O
mechanisms	NOUN	O	O
on	ADP	O	O
TAM	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
involvement	NOUN	O	O
of	ADP	O	O
biomembranes	NOUN	O	O
in	ADP	O	O
its	ADJ	O	O
cytostatic	ADJ	O	O
action	NOUN	O	O
mechanisms	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
further	ADV	O	O
evidenced	VERB	O	O
by	ADP	O	O
absence	NOUN	O	O
of	ADP	O	O
oxygen	NOUN	O	I-Entity
consumption	NOUN	O	O
and	CCONJ	O	O
hemoglobin	NOUN	O	O
oxidation	NOUN	O	O
both	CCONJ	O	O
determined	VERB	O	O
in	ADP	O	O
parallel	ADJ	O	O
with	ADP	O	O
TAM	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hemolysis	NOUN	O	I-Entity
.	PUNCT	O	O

Hemolysis	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
TAM	PROPN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
preceded	VERB	O	O
by	ADP	O	O
the	DET	O	O
leakage	NOUN	O	O
of	ADP	O	O
K(+	PROPN	O	I-Entity
)	PUNCT	O	O
from	ADP	O	O
the	DET	O	O
cells	NOUN	O	O
,	PUNCT	O	O
also	ADV	O	O
excluding	VERB	O	O
a	DET	O	O
colloid	NOUN	O	O
-	PUNCT	O	O
osmotic	ADJ	O	O
type	NOUN	O	O
mechanism	NOUN	O	O
of	ADP	O	O
hemolysis	NOUN	O	I-Entity
,	PUNCT	O	O
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
on	ADP	O	O
osmotic	ADJ	O	O
fragility	NOUN	O	O
curves	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
TAM	PROPN	O	I-Entity
induces	VERB	O	O
release	NOUN	O	O
of	ADP	O	O
peripheral	ADJ	O	O
proteins	NOUN	O	O
of	ADP	O	O
membrane	NOUN	O	O
-	PUNCT	O	O
cytoskeleton	NOUN	O	O
and	CCONJ	O	O
cytosol	NOUN	O	O
proteins	NOUN	O	O
essentially	ADV	O	O
bound	VERB	O	O
to	PART	O	O
band	VERB	O	O
3	NUM	O	O
.	PUNCT	O	O

These	DET	O	O
defects	NOUN	O	O
explain	VERB	O	O
the	DET	O	O
abnormal	ADJ	O	O
erythrocyte	NOUN	O	O
shape	NOUN	O	O
and	CCONJ	O	O
decreased	VERB	O	O
mechanical	ADJ	O	O
stability	NOUN	O	O
promoted	VERB	O	O
by	ADP	O	O
TAM	PROPN	O	I-Entity
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
since	ADP	O	O
membrane	NOUN	O	O
leakage	NOUN	O	O
is	VERB	O	O
a	DET	O	O
final	ADJ	O	O
stage	NOUN	O	O
of	ADP	O	O
cytotoxicity	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
disruption	NOUN	O	O
of	ADP	O	O
the	DET	O	O
structural	ADJ	O	O
characteristics	NOUN	O	O
of	ADP	O	O
biomembranes	NOUN	O	O
by	ADP	O	O
TAM	PROPN	O	I-Entity
may	VERB	O	O
contribute	VERB	O	O
to	ADP	O	O
the	DET	O	O
multiple	ADJ	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
its	ADJ	O	O
anticancer	NOUN	O	O
action	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10706004)

Changes	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	I-Entity
and	CCONJ	O	O
ATP	PROPN	O	I-Entity
affinities	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cardiac	NOUN	O	O
(	PUNCT	O	O
Na	PROPN	O	I-Entity
,	PUNCT	O	O
K)-ATPase	PROPN	O	I-Entity
during	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
deficient	ADJ	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O


It	PRON	O	O
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
that	ADP	O	O
bromocriptine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
tachycardia	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
persisted	VERB	O	O
after	ADP	O	O
adrenalectomy	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
(	PUNCT	O	O
i	PUNCT	O	O
)	PUNCT	O	O
mediated	VERB	O	O
by	ADP	O	O
central	ADJ	O	O
dopamine	NOUN	O	I-Entity
D2	PROPN	O	O
receptor	NOUN	O	O
activation	NOUN	O	O
and	CCONJ	O	O
(	PUNCT	O	O
ii	PUNCT	O	O
)	PUNCT	O	O
reduced	VERB	O	O
by	ADP	O	O
5-day	PROPN	O	O
isoproterenol	NOUN	O	I-Entity
pretreatment	NOUN	O	O
,	PUNCT	O	O
supporting	VERB	O	O
therefore	ADV	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
this	DET	O	O
effect	NOUN	O	O
is	VERB	O	O
dependent	ADJ	O	O
on	ADP	O	O
sympathetic	ADJ	O	O
outflow	NOUN	O	O
to	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
control	NOUN	O	O
rats	NOUN	O	O
,	PUNCT	O	O
intravenous	ADJ	O	O
bromocriptine	NOUN	O	I-Entity
(	PUNCT	O	O
150	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
induced	VERB	O	O
significant	ADJ	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
tachycardia	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (10737864)

adrenoceptor	NOUN	O	O
agonist	NOUN	O	O
,	PUNCT	O	O
clonidine	NOUN	O	I-Entity
.	PUNCT	O	O


It	PRON	O	O
tended	VERB	O	O
to	PART	O	O
reduce	VERB	O	O
VAS	PROPN	O	O
scores	NOUN	O	O
of	ADP	O	O
spontaneous	ADJ	O	O
pain	NOUN	O	I-Entity
but	CCONJ	O	O
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
evoked	VERB	O	O
pain	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
development	NOUN	O	O
of	ADP	O	O
thrombotic	ADJ	O	B-Entity
microangiopathy	NOUN	O	I-Entity
(	PUNCT	O	O
TMA	PROPN	O	I-Entity
)	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
cyclosporine	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
well	ADV	O	O
documented	VERB	O	O
.	PUNCT	O	O

As	ADP	O	O
a	DET	O	O
result	NOUN	O	O
,	PUNCT	O	O
switching	VERB	O	O
to	ADP	O	O
tacrolimus	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
viable	ADJ	O	O
therapeutic	ADJ	O	O
option	NOUN	O	O
in	ADP	O	O
the	DET	O	O
setting	NOUN	O	O
of	ADP	O	O
cyclosporine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
TMA	PROPN	O	I-Entity
.	PUNCT	O	O

Introduction	NOUN	O	O
of	ADP	O	O
tacrolimus	NOUN	O	I-Entity
as	ADP	O	O
an	DET	O	O
alternative	NOUN	O	O
immunosuppressive	ADJ	O	O
agent	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
the	DET	O	O
recurrence	NOUN	O	O
of	ADP	O	O
TMA	PROPN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
subsequent	ADJ	O	O
loss	NOUN	O	O
of	ADP	O	O
the	DET	O	O
renal	ADJ	O	O
allograft	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (11256525)

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
70-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
hypertensive	ADJ	O	I-Entity
man	NOUN	O	O
with	ADP	O	O
a	DET	O	O
solitary	ADJ	O	O
kidney	NOUN	O	O
and	CCONJ	O	O
chronic	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
insufficiency	NOUN	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
two	NUM	O	O
episodes	NOUN	O	O
of	ADP	O	O
transient	ADJ	O	O
anuria	NOUN	O	I-Entity
after	ADP	O	O
losartan	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

Surprisingly	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
first	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
50	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
losartan	NOUN	O	I-Entity
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
sudden	ADJ	O	O
anuria	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
lasted	VERB	O	O
eight	NUM	O	O
hours	NOUN	O	O
despite	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
furosemide	NOUN	O	I-Entity
and	CCONJ	O	O
amine	NOUN	O	I-Entity
infusion	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
week	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
by	ADP	O	O
mistake	NOUN	O	O
,	PUNCT	O	O
losartan	NOUN	O	I-Entity
was	VERB	O	O
prescribed	VERB	O	O
again	ADV	O	O
and	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
second	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
50	NUM	O	O
mg	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
developed	VERB	O	O
a	DET	O	O
second	ADJ	O	O
episode	NOUN	O	O
of	ADP	O	O
transient	ADJ	O	O
anuria	NOUN	O	I-Entity
lasting	VERB	O	O
10	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

Ultimately	ADV	O	O
,	PUNCT	O	O
an	DET	O	O
arteriography	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
70	NUM	O	O
-	PUNCT	O	O
80%	NUM	O	O
renal	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
stenosis	NOUN	O	I-Entity
.	PUNCT	O	O

Under	ADP	O	O
such	ADJ	O	O
conditions	NOUN	O	O
,	PUNCT	O	O
angiotensin	NOUN	O	B-Entity
II	PROPN	O	I-Entity
receptor	NOUN	O	O
blockade	NOUN	O	O
by	ADP	O	O
losartan	NOUN	O	I-Entity
probably	ADV	O	O
induced	VERB	O	O
a	DET	O	O
critical	ADJ	O	O
fall	NOUN	O	O
in	ADP	O	O
glomerular	ADJ	O	O
filtration	NOUN	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (11334364)

Additionally	ADV	O	O
,	PUNCT	O	O
this	DET	O	O
may	VERB	O	O
have	VERB	O	O
been	VERB	O	O
the	DET	O	O
first	ADJ	O	O
report	NOUN	O	O
on	ADP	O	O
AMI	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
apoptotic	ADJ	O	O
death	NOUN	O	O
in	ADP	O	O
the	DET	O	O
lung	NOUN	O	O
tissue	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (11642480)


We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
51-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
severe	ADJ	O	O
,	PUNCT	O	O
disabling	VERB	O	O
negative	ADJ	O	O
myoclonus	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
upper	ADJ	O	O
and	CCONJ	O	O
lower	ADJ	O	O
extremities	NOUN	O	O
after	ADP	O	O
the	DET	O	O
infusion	NOUN	O	O
of	ADP	O	O
ifosfamide	NOUN	O	I-Entity
for	ADP	O	O
plasmacytoma	NOUN	O	I-Entity
.	PUNCT	O	O

RATIONALE	NOUN	O	O
:	PUNCT	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
Vinyl	PROPN	O	I-Entity
GABA	PROPN	O	I-Entity
(	PUNCT	O	O
GVG	PROPN	O	I-Entity
)	PUNCT	O	O
irreversibly	ADV	O	O
inhibits	VERB	O	O
GABA	PROPN	O	I-Entity
-	PUNCT	O	O
transaminase	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
blood	NOUN	O	O
amounts	VERB	O	O
and	CCONJ	O	O
hematoma	NOUN	O	I-Entity
volumes	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
correlated	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
hematoma	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
0.014-unit	NUM	O	O
collagenase	NOUN	O	O
was	VERB	O	O
adequate	ADJ	O	O
to	PART	O	O
detect	VERB	O	O
ICH	PROPN	O	I-Entity
deterioration	NOUN	O	O
.	PUNCT	O	O


In	ADP	O	O
males	NOUN	O	O
,	PUNCT	O	O
estradiol	ADV	O	I-Entity
increased	VERB	O	O
the	DET	O	O
total	ADJ	O	O
damage	NOUN	O	O
score	NOUN	O	O
.	PUNCT	O	O


Delirium	NOUN	O	I-Entity
was	VERB	O	O
diagnosed	VERB	O	O
in	ADP	O	O
14	NUM	O	O
(	PUNCT	O	O
10.1	NUM	O	O
%	NOUN	O	O
incidence	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
1.48	NUM	O	O
cases	NOUN	O	O
/	SYM	O	O
person	NOUN	O	O
-	PUNCT	O	O
years	NOUN	O	O
of	ADP	O	O
exposure	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
71.4	NUM	O	O
%	NOUN	O	O
of	ADP	O	O
cases	NOUN	O	O
were	VERB	O	O
moderate	ADJ	O	O
or	CCONJ	O	O
severe	ADJ	O	O
.	PUNCT	O	O

Delirium	NOUN	O	I-Entity
was	VERB	O	O
inconsistently	ADV	O	O
recognized	VERB	O	O
clinically	ADV	O	O
in	ADP	O	O
milder	ADJ	O	O
cases	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
length	NOUN	O	O
-	PUNCT	O	O
of	ADP	O	O
-	PUNCT	O	O
stay	NOUN	O	O
and	CCONJ	O	O
higher	ADJ	O	O
costs	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
inferior	ADJ	O	O
clinical	ADJ	O	O
outcome	NOUN	O	O
.	PUNCT	O	O



Capsaicin	PROPN	O	I-Entity
(	PUNCT	O	O
0.01	NUM	O	O
-	SYM	O	O
1	NUM	O	O
mm	NOUN	O	O
)	PUNCT	O	O
applied	VERB	O	O
to	ADP	O	O
oral	ADJ	O	O
or	CCONJ	O	O
nasal	ADJ	O	O
mucosa	NOUN	O	O
induced	VERB	O	O
increases	NOUN	O	B-Entity
in	ADP	O	I-Entity
dural	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
cortical	ADJ	O	I-Entity
blood	NOUN	O	I-Entity
flow	NOUN	O	I-Entity
and	CCONJ	O	O
provoked	VERB	O	O
lacrimation	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (15120741)

Recurrent	ADJ	O	O
excitation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
dentate	NOUN	O	O
gyrus	NOUN	O	O
of	ADP	O	O
a	DET	O	O
murine	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
temporal	ADJ	O	B-Entity
lobe	NOUN	O	I-Entity
epilepsy	NOUN	O	I-Entity
.	PUNCT	O	O

Population	NOUN	O	O
responses	NOUN	O	O
in	ADP	O	O
granule	NOUN	O	O
cells	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dentate	NOUN	O	O
gyrus	NOUN	O	O
were	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
transverse	ADJ	O	O
slices	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ventral	ADJ	O	O
hippocampus	NOUN	O	O
from	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
and	CCONJ	O	O
untreated	ADJ	O	O
mice	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
SE	PROPN	O	I-Entity
survivors	NOUN	O	O
,	PUNCT	O	O
similar	ADJ	O	O
stimulation	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
population	NOUN	O	O
spike	NOUN	O	O
followed	VERB	O	O
,	PUNCT	O	O
at	ADP	O	O
a	DET	O	O
variable	ADJ	O	O
latency	NOUN	O	O
,	PUNCT	O	O
by	ADP	O	O
negative	ADJ	O	O
DC	PROPN	O	O
shifts	NOUN	O	O
and	CCONJ	O	O
repetitive	ADJ	O	O
afterdischarges	NOUN	O	O
of	ADP	O	O
3	NUM	O	O
-	SYM	O	O
60	NUM	O	O
s	PART	O	O
duration	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
were	VERB	O	O
blocked	VERB	O	O
by	ADP	O	O
ionotropic	ADJ	O	O
glutamate	ADJ	O	I-Entity
receptor	NOUN	O	O
antagonists	NOUN	O	O
.	PUNCT	O	O

mice	NOUN	O	O
were	VERB	O	O
less	ADV	O	O
sensitive	ADJ	O	O
to	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	I-Entity
both	CCONJ	O	O
at	ADP	O	O
low	ADJ	O	O
doses	NOUN	O	O
,	PUNCT	O	O
measured	VERB	O	O
as	ADP	O	O
decreased	VERB	O	O
exploration	NOUN	O	O
in	ADP	O	O
an	DET	O	O
open	ADJ	O	O
field	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
,	PUNCT	O	O
measured	VERB	O	O
as	ADP	O	O
sensitivity	NOUN	O	O
to	ADP	O	O
nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (15602202)

Although	ADP	O	O
most	ADJ	O	O
cases	NOUN	O	O
of	ADP	O	O
antibiotic	ADJ	O	O
induced	VERB	O	O
acute	ADJ	O	O
interstitial	ADJ	O	B-Entity
nephritis	NOUN	O	I-Entity
are	VERB	O	O
benign	ADJ	O	O
and	CCONJ	O	O
self	NOUN	O	O
-	PUNCT	O	O
limited	VERB	O	O
,	PUNCT	O	O
some	DET	O	O
patients	NOUN	O	O
are	VERB	O	O
at	ADP	O	O
risk	NOUN	O	O
for	ADP	O	O
permanent	ADJ	O	O
renal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
proportion	NOUN	O	O
of	ADP	O	O
warfarin	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
cerebral	ADJ	O	B-Entity
haemorrhages	NOUN	O	I-Entity
might	VERB	O	O
have	VERB	O	O
been	VERB	O	O
prevented	VERB	O	O
if	ADP	O	O
greater	ADJ	O	O
caution	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
taken	VERB	O	O
when	ADV	O	O
prescribing	VERB	O	O
drugs	NOUN	O	O
known	VERB	O	O
to	PART	O	O
interact	VERB	O	O
with	ADP	O	O
warfarin	NOUN	O	I-Entity
.	PUNCT	O	O

Sixty	NUM	O	O
percent	NOUN	O	O
in	ADP	O	O
Group	PROPN	O	O
A	PROPN	O	O
developed	VERB	O	O
postoperative	ADJ	O	B-Entity
emetic	ADJ	O	I-Entity
symptoms	NOUN	O	I-Entity
,	PUNCT	O	O
headache	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
both	DET	O	O
;	PUNCT	O	O
1	NUM	O	O
patient	NOUN	O	O
in	ADP	O	O
Group	PROPN	O	O
B	PROPN	O	O
developed	VERB	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
methylprednisolone	NOUN	O	I-Entity
and	CCONJ	O	O
gentamicin	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
posterior	ADJ	O	O
sub	NOUN	O	O
-	PUNCT	O	O
Tenon	PROPN	O	O
's	PART	O	O
space	NOUN	O	O
was	VERB	O	O
related	VERB	O	O
to	ADP	O	O
a	DET	O	O
high	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
side	NOUN	O	O
effects	NOUN	O	O
including	VERB	O	O
nausea	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
vomiting	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
headache	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (17562951)

No	DET	O	O
direct	ADJ	O	O
comparisons	NOUN	O	O
exist	VERB	O	O
of	ADP	O	O
the	DET	O	O
renal	ADJ	O	O
tolerability	NOUN	O	O
of	ADP	O	O
the	DET	O	O
low	ADJ	O	O
-	PUNCT	O	O
osmolality	NOUN	O	O
contrast	NOUN	O	B-Entity
medium	NOUN	O	I-Entity
iopamidol	NOUN	O	I-Entity
with	ADP	O	O
that	DET	O	O
of	ADP	O	O
the	DET	O	O
iso	NOUN	O	O
-	PUNCT	O	O
osmolality	NOUN	O	O
contrast	NOUN	O	B-Entity
medium	NOUN	O	I-Entity
iodixanol	NOUN	O	I-Entity
in	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
risk	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
is	VERB	O	O
a	DET	O	O
multicenter	ADJ	O	O
,	PUNCT	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
comparison	NOUN	O	O
of	ADP	O	O
iopamidol	NOUN	O	I-Entity
and	CCONJ	O	O
iodixanol	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	B-Entity
kidney	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
estimated	VERB	O	O
glomerular	ADJ	O	O
filtration	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
20	NUM	O	O
to	PART	O	O
59	NUM	O	O
mL	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
)	PUNCT	O	O
who	NOUN	O	O
underwent	VERB	O	O
cardiac	ADJ	O	O
angiography	NOUN	O	O
or	CCONJ	O	O
percutaneous	ADJ	O	O
coronary	ADJ	O	O
interventions	NOUN	O	O
.	PUNCT	O	O

Serum	PROPN	O	O
creatinine	NOUN	O	I-Entity
(	PUNCT	O	O
SCr	PROPN	O	O
)	PUNCT	O	O
levels	NOUN	O	O
and	CCONJ	O	O
estimated	VERB	O	O
glomerular	ADJ	O	O
filtration	NOUN	O	O
rate	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
2	NUM	O	O
to	PART	O	O
5	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
receiving	VERB	O	O
medications	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (17600377)

A	DET	O	O
novel	NOUN	O	O
compound	NOUN	O	O
,	PUNCT	O	O
maltolyl	NOUN	O	B-Entity
p	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
coumarate	NOUN	O	I-Entity
,	PUNCT	O	O
attenuates	VERB	O	O
cognitive	ADJ	O	B-Entity
deficits	NOUN	O	I-Entity
and	CCONJ	O	O
shows	NOUN	O	O
neuroprotective	ADJ	O	O
effects	NOUN	O	O
in	ADP	O	O
vitro	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
vivo	NOUN	O	O
dementia	NOUN	O	I-Entity
models	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
investigated	VERB	O	O
whether	ADP	O	O
maltolyl	NOUN	O	B-Entity
p	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
coumarate	NOUN	O	I-Entity
could	VERB	O	O
improve	VERB	O	O
cognitive	ADJ	O	B-Entity
decline	NOUN	O	I-Entity
in	ADP	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
injected	VERB	O	O
rats	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
amyloid	NOUN	O	B-Entity
beta	NOUN	O	I-Entity
peptide(1	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
42)-infused	VERB	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
also	ADV	O	O
examined	VERB	O	O
the	DET	O	O
neuroprotective	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
maltolyl	NOUN	O	B-Entity
p	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
coumarate	NOUN	O	I-Entity
in	ADP	O	O
vitro	NOUN	O	O
using	VERB	O	O
SH	PROPN	O	O
-	PUNCT	O	O
SY5Y	PROPN	O	O
cells	NOUN	O	O
.	PUNCT	O	O

Cells	NOUN	O	O
were	VERB	O	O
pretreated	VERB	O	O
with	ADP	O	O
maltolyl	NOUN	O	B-Entity
p	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
coumarate	NOUN	O	I-Entity
,	PUNCT	O	O
before	ADP	O	O
exposed	VERB	O	O
to	ADP	O	O
amyloid	NOUN	O	B-Entity
beta	NOUN	O	I-Entity
peptide(1	NUM	O	I-Entity
-	PUNCT	O	I-Entity
42	NUM	O	I-Entity
)	PUNCT	O	I-Entity
,	PUNCT	O	O
glutamate	NOUN	O	I-Entity
or	CCONJ	O	O
H2O2	PROPN	O	I-Entity
.	PUNCT	O	O

Taking	VERB	O	O
these	DET	O	O
in	ADP	O	O
vitro	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
vivo	NOUN	O	O
results	NOUN	O	O
together	ADV	O	O
,	PUNCT	O	O
our	ADJ	O	O
study	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
maltolyl	NOUN	O	B-Entity
p	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
coumarate	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
potentially	ADV	O	O
effective	ADJ	O	O
candidate	NOUN	O	O
against	ADP	O	O
Alzheimer	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
that	ADJ	O	O
is	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
wide	ADJ	O	O
spread	VERB	O	O
neuronal	ADJ	O	B-Entity
death	NOUN	O	I-Entity
and	CCONJ	O	O
progressive	ADJ	O	O
decline	NOUN	O	B-Entity
of	ADP	O	I-Entity
cognitive	ADJ	O	I-Entity
function	NOUN	O	I-Entity
.	PUNCT	O	O


Interaction	NOUN	O	O
between	ADP	O	O
warfarin	NOUN	O	I-Entity
and	CCONJ	O	O
levofloxacin	NOUN	O	I-Entity
:	PUNCT	O	O
case	NOUN	O	O
series	NOUN	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
-	PUNCT	O	O
five	NUM	O	O
lamivudine	NOUN	O	I-Entity
-	PUNCT	O	O
na	NOUN	O	I-Entity


For	ADP	O	O
comparison	NOUN	O	O
,	PUNCT	O	O
tests	NOUN	O	O
were	VERB	O	O
conducted	VERB	O	O
in	ADP	O	O
two	NUM	O	O
acute	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
models	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
hotplate	NOUN	O	O
and	CCONJ	O	O
warm	ADJ	O	O
water	NOUN	O	O
tail	NOUN	O	O
-	PUNCT	O	O
withdrawal	NOUN	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

Calcineurin	PROPN	O	O
-	PUNCT	O	O
inhibitor	NOUN	O	O
therapy	NOUN	O	O
can	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
renal	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
in	ADP	O	O
heart	NOUN	O	O
transplantation	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
novel	NOUN	O	O
immunosuppressive	NOUN	O	O
(	PUNCT	O	O
IS	PROPN	O	O
)	PUNCT	O	O
drug	NOUN	O	O
sirolmus	NOUN	O	I-Entity
(	PUNCT	O	O
Srl	PROPN	O	I-Entity
)	PUNCT	O	O
lacks	VERB	O	O
nephrotoxic	ADJ	O	I-Entity
effects	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
proteinuria	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
Srl	PROPN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
following	VERB	O	O
renal	ADJ	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
proteinuria	NOUN	O	I-Entity
may	VERB	O	O
develop	VERB	O	O
in	ADP	O	O
cardiac	ADJ	O	O
transplant	NOUN	O	O
patients	NOUN	O	O
after	ADP	O	O
switch	NOUN	O	O
to	ADP	O	O
Srl	PROPN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
may	VERB	O	O
have	VERB	O	O
an	DET	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (18410508)

Methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neurotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
microglial	ADJ	O	O
activation	NOUN	O	O
are	VERB	O	O
not	ADV	O	O
mediated	VERB	O	O
by	ADP	O	O
fractalkine	NOUN	O	O
receptor	NOUN	O	O
signaling	VERB	O	O
.	PUNCT	O	O

Neurosci	PROPN	O	O
.	PUNCT	O	O
9	NUM	O	O
(	PUNCT	O	O
2006	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
917	NUM	O	O
]	PUNCT	O	O
recently	ADV	O	O
identified	VERB	O	O
the	DET	O	O
microglial	ADJ	O	O
-	PUNCT	O	O
specific	ADJ	O	O
fractalkine	NOUN	O	O
receptor	NOUN	O	O
(	PUNCT	O	O
CX3CR1	PROPN	O	O
)	PUNCT	O	O
as	ADP	O	O
an	DET	O	O
important	ADJ	O	O
mediator	NOUN	O	O
of	ADP	O	O
MPTP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neurodegeneration	NOUN	O	I-Entity
of	ADP	O	O
DA	PROPN	O	I-Entity
neurons	NOUN	O	O
.	PUNCT	O	O

Striatal	ADJ	O	O
microglia	NOUN	O	O
expressing	VERB	O	O
eGFP	PROPN	O	O
constitutively	ADV	O	O
show	VERB	O	O
morphological	ADJ	O	O
changes	NOUN	O	O
after	ADP	O	O
METH	PROPN	O	I-Entity
that	ADJ	O	O
are	VERB	O	O
characteristic	ADJ	O	O
of	ADP	O	O
activation	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (18503483)

Recovery	NOUN	O	O
of	ADP	O	O
tacrolimus	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
brachial	NOUN	O	B-Entity
neuritis	NOUN	O	I-Entity
after	ADP	O	O
conversion	NOUN	O	O
to	ADP	O	O
everolimus	VERB	O	I-Entity
in	ADP	O	O
a	DET	O	O
pediatric	ADJ	O	O
renal	ADJ	O	O
transplant	NOUN	O	O
recipient	NOUN	O	O
--	PUNCT	O	O
case	NOUN	O	O
report	NOUN	O	O
and	CCONJ	O	O
review	NOUN	O	O
of	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
.	PUNCT	O	O

TAC	PROPN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
potent	ADJ	O	O
immunosuppressive	ADJ	O	O
agent	NOUN	O	O
for	ADP	O	O
solid	ADJ	O	O
organ	ADJ	O	O
transplantation	NOUN	O	O
in	ADP	O	O
pediatrics	NOUN	O	O
.	PUNCT	O	O

Improvement	NOUN	O	O
and	CCONJ	O	O
eventually	ADV	O	O
full	ADJ	O	O
recovery	NOUN	O	O
only	ADV	O	O
occurred	VERB	O	O
after	ADP	O	O
TAC	PROPN	O	I-Entity
was	VERB	O	O
completely	ADV	O	O
discontinued	VERB	O	O
and	CCONJ	O	O
successfully	ADV	O	O
replaced	VERB	O	O
by	ADP	O	O
everolimus	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (18560792)

Compared	VERB	O	O
to	ADP	O	O
controls	NOUN	O	O
,	PUNCT	O	O
aortic	ADJ	O	B-Entity
regurgitation	NOUN	O	I-Entity
(	PUNCT	O	O
OR	PROPN	O	O
:	PUNCT	O	O
3.1	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
IC	NOUN	O	O
:	PUNCT	O	O
1.1	NUM	O	O
-	PUNCT	O	O
8.8	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
mitral	ADJ	O	B-Entity
regurgitation	NOUN	O	I-Entity
(	PUNCT	O	O
OR	PROPN	O	O
:	PUNCT	O	O
10.7	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
IC	NOUN	O	O
:	PUNCT	O	O
2.1	NUM	O	O
-	SYM	O	O
53	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
more	ADJ	O	O
frequent	ADJ	O	O
in	ADP	O	O
PD	NOUN	O	I-Entity
patients	NOUN	O	O
(	PUNCT	O	O
tricuspid	NOUN	O	O
:	PUNCT	O	O
NS	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	O
of	ADP	O	O
affected	VERB	O	O
valves	NOUN	O	O
(	PUNCT	O	O
n=2.4+/-0.7	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
sum	NOUN	O	O
of	ADP	O	O
regurgitation	NOUN	O	O
grades	NOUN	O	O
(	PUNCT	O	O
n=2.8+/-1.09	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
higher	ADJ	O	O
(	PUNCT	O	O
p=0.008	NOUN	O	O
and	CCONJ	O	O
p=0.006	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
pergolide	NOUN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

Severity	NOUN	O	O
of	ADP	O	O
regurgitation	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
correlated	VERB	O	O
with	ADP	O	O
pergolide	NOUN	O	I-Entity
cumulative	ADJ	O	O
dose	NOUN	O	O
.	PUNCT	O	O

Pergolide	PROPN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
in	ADP	O	O
10	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
valvular	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
a	DET	O	O
lower	ADJ	O	O
regurgitation	NOUN	O	O
grade	NOUN	O	O
(	PUNCT	O	O
p=0.01	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
second	ADJ	O	O
transthoracic	NOUN	O	O
echocardiography	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
two	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
returned	VERB	O	O
to	ADP	O	O
nearly	ADV	O	O
normal	ADJ	O	O
clinical	ADJ	O	O
examination	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
average	ADJ	O	O
temporal	ADJ	O	O
delay	NOUN	O	O
between	ADP	O	O
papaverine	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
an	DET	O	O
adverse	ADJ	O	O
BAEP	NOUN	O	O
change	NOUN	O	O
was	VERB	O	O
5	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (18754075)

Within	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
the	DET	O	O
oral	ADJ	O	O
bisphosphonate	NOUN	O	I-Entity
(	PUNCT	O	O
alendronate	ADJ	O	B-Entity
sodium	NOUN	O	I-Entity
)	PUNCT	O	O
administration	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
daily	ADJ	O	O
urinary	NOUN	O	O
protein	NOUN	O	O
increased	VERB	O	O
rapidly	ADV	O	O
up	ADP	O	O
to	ADP	O	O
12.8	NUM	O	O
g	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
aldosterone	NOUN	O	I-Entity
-	PUNCT	O	O
sensitive	ADJ	O	O
serum-	NOUN	O	O
and	CCONJ	O	O
glucocorticoid	NOUN	O	O

5	NUM	O	O
mumol	PROPN	O	O
/	SYM	O	O
mg	INTJ	O	O
crea	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
significantly	ADV	O	O
higher	ADJ	O	O
body	NOUN	O	O
weight	NOUN	O	B-Entity
gain	NOUN	O	I-Entity
in	ADP	O	O
sgk1(+/+	PROPN	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
sgk1(-/-	NOUN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
6.6	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

mice	NOUN	O	O
leading	VERB	O	O
to	ADP	O	O
uremia	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
reduced	ADJ	O	O
median	ADJ	O	O
survival	NOUN	O	O
in	ADP	O	O
sgk1(-/-	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
(	PUNCT	O	O
29	NUM	O	O
vs.	SYM	O	O
40	NUM	O	O
days	NOUN	O	O
in	ADP	O	O
sgk1(+/+	NUM	O	O
)	PUNCT	O	O
mice	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

-DOCSTART- (19299179)

Clinically	PROPN	O	O
significant	ADJ	O	O
proteinuria	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
sirolimus	NOUN	O	I-Entity
to	ADP	O	O
renal	ADJ	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
encountered	VERB	O	O
several	ADJ	O	O
patients	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
substantial	ADJ	O	O
proteinuria	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
sirolimus	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
each	DET	O	O
patient	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
close	ADJ	O	O
temporal	ADJ	O	O
association	NOUN	O	O
between	ADP	O	O
the	DET	O	O
commencement	NOUN	O	O
of	ADP	O	O
sirolimus	NOUN	O	I-Entity
therapy	NOUN	O	O
and	CCONJ	O	O
proteinuria	NOUN	O	I-Entity
implicated	VERB	O	O
sirolimus	NOUN	O	I-Entity
as	ADP	O	O
the	DET	O	O
most	ADV	O	O
likely	ADJ	O	O
etiology	NOUN	O	O
of	ADP	O	O
the	DET	O	O
proteinuria	NOUN	O	I-Entity
.	PUNCT	O	O

Proteinuria	PROPN	O	I-Entity
correlated	VERB	O	O
most	ADV	O	O
strongly	ADV	O	O
with	ADP	O	O
sirolimus	NOUN	O	I-Entity
therapy	NOUN	O	O
when	ADV	O	O
compared	VERB	O	O
to	ADP	O	O
other	ADJ	O	O
demographic	ADJ	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
variables	NOUN	O	O
.	PUNCT	O	O


Comparative	ADJ	O	O
cognitive	ADJ	O	O
and	CCONJ	O	O
subjective	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
immediate	ADJ	O	O
-	PUNCT	O	O
release	NOUN	O	O
oxycodone	NOUN	O	I-Entity
in	ADP	O	O
healthy	ADJ	O	O
middle	NOUN	O	O
-	PUNCT	O	O
aged	ADJ	O	O
and	CCONJ	O	O
older	ADJ	O	O
adults	NOUN	O	O
.	PUNCT	O	O

Significant	ADJ	O	O
declines	NOUN	O	B-Entity
in	ADP	O	I-Entity
simple	ADJ	O	I-Entity
and	CCONJ	O	I-Entity
sustained	ADJ	O	I-Entity
attention	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
working	VERB	O	I-Entity
memory	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
and	CCONJ	O	I-Entity
verbal	ADJ	O	I-Entity
memory	NOUN	O	I-Entity
were	VERB	O	O
observed	VERB	O	O
at	ADP	O	O
1	NUM	O	O
hour	NOUN	O	O
postdose	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
baseline	NOUN	O	O
for	ADP	O	O
both	DET	O	O
age	NOUN	O	O
groups	NOUN	O	O
with	ADP	O	O
a	DET	O	O
trend	NOUN	O	O
toward	ADP	O	O
return	NOUN	O	O
to	ADP	O	O
baseline	NOUN	O	O
by	ADP	O	O
5	NUM	O	O
hours	NOUN	O	O
postdose	NOUN	O	O
.	PUNCT	O	O

Study	VERB	O	O
findings	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
the	DET	O	O
metabolism	NOUN	O	O
,	PUNCT	O	O
neurocognitive	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
physical	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
oxycodone	NOUN	O	I-Entity
are	VERB	O	O
similar	ADJ	O	O
for	ADP	O	O
healthy	ADJ	O	O
middle	NOUN	O	O
-	PUNCT	O	O
aged	ADJ	O	O
and	CCONJ	O	O
older	ADJ	O	O
adults	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (20080983)

Modafinil	PROPN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
daytime	NOUN	O	O
sleep	NOUN	O	O
latency	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
measured	VERB	O	O
by	ADP	O	O
the	DET	O	O
Multiple	PROPN	O	O
Sleep	PROPN	O	O
Latency	PROPN	O	O
Test	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
nearly	ADV	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
subjective	ADJ	O	O
daytime	NOUN	O	B-Entity
sleepiness	NOUN	O	I-Entity
.	PUNCT	O	O

Asenapine	PROPN	O	I-Entity
is	VERB	O	O
approved	VERB	O	O
by	ADP	O	O
the	DET	O	O
Food	PROPN	O	O
and	CCONJ	O	O
Drugs	PROPN	O	O
Administration	PROPN	O	O
in	ADP	O	O
adults	NOUN	O	O
for	ADP	O	O
acute	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
schizophrenia	NOUN	O	I-Entity
or	CCONJ	O	O
of	ADP	O	O
manic	ADJ	O	I-Entity
or	CCONJ	O	O
mixed	ADJ	O	O
episodes	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
bipolar	NOUN	O	B-Entity
I	PRON	O	I-Entity
disorder	VERB	O	I-Entity
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
psychotic	ADJ	O	I-Entity
features	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
Positive	ADJ	O	O
and	CCONJ	O	O
Negative	ADJ	O	O
Syndrome	PROPN	O	O
Scale	PROPN	O	O
positive	ADJ	O	O
subscale	NOUN	O	O
,	PUNCT	O	O
all	DET	O	O
treatments	NOUN	O	O
were	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
placebo	NOUN	O	O
with	ADP	O	O
LOCF	PROPN	O	O
and	CCONJ	O	O
MMRM	PROPN	O	O
;	PUNCT	O	O
asenapine	NOUN	O	I-Entity
at	ADP	O	O
5	NUM	O	O
mg	NUM	O	O
BID	NOUN	O	O
was	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
placebo	NOUN	O	O
on	ADP	O	O
the	DET	O	O
negative	ADJ	O	O
subscale	NOUN	O	O
with	ADP	O	O
MMRM	PROPN	O	O
and	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
general	ADJ	O	O
psychopathology	NOUN	O	O
subscale	NOUN	O	O
with	ADP	O	O
LOCF	PROPN	O	O
and	CCONJ	O	O
MMRM	PROPN	O	O
.	PUNCT	O	O

Post	PROPN	O	O
hoc	NOUN	O	O
analyses	NOUN	O	O
indicated	VERB	O	O
that	ADP	O	O
efficacy	NOUN	O	O
was	VERB	O	O
similar	ADJ	O	O
with	ADP	O	O
asenapine	NOUN	O	I-Entity
and	CCONJ	O	O
haloperidol	NOUN	O	I-Entity
;	PUNCT	O	O
greater	ADJ	O	O
contrasts	NOUN	O	O
were	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
AEs	PROPN	O	O
,	PUNCT	O	O
especially	ADV	O	O
extrapyramidal	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (20588063)


In	ADP	O	O
Group	PROPN	O	O
1	NUM	O	O
the	DET	O	O
rats	NOUN	O	O
were	VERB	O	O
trained	VERB	O	O
under	ADP	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
pentobarbital	ADJ	O	I-Entity
to	PART	O	O
run	VERB	O	O
to	ADP	O	O
the	DET	O	O
same	ADJ	O	O
shelf	NOUN	O	O
as	ADP	O	O
in	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
state	NOUN	O	O
.	PUNCT	O	O

Dex	PROPN	O	I-Entity
increased	VERB	O	B-Entity
SBP	PROPN	O	I-Entity
(	PUNCT	O	O
110	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

3	NUM	O	O
mmHg	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
decreased	VERB	O	B-Entity
thymus	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
P	NOUN	O	I-Entity
<	X	O	I-Entity
0.001	NUM	O	I-Entity
)	PUNCT	O	I-Entity
and	CCONJ	O	I-Entity
bodyweights	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
"	PUNCT	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Allopurinol	PROPN	O	I-Entity
decreased	VERB	O	O
serum	NOUN	O	O
urate	NOUN	O	I-Entity
from	ADP	O	O
76	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Extrapyramidal	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
and	CCONJ	O	O
haloperidol	NOUN	O	I-Entity
at	ADP	O	O
comparable	ADJ	O	O
D2	NOUN	O	O
receptor	NOUN	O	O
occupancy	NOUN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

Risperidone	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
antipsychotic	ADJ	O	O
drug	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
affinity	NOUN	O	O
at	ADP	O	O
dopamine	NOUN	O	I-Entity
D2	PROPN	O	O
and	CCONJ	O	O
serotonin	NOUN	O	B-Entity
5-HT2	NUM	O	I-Entity
receptors	NOUN	O	O
.	PUNCT	O	O

Drug	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
induced	VERB	O	I-Entity
parkinsonism	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
subjects	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
(	PUNCT	O	O
42%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
haloperidol	NOUN	O	I-Entity
(	PUNCT	O	O
29%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
was	VERB	O	O
observed	VERB	O	O
at	ADP	O	O
occupancy	NOUN	O	O
levels	NOUN	O	O
above	ADV	O	O
60%	NUM	O	O
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
these	DET	O	O
observations	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
5-HT2	NUM	O	O
blockade	NOUN	O	O
obtained	VERB	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
at	ADP	O	O
D2	PROPN	O	O
occupancy	NOUN	O	O
rates	NOUN	O	O
of	ADP	O	O
60%	NUM	O	O
and	CCONJ	O	O
above	ADP	O	O
does	VERB	O	O
not	ADV	O	O
appear	VERB	O	O
to	PART	O	O
protect	VERB	O	O
against	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
for	ADP	O	O
extrapyramidal	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (18752389)


The	DET	O	O
patient	NOUN	O	O
's	PART	O	O
medical	ADJ	O	O
and	CCONJ	O	O
dental	ADJ	O	O
histories	NOUN	O	O
along	ADP	O	O
with	ADP	O	O
radiographic	ADJ	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
findings	NOUN	O	O
lead	VERB	O	O
to	ADP	O	O
a	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
"	PUNCT	O	O
meth	ADJ	O	B-Entity
mouth	NOUN	O	I-Entity
.	PUNCT	O	O

Eating	VERB	O	B-Entity
disorders	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
associated	VERB	O	O
behavioural	NOUN	O	O
problems	NOUN	O	O
and	CCONJ	O	O
drug	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
are	VERB	O	O
uncommon	ADJ	O	O
in	ADP	O	O
pregnancy	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
particular	ADJ	O	O
it	PRON	O	O
illustrates	VERB	O	O
the	DET	O	O
derangements	NOUN	O	O
of	ADP	O	O
thyroid	NOUN	O	O
function	NOUN	O	O
seen	VERB	O	O
in	ADP	O	O
pregnant	ADJ	O	O
women	NOUN	O	O
with	ADP	O	O
eating	VERB	O	B-Entity
disorders	NOUN	O	I-Entity
and	CCONJ	O	O
reminds	VERB	O	O
us	PRON	O	O
that	ADP	O	O
when	ADV	O	O
a	DET	O	O
cause	NOUN	O	O
for	ADP	O	O
thyrotoxicosis	NOUN	O	I-Entity
remains	VERB	O	O
obscure	ADJ	O	O
,	PUNCT	O	O
thyroxine	ADJ	O	I-Entity
abuse	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
and	CCONJ	O	O
explored	VERB	O	O
.	PUNCT	O	O


Lipopolysaccharide	PROPN	O	I-Entity
pretreatment	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
the	DET	O	O
basal	NOUN	O	O
body	NOUN	O	O
temperature	NOUN	O	O
or	CCONJ	O	O
methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
elicited	VERB	O	O
hyperthermia	NOUN	O	I-Entity
three	NUM	O	O
days	NOUN	O	O
later	ADV	O	O
.	PUNCT	O	O

We	PRON	O	O
concluded	VERB	O	O
a	DET	O	O
critical	ADJ	O	O
time	NOUN	O	O
window	NOUN	O	O
for	ADP	O	O
systemic	ADJ	O	O
lipopolysaccharide	NOUN	O	I-Entity
pretreatment	NOUN	O	O
in	ADP	O	O
exerting	VERB	O	O
effective	ADJ	O	O
protection	NOUN	O	O
against	ADP	O	O
methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nigrostriatal	ADJ	O	O
dopamine	NOUN	O	I-Entity
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

patients	NOUN	O	O
undergoing	VERB	O	O
electroconvulsive	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
ECT	PROPN	O	O
)	PUNCT	O	O
often	ADV	O	O
receive	VERB	O	O
succinylcholine	NOUN	O	I-Entity
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
the	DET	O	O
anesthetic	ADJ	O	O
procedure	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (10901305)

Any	DET	O	O
pain	NOUN	O	I-Entity
during	ADP	O	O
the	DET	O	O
reduction	NOUN	O	O
was	VERB	O	O
rated	VERB	O	O
by	ADP	O	O
the	DET	O	O
orthopaedic	NOUN	O	O
surgeon	NOUN	O	O
treating	VERB	O	O
the	DET	O	O
patient	NOUN	O	O
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
Children	PROPN	O	O
's	PART	O	O
Hospital	PROPN	O	O
of	ADP	O	O
Eastern	PROPN	O	O
Ontario	PROPN	O	O
Pain	PROPN	O	I-Entity
Scale	PROPN	O	O
(	PUNCT	O	O
CHEOPS	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Minor	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
included	VERB	O	O
nausea	NOUN	O	I-Entity
(	PUNCT	O	O
thirteen	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
emesis	NOUN	O	I-Entity
(	PUNCT	O	O
eight	NUM	O	O
of	ADP	O	O
the	DET	O	O
thirteen	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
nausea	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
clumsiness	NOUN	O	I-Entity
(	PUNCT	O	O
evident	ADJ	O	O
as	ADP	O	O
ataxic	ADJ	O	B-Entity
movements	NOUN	O	I-Entity
in	ADP	O	O
ten	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
dysphoric	ADJ	O	B-Entity
reaction	NOUN	O	I-Entity
(	PUNCT	O	O
one	NUM	O	O
patient	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
sequelae	NOUN	O	O
were	VERB	O	O
noted	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
hallucinations	NOUN	O	I-Entity
or	CCONJ	O	O
nightmares	NOUN	O	O
.	PUNCT	O	O

From	ADP	O	O
June	PROPN	O	O
2004	NUM	O	O
to	ADP	O	O
October	PROPN	O	O
2006	NUM	O	O
,	PUNCT	O	O
11	NUM	O	O
HBs	PROPN	O	B-Entity
Ag	PROPN	O	I-Entity
positive	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
rheumatologic	ADJ	O	B-Entity
diseases	NOUN	O	I-Entity
,	PUNCT	O	O
who	NOUN	O	O
were	VERB	O	O
on	ADP	O	O
both	DET	O	O
immunosuppressive	ADJ	O	O
and	CCONJ	O	O
prophylactic	ADJ	O	O
lamivudine	NOUN	O	I-Entity
therapies	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
retrospectively	ADV	O	O
assessed	VERB	O	O
.	PUNCT	O	O

Shortly	ADV	O	O
after	ADP	O	O
treatment	NOUN	O	O
their	ADJ	O	O
tests	NOUN	O	O
normalized	ADJ	O	O
and	CCONJ	O	O
during	ADP	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
period	NOUN	O	O
none	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
abnormal	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
function	NOUN	O	I-Entity
tests	NOUN	O	O
.	PUNCT	O	O

Mild	PROPN	O	O
hypoxia	NOUN	O	I-Entity
(	PUNCT	O	O
SO2<90%	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
the	DET	O	O
most	ADV	O	O
common	ADJ	O	O
event	NOUN	O	O
(	PUNCT	O	O
11	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
3	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
2%	NUM	O	O
)	PUNCT	O	O
presented	VERB	O	O
transient	ADJ	O	O
hypoxia	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
upper	ADJ	O	O
airway	NOUN	O	B-Entity
obstruction	NOUN	O	I-Entity
by	ADP	O	O
probe	NOUN	O	O
introduction	NOUN	O	O
and	CCONJ	O	O
8	NUM	O	O
(	PUNCT	O	O
5.8%	NUM	O	O
)	PUNCT	O	O
due	ADJ	O	O
to	ADP	O	O
hypoxia	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
MZ	PROPN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blockers	NOUN	O	O
on	ADP	O	O
bupivacaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (10091617)

Stopping	VERB	O	O
selegiline	NOUN	O	I-Entity
also	ADV	O	O
significantly	ADV	O	O
reduced	VERB	O	B-Entity
the	DET	O	I-Entity
supine	NOUN	O	I-Entity
systolic	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
diastolic	ADJ	O	I-Entity
blood	NOUN	O	I-Entity
pressures	NOUN	O	I-Entity
consistent	ADJ	O	O
with	ADP	O	O
a	DET	O	O
previously	ADV	O	O
undescribed	VERB	O	O
supine	ADJ	O	O
pressor	NOUN	O	O
action	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	PART	O	O
address	VERB	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
pain	NOUN	O	I-Entity
memory	NOUN	O	O
,	PUNCT	O	O
nine	NUM	O	O
healthy	ADJ	O	O
male	ADJ	O	O
volunteers	NOUN	O	O
received	VERB	O	O
intradermal	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
doses	NOUN	O	O
of	ADP	O	O
capsaicin	NOUN	O	I-Entity
(	PUNCT	O	O
0.05	NUM	O	O
,	PUNCT	O	O
1	NUM	O	O
and	CCONJ	O	O
20	NUM	O	O
microg	NOUN	O	O
,	PUNCT	O	O
separated	VERB	O	O
by	ADP	O	O
15	NUM	O	O
min	NOUN	O	O
breaks	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
each	DET	O	O
given	VERB	O	O
three	NUM	O	O
times	NOUN	O	O
in	ADP	O	O
a	DET	O	O
balanced	ADJ	O	O
design	NOUN	O	O
across	ADP	O	O
three	NUM	O	O
sessions	NOUN	O	O
at	ADP	O	O
one	NUM	O	O
week	NOUN	O	O
intervals	NOUN	O	O
.	PUNCT	O	O


Capsaicin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
muscle	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
alters	VERB	O	O
the	DET	O	O
excitability	NOUN	O	O
of	ADP	O	O
the	DET	O	O
human	ADJ	O	O
jaw	NOUN	O	O
-	PUNCT	O	O
stretch	NOUN	O	O
reflex	NOUN	O	O
.	PUNCT	O	O

Capsaicin	PROPN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
micro	NOUN	O	O
g	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
injected	VERB	O	O
into	ADP	O	O
the	DET	O	O
masseter	NOUN	O	O
muscle	NOUN	O	O
to	PART	O	O
induce	VERB	O	O
pain	NOUN	O	I-Entity
in	ADP	O	O
11	NUM	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

Short	ADJ	O	O
-	PUNCT	O	O
latency	NOUN	O	O
reflex	NOUN	O	O
responses	NOUN	O	O
were	VERB	O	O
evoked	VERB	O	O
in	ADP	O	O
the	DET	O	O
masseter	NOUN	O	O
and	CCONJ	O	O
temporalis	NOUN	O	O
muscles	NOUN	O	O
by	ADP	O	O
a	DET	O	O
stretch	NOUN	O	O
device	NOUN	O	O
with	ADP	O	O
different	ADJ	O	O
velocities	NOUN	O	O
and	CCONJ	O	O
displacements	NOUN	O	O
before	ADP	O	O
,	PUNCT	O	O
during	ADP	O	O
,	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
pain	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (18951540)

Similarly	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
patient	NOUN	O	O
diaries	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
both	DET	O	O
treatments	NOUN	O	O
caused	VERB	O	O
reduction	NOUN	O	O
in	ADP	O	O
subjective	ADJ	O	O
dyskinesia	NOUN	O	I-Entity
scores	NOUN	O	O
during	ADP	O	O
the	DET	O	O
days	NOUN	O	O
of	ADP	O	O
intervention	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
effect	NOUN	O	O
was	VERB	O	O
sustained	VERB	O	O
for	ADP	O	O
3	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
for	ADP	O	O
the	DET	O	O
real	ADJ	O	O
rTMS	PROPN	O	O
only	ADV	O	O
.	PUNCT	O	O


Disulfiram	PROPN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
syndrome	NOUN	O	O
after	ADP	O	O
hydrogen	NOUN	O	B-Entity
cyanamide	NOUN	O	I-Entity
professional	ADJ	O	O
skin	NOUN	O	O
exposure	NOUN	O	O
:	PUNCT	O	O
two	NUM	O	O
case	NOUN	O	O
reports	VERB	O	O
in	ADP	O	O
France	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
report	NOUN	O	O
is	VERB	O	O
to	PART	O	O
describe	VERB	O	O
two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
a	DET	O	O
disulfiram	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
syndrome	NOUN	O	O
following	VERB	O	O
occupational	ADJ	O	O
exposure	NOUN	O	O
to	ADP	O	O
hydrogen	NOUN	O	B-Entity
cyanamide	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
first	ADJ	O	O
case	NOUN	O	O
involved	VERB	O	O
a	DET	O	O
59-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
who	NOUN	O	O
used	VERB	O	O
Dormex	PROPN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
contains	VERB	O	O
hydrogen	NOUN	O	B-Entity
cyanamide	NOUN	O	I-Entity
,	PUNCT	O	O
without	ADP	O	O
protection	NOUN	O	O
after	ADP	O	O
consuming	VERB	O	O
a	DET	O	O
large	ADJ	O	O
amount	NOUN	O	O
of	ADP	O	O
alcohol	NOUN	O	I-Entity
during	ADP	O	O
a	DET	O	O
meal	NOUN	O	O
.	PUNCT	O	O

Trimipramine	PROPN	O	I-Entity
(	PUNCT	O	O
TRI	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
which	ADJ	O	O
shows	VERB	O	O
a	DET	O	O
clinical	ADJ	O	O
antidepressant	NOUN	O	I-Entity
activity	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
chemically	ADV	O	O
related	VERB	O	O
to	ADP	O	O
imipramine	NOUN	O	I-Entity
but	CCONJ	O	O
does	VERB	O	O
not	ADV	O	O
inhibit	VERB	O	O
the	DET	O	O
reuptake	NOUN	O	O
of	ADP	O	O
noradrenaline	NOUN	O	I-Entity
and	CCONJ	O	O
5-hydroxytryptamine	NUM	O	I-Entity
,	PUNCT	O	O
nor	CCONJ	O	O
does	VERB	O	O
it	PRON	O	O
induce	VERB	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenergic	ADJ	O	O
down	ADV	O	O
-	PUNCT	O	O
regulation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
find	VERB	O	O
out	PART	O	O
whether	ADP	O	O
TRI	PROPN	O	I-Entity
given	VERB	O	O
repeatedly	ADV	O	O
was	VERB	O	O
able	ADJ	O	O
to	PART	O	O
induce	VERB	O	O
adaptive	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
dopaminergic	NOUN	O	O
and	CCONJ	O	O
alpha1-adrenergic	ADJ	O	O
systems	NOUN	O	O
,	PUNCT	O	O
demonstrated	VERB	O	O
by	ADP	O	O
us	PRON	O	O
previously	ADV	O	O
for	ADP	O	O
various	ADJ	O	O
antidepressants	NOUN	O	I-Entity
.	PUNCT	O	O

TRI	PROPN	O	I-Entity
given	VERB	O	O
repeatedly	ADV	O	O
to	ADP	O	O
rats	NOUN	O	O
increases	VERB	O	O
the	DET	O	O
locomotor	NOUN	O	O
hyperactivity	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
d	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
amphetamine	NOUN	O	I-Entity
,	PUNCT	O	O
quinpirole	NOUN	O	I-Entity
and	CCONJ	O	O
(	PUNCT	O	O
+	PUNCT	O	O
)	PUNCT	O	O
-7-hydroxy	PUNCT	O	O
-	PUNCT	O	O
dipropyloaminotetralin	NOUN	O	O
(	PUNCT	O	O

dopamine	NOUN	O	I-Entity
D2	PROPN	O	O
and	CCONJ	O	O
D3	PROPN	O	O
effects	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

-DOCSTART- (11431197)


Lindane	PROPN	O	I-Entity
is	VERB	O	O
also	ADV	O	O
widely	ADV	O	O
used	VERB	O	O
as	ADP	O	O
an	DET	O	O
agricultural	ADJ	O	O
and	CCONJ	O	O
industrial	ADJ	O	O
pesticide	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
as	ADP	O	O
a	DET	O	O
result	NOUN	O	O
the	DET	O	O
toxic	ADJ	O	O
profile	NOUN	O	O
of	ADP	O	O
this	DET	O	O
insecticide	NOUN	O	O
is	VERB	O	O
well	ADV	O	O
understood	VERB	O	O
.	PUNCT	O	O

-DOCSTART- (19803309)

The	DET	O	O
selected	VERB	O	O
doses	NOUN	O	O
of	ADP	O	O
WR242511	PROPN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
produced	VERB	O	O
significant	ADJ	O	O
methemoglobinemia	NOUN	O	I-Entity
in	ADP	O	O
beagle	NOUN	O	O
dogs	NOUN	O	O
in	ADP	O	O
earlier	ADJ	O	O
studies	NOUN	O	O
conducted	VERB	O	O
elsewhere	ADV	O	O
,	PUNCT	O	O
produced	VERB	O	O
very	ADV	O	O
little	ADJ	O	O
MHb	PROPN	O	O
(	PUNCT	O	O
mean	VERB	O	O
<	PROPN	O	O
2.0%	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
rhesus	ADJ	O	O
monkey	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
transient	ADJ	O	O
hemoglobinuria	NOUN	O	I-Entity
was	VERB	O	O
noted	VERB	O	O
approximately	ADV	O	O
60	NUM	O	O
minutes	NOUN	O	O
postinjection	NOUN	O	O
of	ADP	O	O
WR242511	PROPN	O	I-Entity
(	PUNCT	O	O
3.5	NUM	O	O
or	CCONJ	O	O
7.0	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
2	NUM	O	O
lethalities	NOUN	O	O
occurred	VERB	O	O
(	PUNCT	O	O
one	NUM	O	O
IV	PROPN	O	O
and	CCONJ	O	O
one	NUM	O	O
PO	NOUN	O	O
)	PUNCT	O	O
following	VERB	O	O
the	DET	O	O
7.0	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
dose	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
WR242511	PRON	O	I-Entity
should	VERB	O	O
not	ADV	O	O
be	VERB	O	O
pursued	VERB	O	O
as	ADP	O	O
a	DET	O	O
pretreatment	NOUN	O	O
for	ADP	O	O
CN	NOUN	O	O
poisoning	NOUN	O	I-Entity
unless	ADP	O	O
the	DET	O	O
anti	ADJ	O	O
-	PUNCT	O	O
CN	NOUN	O	O
characteristics	NOUN	O	O
of	ADP	O	O
this	DET	O	O
compound	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
successfully	ADV	O	O
dissociated	VERB	O	O
from	ADP	O	O
those	DET	O	O
producing	VERB	O	O
undesirable	ADJ	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (9195768)

Two	NUM	O	O
patients	NOUN	O	O
are	VERB	O	O
presented	VERB	O	O
with	ADP	O	O
tingling	VERB	O	B-Entity
or	CCONJ	O	I-Entity
burning	VERB	O	I-Entity
sensations	NOUN	O	I-Entity
limited	VERB	O	O
to	ADP	O	O
areas	NOUN	O	O
of	ADP	O	O
heat	NOUN	O	O
exposure	NOUN	O	O
or	CCONJ	O	O
sunburn	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (15338796)

Tremor	NOUN	O	I-Entity
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
salbutamol	NOUN	O	I-Entity
,	PUNCT	O	O
quantified	VERB	O	O
by	ADP	O	O
a	DET	O	O
laser	NOUN	O	O
pointer	NOUN	O	O
technique	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Tremor	NOUN	O	I-Entity
was	VERB	O	O
measured	VERB	O	O
using	VERB	O	O
a	DET	O	O
laser	NOUN	O	O
pointer	NOUN	O	O
technique	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
another	DET	O	O
series	NOUN	O	O
of	ADP	O	O
measurements	NOUN	O	O
,	PUNCT	O	O
reproducibility	NOUN	O	O
and	CCONJ	O	O
reference	NOUN	O	O
values	NOUN	O	O
of	ADP	O	O
the	DET	O	O
tremor	NOUN	O	I-Entity
was	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
65	NUM	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
in	ADP	O	O
three	NUM	O	O
sessions	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
9	NUM	O	O
a.m.	NOUN	O	O
,	PUNCT	O	O
4	NUM	O	O
p.m.	NOUN	O	O
and	CCONJ	O	O
9	NUM	O	O
a.m.	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
1	NUM	O	O
week	NOUN	O	O
later	ADV	O	O
.	PUNCT	O	O

Tremor	NOUN	O	I-Entity
was	VERB	O	O
measured	VERB	O	O
simultaneously	ADV	O	O
by	ADP	O	O
two	NUM	O	O
independent	ADJ	O	O
observers	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
thromboembolism	NOUN	O	I-Entity
(	PUNCT	O	O
VTE	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	ADJ	O	O
androgen	NOUN	O	O
-	PUNCT	O	O
independent	ADJ	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
who	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
docetaxel	NOUN	O	I-Entity
alone	ADV	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
thalidomide	NOUN	O	I-Entity
.	PUNCT	O	O

PATIENTS	NOUN	O	O
:	PUNCT	O	O
Seventy	NUM	O	O
men	NOUN	O	O
,	PUNCT	O	O
aged	VERB	O	O
50	NUM	O	O
-	SYM	O	O
80	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
advanced	ADJ	O	O
androgen	NOUN	O	O
-	PUNCT	O	O
independent	ADJ	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

Each	DET	O	O
patient	NOUN	O	O
received	VERB	O	O
either	CCONJ	O	O
intravenous	ADJ	O	O
docetaxel	ADJ	O	I-Entity
30	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2/week	NOUN	O	O
for	ADP	O	O
3	NUM	O	O
consecutive	ADJ	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
1	NUM	O	O
week	NOUN	O	O
off	ADV	O	O
,	PUNCT	O	O
or	CCONJ	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
continuous	ADJ	O	O
oral	ADJ	O	O
thalidomide	NOUN	O	I-Entity
200	NUM	O	O
mg	NUM	O	O
every	DET	O	O
evening	NOUN	O	O
plus	CCONJ	O	O
the	DET	O	O
same	ADJ	O	O
docetaxel	NOUN	O	I-Entity
regimen	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
evaluations	NOUN	O	O
suggested	VERB	O	O
an	DET	O	O
initial	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
thrombocytopenia	NOUN	O	I-Entity
and	CCONJ	O	O
haemolysis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
progressively	ADV	O	O
developed	VERB	O	O
petechiae	NOUN	O	I-Entity
and	CCONJ	O	O
purpura	NOUN	O	I-Entity
on	ADP	O	O
thorax	NOUN	O	O
and	CCONJ	O	O
lower	ADJ	O	O
limbs	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
54-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
hypothyroid	ADJ	O	I-Entity
male	ADJ	O	O
taking	VERB	O	O
thyroxine	NOUN	O	I-Entity
and	CCONJ	O	O
simvastatin	NOUN	O	I-Entity
presented	VERB	O	O
with	ADP	O	O
bilateral	ADJ	O	O
leg	NOUN	O	O
compartment	NOUN	O	B-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
myonecrosis	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
bile	NOUN	O	B-Entity
duct	NOUN	O	I-Entity
hamartoma	NOUN	O	I-Entity
which	ADJ	O	O
developed	VERB	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
on	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
danazol	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (10807237)

0.007	PUNCT	O	O
)	PUNCT	O	O
were	VERB	O	O
significant	ADJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
outcome	NOUN	O	O
for	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
aneurysms	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (12536034)

Anti	PROPN	O	O
-	PUNCT	O	O
epileptic	ADJ	O	I-Entity
drugs	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
de	NOUN	O	O
novo	ADJ	O	O
absence	NOUN	O	B-Entity
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

By	ADP	O	O
understanding	VERB	O	O
the	DET	O	O
underlying	ADJ	O	O
mechanism	NOUN	O	O
of	ADP	O	O
absence	NOUN	O	B-Entity
epilepsy	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
can	VERB	O	O
avoid	VERB	O	O
the	DET	O	O
inappropriate	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
anticonvulsants	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
epilepsy	NOUN	O	I-Entity
and	CCONJ	O	O
prevent	VERB	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
absence	NOUN	O	B-Entity
seizures	NOUN	O	I-Entity
.	PUNCT	O	O


In	ADP	O	O
two	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
arrhythmia	NOUN	O	I-Entity
degenerated	VERB	O	O
into	ADP	O	O
irreversible	ADJ	O	O
ventricular	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
and	CCONJ	O	O
both	DET	O	O
patients	NOUN	O	O
died	VERB	O	O
.	PUNCT	O	O


Role	NOUN	O	O
of	ADP	O	O
activation	NOUN	O	O
of	ADP	O	O
bradykinin	NOUN	O	I-Entity
B2	NOUN	O	O
receptors	NOUN	O	O
in	ADP	O	O
disruption	NOUN	O	O
of	ADP	O	O
the	DET	O	O
blood	NOUN	O	O
-	PUNCT	O	O
brain	NOUN	O	O
barrier	NOUN	O	O
during	ADP	O	O
acute	ADJ	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

Cellular	ADJ	O	O
mechanisms	NOUN	O	O
which	ADJ	O	O
account	VERB	O	O
for	ADP	O	O
disruption	NOUN	O	O
the	DET	O	O
blood	NOUN	O	O
-	PUNCT	O	O
brain	NOUN	O	O
barrier	NOUN	O	O
during	ADP	O	O
acute	ADJ	O	O
hypertension	NOUN	O	I-Entity
are	VERB	O	O
not	ADV	O	O
clear	ADJ	O	O
.	PUNCT	O	O

-DOCSTART- (2578334)

-DOCSTART- (11532387)

Withdrawal	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
emergent	ADJ	O	I-Entity
rabbit	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
during	ADP	O	O
dose	NOUN	O	O
reduction	NOUN	O	O
of	ADP	O	O
risperidone	NOUN	O	I-Entity
.	PUNCT	O	O

Rabbit	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
RS	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
extrapyramidal	ADJ	O	O
side	NOUN	O	O
effect	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
prolonged	ADJ	O	O
neuroleptic	ADJ	O	O
medication	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
symptom	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
successfully	ADV	O	O
with	ADP	O	O
trihexyphenidyl	ADJ	O	I-Entity
anticholinergic	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Verapamil	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
and	CCONJ	O	O
relatively	ADV	O	O
-	PUNCT	O	O
safe	ADJ	O	O
antihypertensive	ADJ	O	O
drug	NOUN	O	O
.	PUNCT	O	O

Serious	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
are	VERB	O	O
uncommon	ADJ	O	O
and	CCONJ	O	O
mainly	ADV	O	O
have	VERB	O	O
been	VERB	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
depression	NOUN	O	I-Entity
of	ADP	O	O
cardiac	ADJ	O	O
contractility	NOUN	O	O
and	CCONJ	O	O
conduction	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
when	ADV	O	O
the	DET	O	O
drug	NOUN	O	O
is	VERB	O	O
combined	VERB	O	O
with	ADP	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blocking	VERB	O	O
agents	NOUN	O	O
.	PUNCT	O	O

Possible	ADJ	O	O
mechanisms	NOUN	O	O
that	ADJ	O	O
involve	VERB	O	O
a	DET	O	O
verapamil	ADV	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
increase	NOUN	O	O
in	ADP	O	O
platelet	NOUN	O	O
and/or	CCONJ	O	O
vascular	ADJ	O	O
alpha	NOUN	O	O
2-adrenoreceptor	NOUN	O	O
affinity	NOUN	O	O
for	ADP	O	O
catecholamines	NOUN	O	I-Entity
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
methotrexate	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
as	ADP	O	O
a	DET	O	O
loading	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
6,000	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
m2	NOUN	O	O
for	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
one	NUM	O	O
hour	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
an	DET	O	O
infusion	NOUN	O	O
of	ADP	O	O
1,200	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
m2/h	PROPN	O	O
for	ADP	O	O
23	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
common	ADJ	O	O
toxicities	NOUN	O	I-Entity
encountered	VERB	O	O
were	VERB	O	O
transient	ADJ	O	O
serum	NOUN	O	O
transaminase	NOUN	O	O
and	CCONJ	O	O
bilirubin	NOUN	O	I-Entity
elevations	NOUN	O	O
,	PUNCT	O	O
neutropenia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
mucositis	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (2522601)

Hypersensitivity	NOUN	O	I-Entity
to	ADP	O	O
carbamazepine	NOUN	O	I-Entity
presenting	VERB	O	O
with	ADP	O	O
a	DET	O	O
leukemoid	ADJ	O	B-Entity
reaction	NOUN	O	I-Entity
,	PUNCT	O	O
eosinophilia	NOUN	O	I-Entity
,	PUNCT	O	O
erythroderma	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

Lesions	NOUN	O	O
reduced	VERB	O	O
the	DET	O	O
extent	NOUN	O	O
of	ADP	O	O
immunohistological	ADJ	O	O
staining	NOUN	O	O
for	ADP	O	O
choline	NOUN	O	I-Entity
acetyltransferase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
interpeduncular	ADJ	O	O
nucleus	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.025	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
for	ADP	O	O
tyrosine	NOUN	O	I-Entity
hydroxylase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
surrounding	VERB	O	O
catecholaminergic	ADJ	O	O
A10	ADJ	O	O
region	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
the	DET	O	O
interpeduncular	ADJ	O	O
nucleus	NOUN	O	O
mediates	VERB	O	O
nicotinic	ADJ	O	O
depression	NOUN	O	I-Entity
of	ADP	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
and	CCONJ	O	O
dampens	ADJ	O	O
nicotinic	ADJ	O	O
arousal	NOUN	O	O
mechanisms	NOUN	O	O
located	VERB	O	O
elsewhere	ADV	O	O
in	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
.	PUNCT	O	O

dtejc	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
at	ADP	O	O
each	DET	O	O
dobutamine	ADJ	O	I-Entity
level	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
72-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
white	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
underlying	VERB	O	O
human	ADJ	O	B-Entity
immunodeficiency	NOUN	O	I-Entity
virus	NOUN	O	I-Entity
,	PUNCT	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
,	PUNCT	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
hyperlipidemia	NOUN	O	I-Entity
presented	VERB	O	O
with	ADP	O	O
generalized	ADJ	O	O
pain	NOUN	O	I-Entity
,	PUNCT	O	O
fatigue	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
dark	ADJ	O	O
orange	ADJ	O	O
urine	NOUN	O	O
for	ADP	O	O
3	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Laboratory	PROPN	O	O
evaluation	NOUN	O	O
revealed	VERB	O	O
66,680	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
creatine	NOUN	O	I-Entity
kinase	NOUN	O	O
,	PUNCT	O	O
93	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	NOUN	O	O
blood	NOUN	O	B-Entity
urea	NOUN	O	I-Entity
nitrogen	NOUN	O	I-Entity
,	PUNCT	O	O
4.6	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	PROPN	O	O
creatinine	NOUN	O	I-Entity
,	PUNCT	O	O
1579	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
aspartate	NOUN	O	I-Entity
aminotransferase	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
738	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
alanine	NOUN	O	I-Entity
aminotransferase	NOUN	O	O
.	PUNCT	O	O

Nine	NUM	O	O
days	NOUN	O	O
later	ADV	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
creatine	NOUN	O	I-Entity
kinase	NOUN	O	O
had	VERB	O	O
dropped	VERB	O	O
to	ADP	O	O
1695	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
and	CCONJ	O	O
creatinine	NOUN	O	I-Entity
was	VERB	O	O
3.3	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL.	NOUN	O	O
The	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
discharged	VERB	O	O
and	CCONJ	O	O
continued	VERB	O	O
outpatient	ADJ	O	O
dialysis	NOUN	O	O
for	ADP	O	O
1	NUM	O	O
month	NOUN	O	O
until	ADP	O	O
his	ADJ	O	O
renal	ADJ	O	O
function	NOUN	O	O
recovered	VERB	O	O
.	PUNCT	O	O

Simvastatin	PROPN	O	I-Entity
is	VERB	O	O
metabolized	VERB	O	O
by	ADP	O	O
CYP3A4	PROPN	O	O
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
requiring	VERB	O	O
the	DET	O	O
concurrent	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
statins	NOUN	O	I-Entity
and	CCONJ	O	O
CYP3A4	PROPN	O	O
inhibitors	NOUN	O	O
,	PUNCT	O	O
pravastatin	NOUN	O	I-Entity
,	PUNCT	O	O
fluvastatin	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
rosuvastatin	NOUN	O	I-Entity
carry	VERB	O	O
the	DET	O	O
lowest	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
interactions	NOUN	O	O
;	PUNCT	O	O
atorvastatin	ADJ	O	I-Entity
carries	VERB	O	O
moderate	ADJ	O	O
risk	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
simvastatin	NOUN	O	I-Entity
and	CCONJ	O	O
lovastatin	NOUN	O	I-Entity
have	VERB	O	O
the	DET	O	O
highest	ADJ	O	O
risk	NOUN	O	O
and	CCONJ	O	O
should	VERB	O	O
be	VERB	O	O
avoided	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
taking	VERB	O	O
concomitant	ADJ	O	O
CYP3A4	PROPN	O	O
inhibitors	NOUN	O	O
.	PUNCT	O	O

European	ADJ	O	O
Organization	PROPN	O	O
for	ADP	O	O
Research	PROPN	O	O
and	CCONJ	O	O
Treatment	PROPN	O	O
of	ADP	O	O
Cancer	PROPN	O	I-Entity
Gastrointestinal	PROPN	O	O
Treat	PROPN	O	O
Cancer	PROPN	O	I-Entity
Cooperative	PROPN	O	O
Group	PROPN	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
patients	NOUN	O	O
without	ADP	O	O
prior	ADJ	O	O
chemotherapy	NOUN	O	O
and	CCONJ	O	O
16	NUM	O	O
pretreated	VERB	O	O
with	ADP	O	O
cisplatin	NOUN	O	I-Entity
-	PUNCT	O	O
based	VERB	O	O
chemotherapy	NOUN	O	O
were	VERB	O	O
assessable	ADJ	O	O
for	ADP	O	O
toxicity	NOUN	O	I-Entity
and	CCONJ	O	O
response	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
feasibility	NOUN	O	O
,	PUNCT	O	O
response	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
a	DET	O	O
paclitaxel	NOUN	O	I-Entity
,	PUNCT	O	O
cisplatin	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
gemcitabine	NOUN	O	I-Entity
combination	NOUN	O	O
to	PART	O	O
treat	VERB	O	O
metastatic	ADJ	O	O
NSCLC	PROPN	O	I-Entity
.	PUNCT	O	O

All	ADJ	O	O
the	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
examined	VERB	O	O
for	ADP	O	O
toxicity	NOUN	O	I-Entity
;	PUNCT	O	O
34	NUM	O	O
were	VERB	O	O
examinable	ADJ	O	O
for	ADP	O	O
response	NOUN	O	O
.	PUNCT	O	O

World	PROPN	O	O
Health	PROPN	O	O
Organization	PROPN	O	O
Grade	PROPN	O	O
3	NUM	O	O
-	SYM	O	O
4	NUM	O	O
neutropenia	NOUN	O	I-Entity
and	CCONJ	O	O
thrombocytopenia	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
39.9%	NUM	O	O
and	CCONJ	O	O
11.4%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
one	NUM	O	O
treatment	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
death	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
paclitaxel	NOUN	O	I-Entity
,	PUNCT	O	O
cisplatin	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
gemcitabine	NOUN	O	I-Entity
is	VERB	O	O
well	ADV	O	O
tolerated	VERB	O	O
and	CCONJ	O	O
shows	VERB	O	O
high	ADJ	O	O
activity	NOUN	O	O
in	ADP	O	O
metastatic	NOUN	O	O
NSCLC	PROPN	O	I-Entity
.	PUNCT	O	O

Carmofur	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
organic	ADJ	O	B-Entity
mental	ADJ	O	I-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O



The	DET	O	O
areas	NOUN	O	O
where	ADV	O	O
calcitonin	NOUN	O	I-Entity
is	VERB	O	O
most	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
decreasing	VERB	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
are	VERB	O	O
located	VERB	O	O
in	ADP	O	O
the	DET	O	O
hypothalamus	NOUN	O	O
and	CCONJ	O	O
nucleus	NOUN	O	O
accumbens	NOUN	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
these	DET	O	O
areas	NOUN	O	O
are	VERB	O	O
the	DET	O	O
major	ADJ	O	O
sites	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
of	ADP	O	O
calcitonin	NOUN	O	I-Entity
in	ADP	O	O
inhibiting	VERB	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (8953972)

Subsequently	ADV	O	O
,	PUNCT	O	O
acute	ADJ	O	O
cardiac	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
and	CCONJ	O	O
fatal	ADJ	O	O
subarachnoid	NOUN	O	B-Entity
hemorrhage	NOUN	O	I-Entity
occurred	VERB	O	O
.	PUNCT	O	O


The	DET	O	O
clinical	ADJ	O	O
signs	NOUN	O	O
and	CCONJ	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
typical	ADJ	O	O
laboratory	NOUN	O	O
features	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
complications	NOUN	O	O
of	ADP	O	O
rhabdomyolysis	NOUN	O	I-Entity
are	VERB	O	O
presented	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (9100294)

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADJ	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blockers	NOUN	O	O
in	ADP	O	O
general	ADJ	O	O
induce	VERB	O	O
cardiovascular	NOUN	O	B-Entity
malformations	NOUN	O	I-Entity
indicating	VERB	O	O
a	DET	O	O
pharmacologic	ADJ	O	O
class	NOUN	O	O
effect	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
three	NUM	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blockers	NOUN	O	O
of	ADP	O	O
different	ADJ	O	O
structure	NOUN	O	O
,	PUNCT	O	O
nifedipine	NOUN	O	I-Entity
,	PUNCT	O	O
diltiazem	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
verapamil	ADV	O	I-Entity
,	PUNCT	O	O
along	ADP	O	O
with	ADP	O	O
the	DET	O	O
new	ADJ	O	O
agent	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (19889778)

The	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
sevoflurane	NOUN	O	I-Entity
on	ADP	O	O
lidocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
cats	NOUN	O	O
.	PUNCT	O	O

l(-1	PUNCT	O	O
)	PUNCT	O	O
when	ADV	O	O
the	DET	O	O
end	NOUN	O	O
-	PUNCT	O	O
tidal	ADJ	O	O
concentration	NOUN	O	O
of	ADP	O	O
sevoflurane	NOUN	O	I-Entity
was	VERB	O	O
0.8%	NUM	O	O
.	PUNCT	O	O

l(-1	PUNCT	O	O
)	PUNCT	O	O
)	PUNCT	O	O
during	ADP	O	O
1.6%	NUM	O	O
sevoflurane	NOUN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
significant	ADJ	O	O
from	ADP	O	O
that	DET	O	O
during	ADP	O	O
0.8%	NUM	O	O
sevoflurane	NOUN	O	I-Entity
,	PUNCT	O	O
indicating	VERB	O	O
a	DET	O	O
celling	VERB	O	O
effect	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
lidocaine	NOUN	O	I-Entity
concentrations	NOUN	O	O
measured	VERB	O	O
when	ADV	O	O
the	DET	O	O
systolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
became	VERB	O	O
70	NUM	O	O
mmHg	NOUN	O	O
.	PUNCT	O	O

(	PUNCT	O	O
Dex)-induced	VERB	O	I-Entity
hypertension	NOUN	O	I-Entity
is	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
endothelial	ADJ	O	O
dysfunction	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
(	PUNCT	O	O
NO	PROPN	O	I-Entity
)	PUNCT	O	O
deficiency	NOUN	O	O
and	CCONJ	O	O
increased	VERB	O	O
superoxide	NOUN	O	I-Entity
(	PUNCT	O	O
O2-	PROPN	O	I-Entity
)	PUNCT	O	O
production	NOUN	O	O
.	PUNCT	O	O

Atorvastatin	PROPN	O	I-Entity
(	PUNCT	O	O
Ato	PROPN	O	I-Entity
)	PUNCT	O	O
possesses	VERB	O	O
pleiotropic	ADJ	O	O
properties	NOUN	O	O
that	ADJ	O	O
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
to	PART	O	O
improve	VERB	O	O
endothelial	ADJ	O	O
function	NOUN	O	O
through	ADP	O	O
increased	VERB	O	O
availability	NOUN	O	O
of	ADP	O	O
NO	PROPN	O	I-Entity
and	CCONJ	O	O
reduced	VERB	O	O
O2-	ADJ	O	I-Entity
production	NOUN	O	O
in	ADP	O	O
various	ADJ	O	O
forms	NOUN	O	O
of	ADP	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

,	PUNCT	O	O
Ato	PROPN	O	I-Entity
could	VERB	O	O
prevent	VERB	O	O
endothelial	ADJ	O	O

NO	DET	O	I-Entity
synthase	NOUN	O	O
(	PUNCT	O	O
eNOS	PROPN	O	O
)	PUNCT	O	O

downregulation	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
O2-	PROPN	O	I-Entity
in	ADP	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
(	PUNCT	O	O
SD	PROPN	O	O
)	PUNCT	O	O
rats	NOUN	O	O
,	PUNCT	O	O
thereby	ADV	O	O
reducing	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

Dexamethasone	PROPN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
,	PUNCT	O	O
s.c	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
saline	NOUN	O	O
was	VERB	O	O
started	VERB	O	O
after	ADP	O	O
4	NUM	O	O
days	NOUN	O	O
in	ADP	O	O
Ato	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
and	CCONJ	O	O
non	ADJ	O	O
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
and	CCONJ	O	O
continued	VERB	O	O
for	ADP	O	O
11	NUM	O	O
-	SYM	O	O
13	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
Ato	PROPN	O	I-Entity
improved	VERB	O	O
endothelial	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
reduced	VERB	O	O
superoxide	NOUN	O	I-Entity
production	NOUN	O	O
and	CCONJ	O	O
reduced	VERB	O	O
SBP	PROPN	O	O
in	ADP	O	O
Dex	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
SD	NOUN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
the	DET	O	O
60	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
completed	VERB	O	O
phase	NOUN	O	O
A	NOUN	O	O
,	PUNCT	O	O
standard	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
haloperidol	NOUN	O	I-Entity
was	VERB	O	O
efficacious	ADJ	O	O
and	CCONJ	O	O
superior	ADJ	O	O
to	ADP	O	O
both	DET	O	O
low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
haloperidol	NOUN	O	I-Entity
and	CCONJ	O	O
placebo	NOUN	O	O
for	ADP	O	O
scores	NOUN	O	O
on	ADP	O	O
the	DET	O	O
Brief	PROPN	O	O
Psychiatric	PROPN	O	O
Rating	PROPN	O	O
Scale	PROPN	O	O
psychosis	NOUN	O	I-Entity
factor	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
psychomotor	NOUN	O	B-Entity
agitation	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
narrow	ADJ	O	O
therapeutic	ADJ	O	O
window	NOUN	O	O
observed	VERB	O	O
with	ADP	O	O
haloperidol	NOUN	O	I-Entity
may	VERB	O	O
also	ADV	O	O
apply	VERB	O	O
to	ADP	O	O
other	ADJ	O	O
neuroleptics	NOUN	O	O
used	VERB	O	O
in	ADP	O	O
Alzheimer	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
psychosis	NOUN	O	I-Entity
and	CCONJ	O	O
disruptive	ADJ	O	B-Entity
behaviors	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (15572383)

Proteinuria	PROPN	O	I-Entity
was	VERB	O	O
measured	VERB	O	O
every	DET	O	O
2	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
supports	VERB	O	O
the	DET	O	O
assumption	NOUN	O	O
that	ADP	O	O
differences	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
ACE	PROPN	O	O
activity	NOUN	O	O
predispose	VERB	O	O
to	ADP	O	O
a	DET	O	O
less	ADV	O	O
favourable	ADJ	O	O
course	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
.	PUNCT	O	O


In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
62	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
confirmed	VERB	O	O
initial	ADJ	O	O
normal	ADJ	O	O
renal	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
treated	VERB	O	O
with	ADP	O	O
2	NUM	O	O
to	PART	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
of	ADP	O	O
gentamicin	NOUN	O	B-Entity
sulfate	NOUN	O	I-Entity
or	CCONJ	O	O
tobramycin	NOUN	O	B-Entity
sulfate	NOUN	O	I-Entity
for	ADP	O	O
a	DET	O	O
minimum	NOUN	O	O
of	ADP	O	O
seven	NUM	O	O
days	NOUN	O	O
were	VERB	O	O
followed	VERB	O	O
up	PART	O	O
prospectively	ADV	O	O
for	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
aminoglycoside	ADV	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
defined	VERB	O	O
as	ADP	O	O
at	ADV	O	O
least	ADJ	O	O
a	DET	O	O
one	NUM	O	O
-	PUNCT	O	O
third	NOUN	O	O
reduction	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O


Methamphetamine	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
sc	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
administered	VERB	O	O
five	NUM	O	O
times	NOUN	O	O
,	PUNCT	O	O
reduced	VERB	O	O
the	DET	O	O
levels	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
metabolites	NOUN	O	O
in	ADP	O	O
striatal	ADJ	O	O
tissue	NOUN	O	O
when	ADV	O	O
measured	VERB	O	O
72	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
the	DET	O	O
last	ADJ	O	O
injection	NOUN	O	O
.	PUNCT	O	O

Neuroprotection	NOUN	O	O
rendered	VERB	O	O
by	ADP	O	O
MPEP	PROPN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dopamine	NOUN	O	I-Entity
efflux	NOUN	O	O
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
due	ADP	O	O
to	ADP	O	O
the	DET	O	O
blockade	NOUN	O	O
of	ADP	O	O
extrastriatal	NOUN	O	O
mGluR5	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
with	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
hyperthermia	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
vitro	NOUN	O	O
work	NOUN	O	O
has	VERB	O	O
demonstrated	VERB	O	O
that	ADP	O	O
cinacalcet	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
strong	ADJ	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
cytochrome	NOUN	O	O
P450	PROPN	O	O
isoenzyme	NOUN	O	O
(	PUNCT	O	O
CYP	PROPN	O	O
)	PUNCT	O	O
2D6	NUM	O	O
.	PUNCT	O	O

Seventeen	NUM	O	O
subjects	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
genotyped	VERB	O	O
as	ADP	O	O
CYP2D6	PROPN	O	O
extensive	ADJ	O	O
metabolizers	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
in	ADP	O	O
this	DET	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
open	ADJ	O	O
-	PUNCT	O	O
label	NOUN	O	O
,	PUNCT	O	O
crossover	ADJ	O	O
study	NOUN	O	O
to	PART	O	O
receive	VERB	O	O
a	DET	O	O
single	ADJ	O	O
oral	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
desipramine	NOUN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
on	ADP	O	O
two	NUM	O	O
separate	ADJ	O	O
occasions	NOUN	O	O
,	PUNCT	O	O
once	ADV	O	O
alone	ADV	O	O
and	CCONJ	O	O
once	ADV	O	O
after	ADP	O	O
multiple	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
cinacalcet	NOUN	O	I-Entity
(	PUNCT	O	O
90	NUM	O	O
mg	NUM	O	O
for	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
during	ADP	O	O
concomitant	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
cinacalcet	NOUN	O	I-Entity
,	PUNCT	O	O
dose	NOUN	O	O
adjustment	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
necessary	ADJ	O	O
for	ADP	O	O
drugs	NOUN	O	O
that	ADJ	O	O
demonstrate	VERB	O	O
a	DET	O	O
narrow	ADJ	O	O
therapeutic	ADJ	O	O
index	NOUN	O	O
and	CCONJ	O	O
are	VERB	O	O
metabolized	VERB	O	O
by	ADP	O	O
CYP2D6	PROPN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
examinations	NOUN	O	O
and	CCONJ	O	O
skin	NOUN	O	O
,	PUNCT	O	O
oral	ADJ	O	O
and	CCONJ	O	O
parenteral	ADJ	O	O
challenges	NOUN	O	O
with	ADP	O	O
different	ADJ	O	O
corticosteroids	NOUN	O	I-Entity
and	CCONJ	O	O
ELISA	PROPN	O	O
tests	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
.	PUNCT	O	O


The	DET	O	O
typical	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
VPA	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
encephalopathy	NOUN	O	I-Entity
are	VERB	O	O
impaired	ADJ	O	B-Entity
consciousness	NOUN	O	I-Entity
,	PUNCT	O	O
sometimes	ADV	O	O
marked	VERB	O	O
EEG	PROPN	O	O
background	NOUN	O	O
slowing	NOUN	O	O
,	PUNCT	O	O
increased	VERB	O	O
seizure	NOUN	O	I-Entity
frequency	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
hyperammonemia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3173180)

Among	ADP	O	O
547	NUM	O	O
preterm	NOUN	O	O
infants	NOUN	O	O
of	ADP	O	O
<	NUM	O	O
or	CCONJ	O	O
=	SYM	O	O
34	NUM	O	O
weeks	NOUN	O	O
gestation	NOUN	O	O
born	VERB	O	O
between	ADP	O	O
1987	NUM	O	O
and	CCONJ	O	O
1991	NUM	O	O
,	PUNCT	O	O
8	NUM	O	O
children	NOUN	O	O
(	PUNCT	O	O
1.46%	NUM	O	O
)	PUNCT	O	O
developed	VERB	O	O
severe	ADJ	O	O
progressive	ADJ	O	O
and	CCONJ	O	O
bilateral	ADJ	O	O
sensorineural	ADJ	O	B-Entity
hearing	NOUN	O	I-Entity
loss	NOUN	O	I-Entity
.	PUNCT	O	O

Perinatal	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
of	ADP	O	O
infants	NOUN	O	O
with	ADP	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
those	DET	O	O
of	ADP	O	O
two	NUM	O	O
control	NOUN	O	O
groups	NOUN	O	O
matched	VERB	O	O
for	ADP	O	O
gestation	NOUN	O	O
and	CCONJ	O	O
birth	NOUN	O	O
weight	NOUN	O	O
and	CCONJ	O	O
for	ADP	O	O
perinatal	ADJ	O	O
complications	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
6	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
both	DET	O	O
renal	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
liver	NOUN	O	I-Entity
dysfunction	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
cimetidine	NOUN	O	I-Entity
trough	NOUN	O	O
-	PUNCT	O	O
concentrations	NOUN	O	O
of	ADP	O	O
more	ADJ	O	O
than	ADP	O	O
1.25	NUM	O	O
microgram	NOUN	O	O
/	SYM	O	O
ml	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
likely	ADV	O	O
to	PART	O	O
have	VERB	O	O
both	DET	O	O
raised	VERB	O	O
trough	NOUN	O	O
-	PUNCT	O	O
concentrations	NOUN	O	O
and	CCONJ	O	O
mental	ADJ	O	O
confusion	NOUN	O	I-Entity
are	VERB	O	O
those	DET	O	O
with	ADP	O	O
both	DET	O	O
severe	ADJ	O	O
renal	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
hepatic	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
EE	PROPN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
changes	NOUN	O	O
in	ADP	O	O
immunostaining	VERB	O	O
for	ADP	O	O
7H6	NUM	O	O
and	CCONJ	O	O
ZO-1	NUM	O	O
were	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
seen	VERB	O	O
in	ADP	O	O
periportal	NOUN	O	O
hepatocytes	NOUN	O	O
after	ADP	O	O
BDL	PROPN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
distributed	VERB	O	O
more	ADV	O	O
diffusely	ADV	O	O
throughout	ADP	O	O
the	DET	O	O
lobule	NOUN	O	O
.	PUNCT	O	O


Subjects	NOUN	O	O
were	VERB	O	O
receiving	VERB	O	O
desferrioxamine	NOUN	O	I-Entity
(	PUNCT	O	O
DFO	PROPN	O	I-Entity
)	PUNCT	O	O
chelation	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
a	DET	O	O
mean	ADJ	O	O
daily	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
50	NUM	O	O
-	PUNCT	O	O
60	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
,	PUNCT	O	O
5	NUM	O	O
-	SYM	O	O
6	NUM	O	O
days	NOUN	O	O
a	DET	O	O
week	NOUN	O	O
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
six	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
then	ADV	O	O
reduced	VERB	O	O
to	ADP	O	O
40	NUM	O	O
-	SYM	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
for	ADP	O	O
the	DET	O	O
following	VERB	O	O
eight	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Design	NOUN	O	O
and	CCONJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
HYPREN	PROPN	O	O
-	PUNCT	O	O
trial	NOUN	O	O
:	PUNCT	O	O
safety	NOUN	O	O
of	ADP	O	O
enalapril	NOUN	O	I-Entity
and	CCONJ	O	O
prazosin	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
treatment	NOUN	O	O
phase	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O


in	ADP	O	O
control	NOUN	O	O
Krebs	PROPN	O	O
-	PUNCT	O	O
Ringer	PROPN	O	O
containing	VERB	O	O
137	NUM	O	O
mM	NOUN	O	O
Na	PROPN	O	I-Entity
and	CCONJ	O	O
1.35	NUM	O	O
mM	NOUN	O	O
Ca	PROPN	O	I-Entity
(	PUNCT	O	O
N	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

[	PUNCT	O	O
Na]o	PROPN	O	I-Entity
to	ADP	O	O
78	NUM	O	O
mM	NOUN	O	O
and	CCONJ	O	O
[	PUNCT	O	O
Ca]o	PROPN	O	I-Entity
to	ADP	O	O
0.675	NUM	O	O
mM	PROPN	O	O
(	PUNCT	O	O
LNa+LCa	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
31	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

At	ADP	O	O
normal	ADJ	O	O
[	PUNCT	O	O
Na]o	PROPN	O	I-Entity
,	PUNCT	O	O
decrease	NOUN	O	O
(	PUNCT	O	O
0.675	NUM	O	O
mM	PROPN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
increase	NOUN	O	O
(	PUNCT	O	O
3.6	NUM	O	O
mM	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
[	PUNCT	O	O
Ca]o	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
modify	VERB	O	O
BF	PROPN	O	O
;	PUNCT	O	O
a	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
ten	NUM	O	O
times	NOUN	O	O
(	PUNCT	O	O
0.135	PUNCT	O	O
mM	PROPN	O	O
of	ADP	O	O
normal	ADJ	O	O
[	PUNCT	O	O
Ca]o	PROPN	O	I-Entity
was	VERB	O	O
effective	ADJ	O	O
to	PART	O	O
reduce	VERB	O	O
BF	NOUN	O	O
by	ADP	O	O
40	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
bradycardia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
verapamil	NOUN	O	I-Entity
was	VERB	O	O
potentiated	VERB	O	O
by	ADP	O	O
LNa	PROPN	O	O
,	PUNCT	O	O
LCa	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
HCa	PROPN	O	O
.	PUNCT	O	O

-DOCSTART- (19346865)

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
This	DET	O	O
is	VERB	O	O
to	PART	O	O
present	VERB	O	O
reversible	ADJ	O	O
inferior	ADJ	O	B-Entity
colliculus	NOUN	O	I-Entity
lesions	NOUN	O	I-Entity
in	ADP	O	O
metronidazole	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
encephalopathy	NOUN	O	I-Entity
,	PUNCT	O	O
to	PART	O	O
focus	VERB	O	O
on	ADP	O	O
the	DET	O	O
diffusion	NOUN	O	O
-	PUNCT	O	O
weighted	VERB	O	O
imaging	NOUN	O	O
(	PUNCT	O	O
DWI	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
fluid	ADJ	O	O
attenuated	ADJ	O	O
inversion	NOUN	O	O
recovery	NOUN	O	O
(	PUNCT	O	O
FLAIR	PROPN	O	O
)	PUNCT	O	O
imaging	VERB	O	O
.	PUNCT	O	O

From	ADP	O	O
November	PROPN	O	O
2005	NUM	O	O
to	ADP	O	O
September	PROPN	O	O
2007	NUM	O	O
,	PUNCT	O	O
8	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
men	NOUN	O	O
and	CCONJ	O	O
3	NUM	O	O
women	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
diagnosed	VERB	O	O
as	ADP	O	O
having	VERB	O	O
metronidazole	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
encephalopathy	NOUN	O	I-Entity
(	PUNCT	O	O
age	NOUN	O	O
range	NOUN	O	O
;	PUNCT	O	O
43	NUM	O	O
-	PUNCT	O	O
78	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

-DOCSTART- (2334618)

Monitoring	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
airflow	NOUN	O	O
detection	NOUN	O	O
by	ADP	O	O
a	DET	O	O
carbon	NOUN	O	B-Entity
dioxide	NOUN	O	I-Entity
analyser	NOUN	O	O
,	PUNCT	O	O
chest	NOUN	O	O
wall	NOUN	O	O
movement	NOUN	O	O
detected	VERB	O	O
by	ADP	O	O
pneumatic	ADJ	O	O
capsules	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
continuous	ADJ	O	O
electrocardiograph	NOUN	O	O
recorded	VERB	O	O
with	ADP	O	O
a	DET	O	O
Holter	PROPN	O	O
ambulatory	NOUN	O	O
monitor	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (8864707)

Using	VERB	O	O
linear	NOUN	O	O
regression	NOUN	O	O
we	PRON	O	O
found	VERB	O	O
that	ADP	O	O
no	DET	O	O
correlation	NOUN	O	O
exists	VERB	O	O
between	ADP	O	O
seizure	NOUN	O	I-Entity
duration	NOUN	O	O
,	PUNCT	O	O
elevation	NOUN	O	O
of	ADP	O	O
phenytoin	NOUN	O	I-Entity
serum	NOUN	O	O
levels	NOUN	O	O
and	CCONJ	O	O
cerebellar	ADJ	O	O
volume	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
multiple	ADJ	O	O
regression	NOUN	O	O
for	ADP	O	O
the	DET	O	O
daily	ADJ	O	O
dosage	NOUN	O	O
,	PUNCT	O	O
duration	NOUN	O	O
of	ADP	O	O
phenytoin	NOUN	O	I-Entity
treatment	NOUN	O	O
and	CCONJ	O	O
cerebellar	NOUN	O	O
volume	NOUN	O	O
revealed	VERB	O	O
a	DET	O	O
correlation	NOUN	O	O
of	ADP	O	O
these	DET	O	O
parameters	NOUN	O	O
.	PUNCT	O	O

Quantitative	ADJ	O	O
morphometric	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cerebellum	NOUN	O	O
provide	VERB	O	O
valuable	ADJ	O	O
insights	NOUN	O	O
into	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
cerebellar	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

Thirty	NUM	O	O
-	PUNCT	O	O
five	NUM	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
1.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
DOX	PROPN	O	I-Entity
,	PUNCT	O	O
i.v	PROPN	O	O
.	PUNCT	O	O

By	ADP	O	O
using	VERB	O	O
transthoracic	NOUN	O	O
echocardiography	NOUN	O	O
,	PUNCT	O	O
anterior	ADJ	O	O
and	CCONJ	O	O
posterior	ADJ	O	O
wall	NOUN	O	O
thickness	NOUN	O	O
,	PUNCT	O	O
LV	PROPN	O	O
diameters	NOUN	O	O
and	CCONJ	O	O
LV	PROPN	O	O
fractional	ADJ	O	O
shortening	NOUN	O	O
(	PUNCT	O	O
FS	PROPN	O	O
)	PUNCT	O	O
were	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
all	DET	O	O
rats	NOUN	O	O
before	ADP	O	O
DOX	PROPN	O	I-Entity
or	CCONJ	O	O
saline	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
weeks	NOUN	O	O
6	NUM	O	O
and	CCONJ	O	O
9	NUM	O	O
after	ADP	O	O
treatment	NOUN	O	O
in	ADP	O	O
all	DET	O	O
surviving	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Histology	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
DOX	PROPN	O	I-Entity
-	PUNCT	O	O
rats	NOUN	O	O
at	ADP	O	O
6	NUM	O	O
and	CCONJ	O	O
9	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
the	DET	O	O
last	ADJ	O	O
DOX	PROPN	O	I-Entity
dose	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
all	DET	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Calcineurin	PROPN	O	O
-	PUNCT	O	O
inhibitor	NOUN	O	O
induced	VERB	O	O
pain	NOUN	O	I-Entity
syndrome	NOUN	O	O
(	PUNCT	O	O
CIPS	PROPN	O	I-Entity
)	PUNCT	O	O
:	PUNCT	O	O
a	DET	O	O
severe	ADJ	O	O
disabling	VERB	O	O
complication	NOUN	O	O
after	ADP	O	O
organ	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

Nine	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
pain	NOUN	O	I-Entity
in	ADP	O	O
their	ADJ	O	O
feet	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
registered	VERB	O	O
after	ADP	O	O
transplantation	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
investigated	VERB	O	O
.	PUNCT	O	O

-DOCSTART- (10520387)

The	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
ephedrine	NOUN	O	I-Entity
to	ADP	O	O
propofol	NOUN	O	I-Entity
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
method	NOUN	O	O
of	ADP	O	O
obtunding	VERB	O	O
the	DET	O	O
hypotensive	ADJ	O	I-Entity
response	NOUN	O	O
to	ADP	O	O
propofol	VERB	O	I-Entity
at	ADP	O	O
all	ADV	O	O
doses	NOUN	O	O
used	VERB	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
six	NUM	O	O
of	ADP	O	O
the	DET	O	O
probable	ADJ	O	O
cases	NOUN	O	O
the	DET	O	O
neurological	ADJ	O	B-Entity
disturbance	NOUN	O	I-Entity
consisted	VERB	O	O
of	ADP	O	O
an	DET	O	O
acute	ADJ	O	O
reversible	ADJ	O	O
encephalopathy	NOUN	O	I-Entity
usually	ADV	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
ingestion	NOUN	O	O
of	ADP	O	O
a	DET	O	O
high	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
clioquinol	NOUN	O	I-Entity
over	ADP	O	O
a	DET	O	O
short	ADJ	O	O
period	NOUN	O	O
.	PUNCT	O	O

Epileptic	ADJ	O	B-Entity
seizures	NOUN	O	I-Entity
following	VERB	O	O
cortical	ADJ	O	O
application	NOUN	O	O
of	ADP	O	O
fibrin	NOUN	O	O
sealants	NOUN	O	O
containing	VERB	O	O
tranexamic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Male	PROPN	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
(	PUNCT	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
pen	NOUN	O	I-Entity
)	PUNCT	O	O
500	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
for	ADP	O	O
10	NUM	O	O
or	CCONJ	O	O
42	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O


Three	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
after	ADP	O	O
the	DET	O	O
completion	NOUN	O	O
of	ADP	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
estimate	VERB	O	O
the	DET	O	O
association	NOUN	O	O
between	ADP	O	O
antibacterial	ADJ	O	O
medications	NOUN	O	O
and	CCONJ	O	O
selected	VERB	O	O
birth	NOUN	O	B-Entity
defects	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (3970039)

Incidence	NOUN	O	O
of	ADP	O	O
neoplasms	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
exposed	VERB	O	O
to	ADP	O	O
different	ADJ	O	O
treatment	NOUN	O	O
regimens	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
alkylating	VERB	O	B-Entity
agents	NOUN	O	I-Entity
have	VERB	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
development	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
nonlymphocytic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
both	DET	O	O
alkylating	VERB	O	B-Entity
agents	NOUN	O	I-Entity
and	CCONJ	O	O
azathioprine	NOUN	O	I-Entity
are	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
non	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
Hodgkin	PROPN	O	I-Entity
's	PART	O	I-Entity
lymphoma	NOUN	O	I-Entity
.	PUNCT	O	O

Data	NOUN	O	O
on	ADP	O	O
the	DET	O	O
possible	ADJ	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
malignancy	NOUN	O	I-Entity
in	ADP	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
are	VERB	O	O
still	ADV	O	O
being	VERB	O	O
collected	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
until	ADP	O	O
further	ADJ	O	O
information	NOUN	O	O
is	VERB	O	O
available	ADJ	O	O
,	PUNCT	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
immunosuppressive	ADJ	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
alkylating	VERB	O	B-Entity
agents	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
reserved	VERB	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
progressive	ADJ	O	O
disease	NOUN	O	O
or	CCONJ	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
complications	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (424937)

Patterns	NOUN	O	O
of	ADP	O	O
hepatic	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
methyldopa	NOUN	O	I-Entity
.	PUNCT	O	O

Jaundice	PROPN	O	I-Entity
with	ADP	O	O
tender	NOUN	O	O
hepatomegaly	NOUN	O	I-Entity
,	PUNCT	O	O
usually	ADV	O	O
preceded	VERB	O	O
by	ADP	O	O
symptoms	NOUN	O	O
of	ADP	O	O
malaise	NOUN	O	O
,	PUNCT	O	O
anorexia	NOUN	O	I-Entity
,	PUNCT	O	O
nausea	NOUN	O	I-Entity
and	CCONJ	O	O
vomiting	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
associated	VERB	O	O
with	ADP	O	O
upper	ADJ	O	O
abdominal	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
,	PUNCT	O	O
was	VERB	O	O
an	DET	O	O
invariable	ADJ	O	O
finding	NOUN	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (8643971)

With	ADP	O	O
paclitaxel	NOUN	O	I-Entity
doses	NOUN	O	O
of	ADP	O	O
200	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
m2	NOUN	O	O
and	CCONJ	O	O
higher	ADJ	O	O
,	PUNCT	O	O
granulocyte	ADJ	O	O
colony	NOUN	O	O
-	PUNCT	O	O
stimulating	VERB	O	O
factor	NOUN	O	O
5	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	ADV	O	O
/	SYM	O	O
d	PROPN	O	O
is	VERB	O	O
given	VERB	O	O
(	PUNCT	O	O
days	NOUN	O	O
4	NUM	O	O
through	ADP	O	O
12	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

-DOCSTART- (2224762)

Myelosuppression	PROPN	O	I-Entity
was	VERB	O	O
more	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hepatic	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

Pharmacokinetic	ADJ	O	O
analyses	NOUN	O	O
in	ADP	O	O
21	NUM	O	O
patients	NOUN	O	O
revealed	VERB	O	O
Pirarubicin	PROPN	O	I-Entity
plasma	NOUN	O	O
T	PROPN	O	O
1/2	NUM	O	O
alpha	NOUN	O	O
(	PUNCT	O	O
+	X	O	O
/-	PUNCT	O	O

Gamma	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
hexachlorocyclohexane	PROPN	O	I-Entity
(	PUNCT	O	O
gamma	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
HCH	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
active	ADJ	O	O
ingredient	NOUN	O	O
of	ADP	O	O
the	DET	O	O
insecticide	NOUN	O	O
lindane	NOUN	O	I-Entity
,	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
decrease	VERB	O	O
seizure	NOUN	O	I-Entity
threshold	NOUN	O	O
to	ADP	O	O
pentylenetrazol	NOUN	O	O
(	PUNCT	O	O
PTZ	PROPN	O	I-Entity
)	PUNCT	O	O
3	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
gamma	VERB	O	B-Entity
-	PUNCT	O	I-Entity
HCH	PROPN	O	I-Entity
and	CCONJ	O	O
conversely	ADV	O	O
increase	VERB	O	O
threshold	NOUN	O	O
to	ADP	O	O
PTZ	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
24	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
gamma	VERB	O	B-Entity
-	PUNCT	O	I-Entity
HCH	PROPN	O	I-Entity
(	PUNCT	O	O
Vohland	PROPN	O	O
et	PROPN	O	O
al	PROPN	O	O
.	PUNCT	O	O
1981	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Seizure	NOUN	O	I-Entity
activity	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
PTZ	PROPN	O	I-Entity
and	CCONJ	O	O
picrotoxin	NOUN	O	I-Entity
(	PUNCT	O	O
PTX	PROPN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
decreased	VERB	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
seizure	NOUN	O	I-Entity
activity	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
3-mercaptopropionic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
MPA	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
bicuculline	NOUN	O	I-Entity
(	PUNCT	O	O
BCC	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
methyl	NOUN	O	B-Entity
6,7-dimethoxy-4-ethyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
B	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
carboline-3-carboxylate	NOUN	O	I-Entity
(	PUNCT	O	O
DMCM	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
strychnine	NOUN	O	I-Entity
(	PUNCT	O	O
STR	PROPN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
not	ADV	O	O
different	ADJ	O	O
from	ADP	O	O
control	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
experienced	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
ocular	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
orbital	ADJ	O	I-Entity
toxicity	NOUN	O	I-Entity
after	ADP	O	O
intracarotid	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
carboplatin	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
infrequently	ADV	O	O
reported	VERB	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
intraocular	NOUN	O	O
pressure	NOUN	O	O
elevation	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
secondary	ADJ	O	O
acute	ADJ	O	O
angle	NOUN	O	O
-	PUNCT	O	O
closure	NOUN	O	O
glaucoma	NOUN	O	I-Entity
decreased	VERB	O	O
and	CCONJ	O	O
ocular	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
diminished	VERB	O	O
,	PUNCT	O	O
inexorable	ADJ	O	O
papilledema	NOUN	O	I-Entity
and	CCONJ	O	O
exudative	ADJ	O	O
retinal	ADJ	O	B-Entity
detachment	NOUN	O	I-Entity
continued	VERB	O	O
for	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18809400)

Alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
lipoic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
prevents	VERB	O	O
mitochondrial	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
and	CCONJ	O	O
neurotoxicity	NOUN	O	I-Entity
in	ADP	O	O
experimental	ADJ	O	O
chemotherapy	NOUN	O	O
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
investigates	VERB	O	O
if	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
lipoic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
is	VERB	O	O
neuroprotective	ADJ	O	O
against	ADP	O	O
chemotherapy	NOUN	O	O
induced	VERB	O	O
neurotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
if	ADP	O	O
mitochondrial	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
plays	VERB	O	O
a	DET	O	O
critical	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
toxic	ADJ	O	B-Entity
neurodegenerative	ADJ	O	I-Entity
cascade	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
if	ADP	O	O
neuroprotective	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
lipoic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
depend	VERB	O	O
on	ADP	O	O
mitochondria	ADJ	O	O
protection	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
approach	NOUN	O	O
allowed	VERB	O	O
investigating	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
lipoic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
in	ADP	O	O
preventing	VERB	O	O
axonal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
and	CCONJ	O	O
apoptosis	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
function	NOUN	O	O
and	CCONJ	O	O
ultrastructural	ADJ	O	O
morphology	NOUN	O	O
of	ADP	O	O
mitochondria	NOUN	O	O
after	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
toxic	ADJ	O	O
agents	NOUN	O	O
and	CCONJ	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
lipoic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O

Optimising	VERB	O	O
stroke	NOUN	O	I-Entity
prevention	NOUN	O	O
in	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
valvular	ADJ	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
.	PUNCT	O	O

Pooled	VERB	O	O
data	NOUN	O	O
from	ADP	O	O
trials	NOUN	O	O
comparing	VERB	O	O
antithrombotic	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
placebo	NOUN	O	O
have	VERB	O	O
shown	VERB	O	O
that	ADP	O	O
warfarin	NOUN	O	I-Entity
reduces	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
stroke	NOUN	O	I-Entity
by	ADP	O	O
62%	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
that	ADP	O	O
aspirin	NOUN	O	I-Entity
alone	ADV	O	O
reduces	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
by	ADP	O	O
22%	NUM	O	O
.	PUNCT	O	O

A	DET	O	O
synergistic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
etoposide	ADV	O	I-Entity
and	CCONJ	O	O
cyclosporin	VERB	O	B-Entity
A	DET	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
T	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
lymphocytic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
in	ADP	O	O
relapse	NOUN	O	O
.	PUNCT	O	O

Severe	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
mental	ADJ	O	O
confusion	NOUN	O	I-Entity
and	CCONJ	O	O
progressive	ADJ	O	O
hyperbilirubinemia	NOUN	O	I-Entity
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
point	NOUN	O	O
to	ADP	O	O
an	DET	O	O
enhancement	NOUN	O	O
not	ADV	O	O
only	ADV	O	O
of	ADP	O	O
antineoplastic	ADJ	O	O
effects	NOUN	O	O
but	CCONJ	O	O
also	ADV	O	O
of	ADP	O	O
toxicity	NOUN	O	I-Entity
in	ADP	O	O
normal	ADJ	O	O
tissues	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
report	NOUN	O	O
demonstrates	VERB	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
time	NOUN	O	O
that	ADP	O	O
the	DET	O	O
pharmacodynamic	ADJ	O	O
properties	NOUN	O	O
of	ADP	O	O
cyclosporin	NOUN	O	B-Entity
A	NOUN	O	I-Entity
may	VERB	O	O
not	ADV	O	O
be	VERB	O	O
confined	VERB	O	O
strictly	ADV	O	O
to	ADP	O	O
suppression	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	O
T	PROPN	O	O
-	PUNCT	O	O
cell	NOUN	O	O
functions	NOUN	O	O
.	PUNCT	O	O

Upon	ADP	O	O
rechallenge	NOUN	O	O
with	ADP	O	O
either	CCONJ	O	O
cephalosporin	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
hematologic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
was	VERB	O	O
reproduced	VERB	O	O
in	ADP	O	O
most	ADJ	O	O
dogs	NOUN	O	O
tested	VERB	O	O
;	PUNCT	O	O
cefonicid	NOUN	O	I-Entity
(	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
cefazedone)-treated	VERB	O	I-Entity
dogs	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
substantially	ADV	O	O
reduced	VERB	O	O
induction	NOUN	O	O
period	NOUN	O	O
(	PUNCT	O	O
15	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

A	DET	O	O
pyridoxine	NOUN	O	I-Entity
-	PUNCT	O	O
dependent	ADJ	O	O
behavioral	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
unmasked	VERB	O	O
by	ADP	O	O
isoniazid	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
placebo	NOUN	O	O
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
niacinamide	ADV	O	I-Entity
was	VERB	O	O
as	ADV	O	O
effective	ADJ	O	O
as	ADP	O	O
pyridoxine	NOUN	O	I-Entity
.	PUNCT	O	O

NRA0160	PUNCT	O	I-Entity
has	VERB	O	O
negligible	ADJ	O	O
affinity	NOUN	O	O
for	ADP	O	O
the	DET	O	O
human	NOUN	O	O
cloned	VERB	O	O
dopamine	NOUN	O	I-Entity
D3	PROPN	O	O
receptor	NOUN	O	O
(	PUNCT	O	O
Ki=39	PROPN	O	O
nM	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
rat	NOUN	O	O
serotonin	NOUN	O	I-Entity
(	PUNCT	O	O
5-HT)2A	ADJ	O	I-Entity
receptors	NOUN	O	O
(	PUNCT	O	O
Ki=180	PROPN	O	O
nM	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
rat	NOUN	O	O
alpha1	NOUN	O	O
adrenoceptor	NOUN	O	O
(	PUNCT	O	O
Ki=237	PROPN	O	O
nM	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

NRA0160	PROPN	O	I-Entity
and	CCONJ	O	O
clozapine	NOUN	O	I-Entity
antagonized	VERB	O	O
MAP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
stereotyped	ADJ	O	O
behavior	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
their	ADJ	O	O
effects	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
exceed	VERB	O	O
50%	NUM	O	O
inhibition	NOUN	O	O
,	PUNCT	O	O
even	ADV	O	O
at	ADP	O	O
the	DET	O	O
highest	ADJ	O	O
dose	NOUN	O	O
given	VERB	O	O
.	PUNCT	O	O

clozapine	NOUN	O	I-Entity
significantly	ADV	O	O
shortened	VERB	O	O
the	DET	O	O
phencyclidine	NOUN	O	I-Entity
(	PUNCT	O	O
PCP)-induced	PROPN	O	I-Entity
prolonged	ADJ	O	O
swimming	NOUN	O	O
latency	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
in	ADP	O	O
a	DET	O	O
water	NOUN	O	O
maze	NOUN	O	O
task	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (3496378)

-DOCSTART- (3076126)

Modest	ADJ	O	O
increases	NOUN	O	O
in	ADP	O	O
HDL	PROPN	O	O
-	PUNCT	O	O
cholesterol	NOUN	O	I-Entity
levels	NOUN	O	O
of	ADP	O	O
about	ADV	O	O
10%	NUM	O	O
are	VERB	O	O
also	ADV	O	O
reported	VERB	O	O
.	PUNCT	O	O

Lovastatin	PROPN	O	I-Entity
and	CCONJ	O	O
simvastatin	NOUN	O	I-Entity
are	VERB	O	O
both	DET	O	O
effective	ADJ	O	O
and	CCONJ	O	O
well	ADV	O	O
-	PUNCT	O	O
tolerated	VERB	O	O
agents	NOUN	O	O
for	ADP	O	O
lowering	VERB	O	O
elevated	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
cholesterol	NOUN	O	I-Entity
.	PUNCT	O	O

As	ADP	O	O
wider	ADJ	O	O
use	NOUN	O	O
confirms	VERB	O	O
their	ADJ	O	O
safety	NOUN	O	O
profile	NOUN	O	O
,	PUNCT	O	O
they	PRON	O	O
will	VERB	O	O
gain	VERB	O	O
increasing	VERB	O	O
importance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
therapeutic	ADJ	O	O
approach	NOUN	O	O
to	ADP	O	O
hypercholesterolaemia	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
consequences	NOUN	O	O
.	PUNCT	O	O

Optimization	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
fourth	ADJ	O	O
patient	NOUN	O	O
who	NOUN	O	O
was	VERB	O	O
unconscious	ADJ	O	O
after	ADP	O	O
chlormethiazole	ADJ	O	I-Entity
administration	NOUN	O	O
exhibite	ADV	O	O
generalized	ADJ	O	O
non	ADJ	O	O
-	PUNCT	O	O
reactive	ADJ	O	O
activity	NOUN	O	O
in	ADP	O	O
the	DET	O	O
slow	ADJ	O	O
beta	NOUN	O	O
range	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
similarities	NOUN	O	O
between	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
structural	ADJ	O	O
lesions	NOUN	O	O
and	CCONJ	O	O
pharmacological	ADJ	O	O
depression	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
stem	VERB	O	O
reticular	ADJ	O	O
formation	NOUN	O	O
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O

-DOCSTART- (18544179)

Omission	NOUN	O	O
of	ADP	O	O
fentanyl	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
reduce	VERB	O	O
the	DET	O	O
overall	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	B-Entity
nausea	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
vomiting	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
did	VERB	O	O
reduce	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
vomiting	NOUN	O	I-Entity
and/or	CCONJ	O	O
moderate	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
nausea	NOUN	O	I-Entity
prior	ADV	O	O
to	PART	O	O
discharge	NOUN	O	O
from	ADP	O	O
20%	NUM	O	O
and	CCONJ	O	O
17%	NUM	O	O
with	ADP	O	O
fentanyl	NOUN	O	I-Entity
and	CCONJ	O	O
fentanyl	NOUN	O	I-Entity
-	PUNCT	O	O
dexamethasone	NOUN	O	I-Entity
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
to	ADP	O	O
5%	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.013	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
a	DET	O	O
15-yr	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
girl	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
orthotopic	ADJ	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
Wilson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Tacrolimus	PROPN	O	I-Entity
,	PUNCT	O	O
MMF	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
steroids	NOUN	O	I-Entity
were	VERB	O	O
given	VERB	O	O
as	ADP	O	O
immunosuppressant	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (16867021)

Antipsychotic	ADJ	O	O
-	PUNCT	O	O
like	ADJ	O	O
profile	NOUN	O	O
of	ADP	O	O
thioperamide	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
selective	ADJ	O	O
H3-receptor	NOUN	O	O
antagonist	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
THP	PROPN	O	I-Entity
(	PUNCT	O	O
3.75	NUM	O	O
,	PUNCT	O	O
7.5	NUM	O	O
and	CCONJ	O	O
15	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
1	NUM	O	O

Climbing	VERB	O	O
behavior	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
apomorphine	NOUN	O	I-Entity
was	VERB	O	O
reduced	VERB	O	O
in	ADP	O	O
animals	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
THP	PROPN	O	I-Entity
.	PUNCT	O	O

Such	ADJ	O	O
an	DET	O	O
effect	NOUN	O	O
was	VERB	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
reversed	VERB	O	O
in	ADP	O	O
presence	NOUN	O	O
of	ADP	O	O
RAMH	PROPN	O	I-Entity
.	PUNCT	O	O

THP	PROPN	O	I-Entity
exhibited	VERB	O	O
an	DET	O	O
antipsychotic	ADJ	O	O
-	PUNCT	O	O
like	ADJ	O	O
profile	NOUN	O	O
by	ADP	O	O
potentiating	VERB	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
,	PUNCT	O	O
reducing	VERB	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
and	CCONJ	O	O
reducing	VERB	O	O
apomorphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
climbing	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11745184)

Amifostine	PROPN	O	I-Entity
subsequently	ADV	O	O
was	VERB	O	O
shown	VERB	O	O
to	PART	O	O
protect	VERB	O	O
normal	ADJ	O	O
tissues	NOUN	O	O
from	ADP	O	O
the	DET	O	O
toxic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
alkylating	VERB	O	B-Entity
agents	NOUN	O	I-Entity
and	CCONJ	O	O
cisplatin	NOUN	O	I-Entity
without	ADP	O	O
decreasing	VERB	O	O
the	DET	O	O
antitumor	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
received	VERB	O	O
amifostine	NOUN	O	I-Entity
,	PUNCT	O	O
910	NUM	O	O
mg	CCONJ	O	O
/	SYM	O	O
m2	NOUN	O	O
intravenously	ADV	O	O
over	ADP	O	O
15	NUM	O	O
minutes	NOUN	O	O
.	PUNCT	O	O

Intravenous	ADJ	O	O
hydration	NOUN	O	O
and	CCONJ	O	O
mannitol	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
before	ADV	O	O
and	CCONJ	O	O
after	ADP	O	O
cisplatin	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
cisplatin	NOUN	O	I-Entity
and	CCONJ	O	O
amifostine	NOUN	O	I-Entity
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
an	DET	O	O
overall	ADJ	O	O
response	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
16%	NUM	O	O
.	PUNCT	O	O

Neither	DET	O	O
a	DET	O	O
tumor	NOUN	O	I-Entity
-	PUNCT	O	O
protective	ADJ	O	O
effect	NOUN	O	O
nor	CCONJ	O	O
reduced	VERB	O	O
toxicity	NOUN	O	I-Entity
to	ADP	O	O
normal	ADJ	O	O
tissues	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
with	ADP	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
amifostine	NOUN	O	I-Entity
to	ADP	O	O
cisplatin	NOUN	O	I-Entity
in	ADP	O	O
this	DET	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Anticoagulant	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
femoral	ADJ	O	B-Entity
nerve	NOUN	O	I-Entity
palsy	NOUN	O	I-Entity
represents	VERB	O	O
the	DET	O	O
most	ADV	O	O
common	ADJ	O	O
form	NOUN	O	O
of	ADP	O	O
warfarin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
;	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
severe	ADJ	O	O
pain	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
inguinal	ADJ	O	O
region	NOUN	O	O
,	PUNCT	O	O
varying	VERB	O	O
degrees	NOUN	O	O
of	ADP	O	O
motor	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
sensory	ADJ	O	I-Entity
impairment	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
flexure	NOUN	O	O
contracture	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
involved	ADJ	O	O
extremity	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
anti	ADJ	O	O
-	PUNCT	O	O
dementia	NOUN	O	I-Entity
effects	NOUN	O	O
of	ADP	O	O
s	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
limonene	NOUN	O	I-Entity
and	CCONJ	O	O
s	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
perillyl	NOUN	O	I-Entity
alcohol	NOUN	O	I-Entity
were	VERB	O	O
observed	VERB	O	O
using	VERB	O	O
the	DET	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
test	NOUN	O	O
(	PUNCT	O	O
PA	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
open	ADJ	O	O
field	NOUN	O	O
habituation	NOUN	O	O
test	NOUN	O	O
(	PUNCT	O	O
OFH	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Analysis	NOUN	O	O
of	ADP	O	O
neurotransmitter	NOUN	O	O
concentration	NOUN	O	O
in	ADP	O	O
some	DET	O	O
brain	NOUN	O	O
regions	NOUN	O	O
on	ADP	O	O
the	DET	O	O
test	NOUN	O	O
day	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
dopamine	NOUN	O	I-Entity
concentration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
vehicle	NOUN	O	O
/	SYM	O	O
scopolamine	NOUN	O	I-Entity
group	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
than	ADP	O	O
that	DET	O	O
of	ADP	O	O
the	DET	O	O
vehicle	NOUN	O	O
/	SYM	O	O
vehicle	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
this	DET	O	O
phenomenon	NOUN	O	O
was	VERB	O	O
reversed	VERB	O	O
when	ADV	O	O
s	VERB	O	B-Entity
-	PUNCT	O	I-Entity
limonene	NOUN	O	I-Entity
or	CCONJ	O	O
s	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
perillyl	NOUN	O	I-Entity
alcohol	NOUN	O	I-Entity
were	VERB	O	O
administered	VERB	O	O
before	ADP	O	O
the	DET	O	O
injection	NOUN	O	O
of	ADP	O	O
scopolamine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
selective	ADJ	O	O
5-HT6	ADJ	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
Ro4368554	NOUN	O	I-Entity
restores	VERB	O	O
memory	NOUN	O	O
performance	NOUN	O	O
in	ADP	O	O
cholinergic	NOUN	O	O
and	CCONJ	O	O
serotonergic	ADJ	O	O
models	NOUN	O	O
of	ADP	O	O
memory	NOUN	O	B-Entity
deficiency	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
underlying	VERB	O	O
mechanism(s	NOUN	O	O
)	PUNCT	O	O
are	VERB	O	O
not	ADV	O	O
well	ADV	O	O
understood	VERB	O	O
,	PUNCT	O	O
these	DET	O	O
effects	NOUN	O	O
may	VERB	O	O
involve	VERB	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
acetylcholine	NOUN	O	I-Entity
(	PUNCT	O	O
ACh	PROPN	O	I-Entity
)	PUNCT	O	O
levels	NOUN	O	O
.	PUNCT	O	O

Initial	ADJ	O	O
testing	NOUN	O	O
in	ADP	O	O
a	DET	O	O
time	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
forgetting	VERB	O	O
task	NOUN	O	O
employing	VERB	O	O
a	DET	O	O
24-h	NUM	O	O
delay	NOUN	O	O
between	ADP	O	O
training	NOUN	O	O
and	CCONJ	O	O
testing	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
metrifonate	NOUN	O	I-Entity
improved	VERB	O	O
object	NOUN	O	O
recognition	NOUN	O	O
(	PUNCT	O	O
at	ADP	O	O
10	NUM	O	O
and	CCONJ	O	O
30	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
p.o	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
Ro4368554	PROPN	O	I-Entity
was	VERB	O	O
inactive	ADJ	O	O
.	PUNCT	O	O


Therefore	ADV	O	O
,	PUNCT	O	O
when	ADV	O	O
the	DET	O	O
arrhythmia	NOUN	O	I-Entity
is	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
this	DET	O	O
population	NOUN	O	O
,	PUNCT	O	O
reversible	ADJ	O	O
causes	NOUN	O	O
must	VERB	O	O
be	VERB	O	O
identified	VERB	O	O
and	CCONJ	O	O
resolved	VERB	O	O
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
developmental	ADJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
selective	ADJ	O	O
and	CCONJ	O	O
non	ADJ	O	O
-	PUNCT	O	O
selective	ADJ	O	O
cyclooxygenase-2	NOUN	O	O
inhibitors	NOUN	O	O
in	ADP	O	O
CRL:(WI)WUBR	PROPN	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
--	PUNCT	O	O
DFU	PROPN	O	I-Entity
and	CCONJ	O	O
piroxicam	ADJ	O	I-Entity
study	NOUN	O	O
.	PUNCT	O	O

Unlike	ADP	O	O
general	ADJ	O	O
toxicity	NOUN	O	I-Entity
data	NOUN	O	O
,	PUNCT	O	O
their	ADJ	O	O
prenatal	ADJ	O	O
toxic	ADJ	O	O
effects	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
extensively	ADV	O	O
studied	VERB	O	O
before	ADV	O	O
.	PUNCT	O	O

-DOCSTART- (12921865)

Neuroactive	ADJ	O	O
steroids	NOUN	O	I-Entity
demonstrate	VERB	O	O
pharmacological	ADJ	O	O
actions	NOUN	O	O
that	ADJ	O	O
have	VERB	O	O
relevance	NOUN	O	O
for	ADP	O	O
a	DET	O	O
host	NOUN	O	O
of	ADP	O	O
neurological	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
psychiatric	ADJ	O	I-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

Allopregnanolone	PROPN	O	I-Entity
(	PUNCT	O	O
3alpha	NUM	O	B-Entity
-	PUNCT	O	I-Entity
hydroxy-5alpha	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
pregnan-20-one	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
pregnanolone	NOUN	O	I-Entity
(	PUNCT	O	O
3alpha	NUM	O	B-Entity
-	PUNCT	O	I-Entity
hydroxy-5beta	NUM	O	I-Entity
-	PUNCT	O	I-Entity
pregnan-20-one	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
ganaxolone	NOUN	O	I-Entity
(	PUNCT	O	O
a	DET	O	O
synthetic	ADJ	O	O
derivative	NOUN	O	O
of	ADP	O	O
allopregnanolone	NOUN	O	I-Entity
3alpha	NUM	O	B-Entity
-	PUNCT	O	I-Entity
hydroxy-3beta	NUM	O	I-Entity
-	PUNCT	O	I-Entity
methyl-5alpha	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
pregnan-20-one	NOUN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
tested	VERB	O	O
for	ADP	O	O
their	ADJ	O	O
ability	NOUN	O	O
to	PART	O	O
suppress	VERB	O	O
the	DET	O	O
expression	NOUN	O	O
(	PUNCT	O	O
anticonvulsant	ADJ	O	O
effect	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
development	NOUN	O	O
(	PUNCT	O	O
antiepileptogenic	ADJ	O	O
effect	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
kindled	VERB	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
male	NOUN	O	O
,	PUNCT	O	O
Swiss	PROPN	O	O
-	PUNCT	O	O
Webster	PROPN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Kindled	VERB	O	O
seizures	NOUN	O	I-Entity
were	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
daily	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
60	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADP	O	O
cocaine	NOUN	O	I-Entity
for	ADP	O	O
5	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
are	VERB	O	O
nephrotoxic	ADJ	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
SRL	PROPN	O	I-Entity
seems	VERB	O	O
to	PART	O	O
act	VERB	O	O
differently	ADV	O	O
displaying	VERB	O	O
only	ADJ	O	O
minor	ADJ	O	O
nephrotoxic	ADJ	O	I-Entity
effects	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
this	DET	O	O
question	NOUN	O	O
is	VERB	O	O
still	ADV	O	O
open	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
semi	NOUN	O	O
-	PUNCT	O	O
quantitative	ADJ	O	O
scoring	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
worst	ADJ	O	O
in	ADP	O	O
the	DET	O	O
group	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
CsA	PROPN	O	I-Entity
plus	CCONJ	O	O
SRL	PROPN	O	I-Entity
(	PUNCT	O	O
P<0.001	PROPN	O	O
compared	VERB	O	O
with	ADP	O	O
controls	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
analysis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
total	ADJ	O	O
grade	NOUN	O	O
of	ADP	O	O
fibrosis	NOUN	O	I-Entity
also	ADV	O	O
showed	VERB	O	O
the	DET	O	O
highest	ADJ	O	O
proportion	NOUN	O	O
in	ADP	O	O
the	DET	O	O
same	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
significantly	ADV	O	O
different	ADJ	O	O
from	ADP	O	O
controls	NOUN	O	O
(	PUNCT	O	O
P<0.02	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

-DOCSTART- (10406016)

Rats	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
seven	NUM	O	O
day	NOUN	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
fucoidan	NOUN	O	I-Entity
(	PUNCT	O	O
30	NUM	O	O
micrograms	NOUN	O	O
h-1	PROPN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
vehicle	NOUN	O	O
.	PUNCT	O	O

Investigation	NOUN	O	O
of	ADP	O	O
more	ADV	O	O
specific	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
agents	NOUN	O	O
and	CCONJ	O	O
hemodiluting	VERB	O	O
agents	NOUN	O	O
are	VERB	O	O
warranted	VERB	O	O
in	ADP	O	O
intracerebral	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
liver	NOUN	O	O
function	NOUN	O	O
tests	NOUN	O	O
suggested	VERB	O	O
hepatocellular	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
in	ADP	O	O
10	NUM	O	O
(	PUNCT	O	O
63%	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
the	DET	O	O
rest	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
mixed	ADJ	O	O
pattern	NOUN	O	O
.	PUNCT	O	O

Allergic	ADJ	O	O
manifestations	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
rash	NOUN	O	I-Entity
and	CCONJ	O	O
eosinophilia	NOUN	O	I-Entity
were	VERB	O	O
rare	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (9088814)

Haemodilution	NOUN	O	I-Entity
in	ADP	O	O
groups	NOUN	O	O
B	PROPN	O	O
and	CCONJ	O	O
C	PROPN	O	O
was	VERB	O	O
produced	VERB	O	O
by	ADP	O	O
withdrawing	VERB	O	O
approximately	ADV	O	O
1000	NUM	O	O
mL	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
and	CCONJ	O	O
replacing	VERB	O	O
it	PRON	O	O
with	ADP	O	O
the	DET	O	O
same	ADJ	O	O
amount	NOUN	O	O
of	ADP	O	O
dextran	NOUN	O	I-Entity
solution	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
final	ADJ	O	O
haematocrit	NOUN	O	O
values	NOUN	O	O
were	VERB	O	O
21	NUM	O	O
or	CCONJ	O	O
22%	NUM	O	O
.	PUNCT	O	O

In	ADP	O	O
group	NOUN	O	O
C	PROPN	O	O
,	PUNCT	O	O
AKBR	PROPN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
at	ADP	O	O
120	NUM	O	O
min	NOUN	O	O
(	PUNCT	O	O
-40%	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
180	NUM	O	O
min	NOUN	O	O
(	PUNCT	O	O
-49%	PROPN	O	O
)	PUNCT	O	O
after	ADP	O	O
the	DET	O	O
start	NOUN	O	O
of	ADP	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
at	ADP	O	O
60	NUM	O	O
min	NOUN	O	O
(	PUNCT	O	O
-32%	PROPN	O	O
)	PUNCT	O	O
after	ADP	O	O
recovery	NOUN	O	O
of	ADP	O	O
normotension	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
SGOT	PROPN	O	O
,	PUNCT	O	O
SGPT	PROPN	O	O
,	PUNCT	O	O
LDH	PROPN	O	O
and	CCONJ	O	O
total	ADJ	O	O
bilirubin	NOUN	O	I-Entity
showed	VERB	O	O
significant	ADJ	O	O
increases	NOUN	O	O
after	ADP	O	O
operation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
a	DET	O	O
prolonged	ADJ	O	O
combination	NOUN	O	O
of	ADP	O	O
more	ADJ	O	O
than	ADP	O	O
120	NUM	O	O
min	NOUN	O	O
of	ADP	O	O
PGE1-induced	PROPN	O	I-Entity
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
moderate	ADJ	O	O
haemodilution	NOUN	O	I-Entity
would	VERB	O	O
cause	VERB	O	O
impairment	NOUN	O	B-Entity
of	ADP	O	I-Entity
hepatic	ADJ	O	I-Entity
function	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (20080419)

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
therapeutic	ADJ	O	O
potential	NOUN	O	O
of	ADP	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
mononuclear	ADJ	O	O
cells	NOUN	O	O
(	PUNCT	O	O
BMCs	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
model	NOUN	O	O
of	ADP	O	O
epilepsy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
pilocarpine	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (19445921)

Isoproterenol	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
showed	VERB	O	O
significant	ADJ	O	O
increases	NOUN	O	O
in	ADP	O	O
the	DET	O	O
levels	NOUN	O	O
of	ADP	O	O
lactate	NOUN	O	I-Entity
dehydrogenase	NOUN	O	O
,	PUNCT	O	O
aspartate	ADJ	O	I-Entity
transaminase	NOUN	O	O
,	PUNCT	O	O
creatine	NOUN	O	I-Entity
kinase	NOUN	O	O
and	CCONJ	O	O
malondialdehyde	NOUN	O	I-Entity
and	CCONJ	O	O
significant	ADJ	O	O
decreases	NOUN	O	O
in	ADP	O	O
the	DET	O	O
activities	NOUN	O	O
of	ADP	O	O
superoxide	NOUN	O	I-Entity
dismutase	NOUN	O	O
,	PUNCT	O	O
catalase	NOUN	O	O
and	CCONJ	O	O
glutathione	NOUN	O	I-Entity
peroxidase	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
our	ADJ	O	O
study	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
salvianolic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
A	NOUN	O	I-Entity
possessing	VERB	O	O
antioxidant	ADJ	O	O
activity	NOUN	O	O
has	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
protective	ADJ	O	O
effect	NOUN	O	O
against	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

Pretreatment	NOUN	O	O
with	ADP	O	O
either	DET	O	O
VPU	PROPN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
and	CCONJ	O	O
100	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
VPA	PROPN	O	I-Entity
(	PUNCT	O	O
300	NUM	O	O
and	CCONJ	O	O
600	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
completely	ADV	O	O
abolished	VERB	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
evoked	VERB	O	O
increases	NOUN	O	O
in	ADP	O	O
extracellular	ADJ	O	O
glutamate	NOUN	O	I-Entity
and	CCONJ	O	O
aspartate	NOUN	O	I-Entity
.	PUNCT	O	O

Acute	PROPN	O	O
hepatitis	NOUN	O	I-Entity
attack	NOUN	O	O
after	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
telithromycin	VERB	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (15632880)

>	X	O	O
5.0	NUM	O	O
mEq	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
renal	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity

The	DET	O	O
calcineurin	NOUN	O	O
inhibitors	VERB	O	O
cyclosporine	NOUN	O	I-Entity
and	CCONJ	O	O
tacrolimus	NOUN	O	I-Entity
are	VERB	O	O
both	DET	O	O
known	VERB	O	O
to	PART	O	O
be	VERB	O	O
nephrotoxic	ADJ	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
retrospective	ADJ	O	O
study	NOUN	O	O
examines	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
ESRD	PROPN	O	I-Entity
and	CCONJ	O	O
chronic	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
CRF	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
OLTX	PROPN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Multivariate	PROPN	O	O
stepwise	NOUN	O	O
logistic	ADJ	O	O
regression	NOUN	O	O
analysis	NOUN	O	O
using	VERB	O	O
preoperative	NOUN	O	O
and	CCONJ	O	O
postoperative	ADJ	O	O
variables	NOUN	O	O
identified	VERB	O	O
that	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
average	ADJ	O	O
at	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
,	PUNCT	O	O
3	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
4	NUM	O	O
weeks	NOUN	O	O
postoperatively	ADV	O	O
were	VERB	O	O
independent	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
CRF	PROPN	O	I-Entity
or	CCONJ	O	O
ESRD	PROPN	O	I-Entity
with	ADP	O	O
odds	NOUN	O	O
ratios	NOUN	O	O
of	ADP	O	O
2.6	NUM	O	O
,	PUNCT	O	O
2.2	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
1.6	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
developing	VERB	O	O
ESRD	PROPN	O	I-Entity
had	VERB	O	O
a	DET	O	O
6-year	ADJ	O	O
survival	NOUN	O	O
after	ADP	O	O
onset	NOUN	O	O
of	ADP	O	O
ESRD	PROPN	O	I-Entity
of	ADP	O	O
27%	NUM	O	O
for	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
receiving	VERB	O	O
hemodialysis	NOUN	O	O
versus	ADP	O	O
71.4%	NUM	O	O
for	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
developing	VERB	O	O
ESRD	PROPN	O	I-Entity
who	NOUN	O	O
subsequently	ADV	O	O
received	VERB	O	O
kidney	NOUN	O	O
transplants	NOUN	O	O
.	PUNCT	O	O


In	ADP	O	O
multivariate	NOUN	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
significant	ADJ	O	O
correlation	NOUN	O	O
between	ADP	O	O
DBP	PROPN	O	B-Entity
reduction	NOUN	O	I-Entity
and	CCONJ	O	O
worsening	VERB	O	O
of	ADP	O	O
the	DET	O	O
neurological	ADJ	O	O
score	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
for	ADP	O	O
the	DET	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
beta=0.49	NOUN	O	O
,	PUNCT	O	O
P=0	PROPN	O	O
.	PUNCT	O	O

(	PUNCT	O	O
n	ADV	O	O
/	SYM	O	O
N=25/26	PROPN	O	O
,	PUNCT	O	O
OR	PROPN	O	O
10	NUM	O	O
.	PUNCT	O	O
16	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	NOUN	O	O
1.02	NUM	O	O
to	ADP	O	O
101.74	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
death	NOUN	O	I-Entity
alone	ADV	O	O
(	PUNCT	O	O
n	ADV	O	O
/	SYM	O	O
N=9/26	PROPN	O	O
,	PUNCT	O	O
OR	PROPN	O	O
4.336	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
1.131	NUM	O	O
16.619	NUM	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
all	DET	O	O
placebo	NOUN	O	O
patients	NOUN	O	O
(	PUNCT	O	O
n	ADV	O	O
/	SYM	O	O
N=62/92	PROPN	O	O
and	CCONJ	O	O
14/92	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

-DOCSTART- (9523805)

Transient	ADJ	O	B-Entity
neurologic	ADJ	O	I-Entity
symptoms	NOUN	O	I-Entity
after	ADP	O	O
spinal	ADJ	O	O
anesthesia	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
lower	ADJ	O	O
incidence	NOUN	O	O
with	ADP	O	O
prilocaine	NOUN	O	I-Entity
and	CCONJ	O	O
bupivacaine	NOUN	O	I-Entity
than	ADP	O	O
with	ADP	O	O
lidocaine	NOUN	O	I-Entity
.	PUNCT	O	O

Prilocaine	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
amide	ADJ	O	O
local	ADJ	O	O
anesthetic	NOUN	O	O
with	ADP	O	O
a	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
similar	ADJ	O	O
to	ADP	O	O
that	DET	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
.	PUNCT	O	O

Accordingly	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
present	ADJ	O	O
,	PUNCT	O	O
prospective	ADJ	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
study	NOUN	O	O
compares	VERB	O	O
prilocaine	NOUN	O	I-Entity
with	ADP	O	O
lidocaine	NOUN	O	I-Entity
and	CCONJ	O	O
bupivacaine	NOUN	O	I-Entity
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
duration	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
and	CCONJ	O	O
relative	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
TNSs	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
evening	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
day	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
for	ADP	O	O
TNSs	NOUN	O	I-Entity
by	ADP	O	O
a	DET	O	O
physician	NOUN	O	O
unaware	ADJ	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
administered	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
details	NOUN	O	O
of	ADP	O	O
the	DET	O	O
anesthetic	ADJ	O	O
procedure	NOUN	O	O
.	PUNCT	O	O

Nine	NUM	O	O
of	ADP	O	O
30	NUM	O	O
patients	NOUN	O	O
receiving	VERB	O	O
lidocaine	NOUN	O	I-Entity
experienced	ADJ	O	O
TNSs	NOUN	O	I-Entity
,	PUNCT	O	O
1	NUM	O	O
of	ADP	O	O
30	NUM	O	O
patients	NOUN	O	O
receiving	VERB	O	O
prilocaine	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
them	PRON	O	O
,	PUNCT	O	O
and	CCONJ	O	O
none	NOUN	O	O
of	ADP	O	O
30	NUM	O	O
patients	NOUN	O	O
receiving	VERB	O	O
bupivacaine	NOUN	O	I-Entity
had	VERB	O	O
TNSs	NOUN	O	I-Entity
.	PUNCT	O	O

Nicotine	NOUN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
appear	VERB	O	O
to	PART	O	O
enhance	VERB	O	O
thrombosis	NOUN	O	I-Entity
among	ADP	O	O
humans	NOUN	O	O
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
dose	NOUN	O	O
response	NOUN	O	O
for	ADP	O	O
cardiovascular	ADJ	O	O
events	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	I-Entity
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
flat	ADJ	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
if	ADP	O	O
nicotine	NOUN	O	I-Entity
is	VERB	O	O
involved	VERB	O	O
,	PUNCT	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
might	VERB	O	O
be	VERB	O	O
seen	VERB	O	O
with	ADP	O	O
relatively	ADV	O	O
low	ADJ	O	O
-	PUNCT	O	O
level	NOUN	O	O
cigarette	NOUN	O	O
exposures	NOUN	O	O
.	PUNCT	O	O


After	ADP	O	O
the	DET	O	O
ingestion	NOUN	O	O
of	ADP	O	O
26	NUM	O	O
venlafaxine	NOUN	O	I-Entity
50-mg	NUM	O	O
tablets	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
experienced	VERB	O	O
a	DET	O	O
witnessed	VERB	O	O
generalized	ADJ	O	O
seizure	NOUN	O	I-Entity
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
nonoverdose	NOUN	O	O
pharmacokinetics	NOUN	O	O
and	CCONJ	O	O
pharmacodynamics	NOUN	O	O
of	ADP	O	O
venlafaxine	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
potential	ADJ	O	O
risks	NOUN	O	O
of	ADP	O	O
available	ADJ	O	O
interventions	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
emergent	ADJ	O	O
therapy	NOUN	O	O
was	VERB	O	O
instituted	VERB	O	O
.	PUNCT	O	O

Sinus	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
continuous	ADJ	O	O
-	PUNCT	O	O
infusion	NOUN	O	O
cimetidine	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
reported	VERB	O	O
case	NOUN	O	O
of	ADP	O	O
sinus	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
continuous	ADJ	O	O
-	PUNCT	O	O
infusion	NOUN	O	O
cimetidine	NOUN	O	I-Entity
.	PUNCT	O	O

Composition	NOUN	O	O
of	ADP	O	O
gall	NOUN	O	B-Entity
bladder	NOUN	O	I-Entity
stones	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
octreotide	NOUN	O	I-Entity
:	PUNCT	O	O
response	NOUN	O	O
to	ADP	O	O
oral	ADJ	O	O
ursodeoxycholic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O

Chemical	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
gall	NOUN	O	B-Entity
stones	NOUN	O	I-Entity
retrieved	VERB	O	O
at	ADP	O	O
cholecystectomy	NOUN	O	O
from	ADP	O	O
two	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
showed	VERB	O	O
that	ADP	O	O
they	PRON	O	O
contained	VERB	O	O
71%	NUM	O	O
and	CCONJ	O	O
87%	NUM	O	O
cholesterol	NOUN	O	I-Entity
by	ADP	O	O
weight	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
remaining	VERB	O	O
12	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
localised	VERB	O	O
computed	VERB	O	O
tomography	NOUN	O	O
of	ADP	O	O
the	DET	O	O
gall	NOUN	O	O
bladder	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
eight	NUM	O	O
had	VERB	O	O
stones	NOUN	O	O
with	ADP	O	O
maximum	ADJ	O	O
attenuation	NOUN	O	O
scores	NOUN	O	O
of	ADP	O	O
<	SYM	O	O
100	NUM	O	O
Hounsfield	PROPN	O	O
units	NOUN	O	O
(	PUNCT	O	O
values	NOUN	O	O
of	ADP	O	O
<	SYM	O	O
100	NUM	O	O
HU	PROPN	O	O
predict	ADJ	O	O
cholesterol	NOUN	O	I-Entity
rich	ADJ	O	O
,	PUNCT	O	O
dissolvable	ADJ	O	O
stones	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
octreotide	ADV	O	I-Entity
induced	VERB	O	O
gall	NOUN	O	B-Entity
stones	NOUN	O	I-Entity
are	VERB	O	O
generally	ADV	O	O
small	ADJ	O	O
,	PUNCT	O	O
multiple	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cholesterol	NOUN	O	I-Entity
rich	ADJ	O	O
although	ADP	O	O
,	PUNCT	O	O
in	ADP	O	O
common	ADJ	O	O
with	ADP	O	O
spontaneous	ADJ	O	O
gall	NOUN	O	B-Entity
stone	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
at	ADP	O	O
presentation	NOUN	O	O
some	DET	O	O
patients	NOUN	O	O
will	VERB	O	O
have	VERB	O	O
a	DET	O	O
blocked	VERB	O	O
cystic	NOUN	O	O
duct	NOUN	O	O
and	CCONJ	O	O
some	DET	O	O
gall	NOUN	O	B-Entity
stones	NOUN	O	I-Entity
containing	VERB	O	O
calcium	NOUN	O	I-Entity
.	PUNCT	O	O

Cardiovascular	ADJ	O	B-Entity
complications	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
terbutaline	NOUN	O	I-Entity
treatment	NOUN	O	O
for	ADP	O	O
preterm	NOUN	O	B-Entity
labor	NOUN	O	I-Entity
.	PUNCT	O	O

N	PROPN	O	O
=	SYM	O	O
15	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
2-chloroprocaine	NUM	O	B-Entity
-	PUNCT	O	I-Entity
CE	PROPN	O	I-Entity
(	PUNCT	O	O
N	CCONJ	O	O
=	SYM	O	O
20	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
low	ADJ	O	O
pH	NOUN	O	O
normal	ADJ	O	O
saline	ADJ	O	O
(	PUNCT	O	O
pH	PROPN	O	O
3.0	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
20	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
normal	ADJ	O	O
saline	NOUN	O	O
(	PUNCT	O	O
N	PROPN	O	O
=	SYM	O	O
10	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
20	NUM	O	O
animals	NOUN	O	O
that	ADJ	O	O
received	VERB	O	O
subarachnoid	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
2-chloroprocaine	NUM	O	B-Entity
-	PUNCT	O	I-Entity
CE	PROPN	O	I-Entity
seven	NUM	O	O
(	PUNCT	O	O
35%	NUM	O	O
)	PUNCT	O	O
developed	VERB	O	O
hind	ADJ	O	O
-	PUNCT	O	O
limb	NOUN	O	O
paralysis	NOUN	O	I-Entity
.	PUNCT	O	O

None	NOUN	O	O
of	ADP	O	O
the	DET	O	O
animals	NOUN	O	O
that	ADJ	O	O
received	VERB	O	O
bupivacaine	NOUN	O	I-Entity
,	PUNCT	O	O
normal	ADJ	O	O
saline	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
normal	ADJ	O	O
saline	NOUN	O	O
titrated	VERB	O	O
to	ADP	O	O
a	DET	O	O
pH	NOUN	O	O
3.0	NUM	O	O
developed	VERB	O	O
hind	ADJ	O	O
-	PUNCT	O	O
limb	NOUN	O	O
paralysis	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (6640832)

A	DET	O	O
multicenter	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
110	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
superficial	ADJ	O	O
transitional	ADJ	O	O
cell	NOUN	O	O
carcinoma	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
bladder	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (3560096)

We	PRON	O	O
describe	VERB	O	O
4	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
whom	NOUN	O	O
hyperkalemia	NOUN	O	I-Entity
ranging	VERB	O	O
from	ADP	O	O
6.1	NUM	O	O
to	ADP	O	O
6.9	NUM	O	O
mEq	PROPN	O	O
/	SYM	O	O
l	NOUN	O	O
developed	VERB	O	O
within	ADP	O	O
3	NUM	O	O
to	PART	O	O
8	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
sulindac	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O


Ventricular	PROPN	O	B-Entity
tachyarrhythmias	NOUN	O	I-Entity
during	ADP	O	O
cesarean	ADJ	O	O
section	NOUN	O	O
after	ADP	O	O
ritodrine	NOUN	O	I-Entity
therapy	NOUN	O	O
:	PUNCT	O	O

Careful	ADJ	O	O
fluid	ADJ	O	O
administration	NOUN	O	O
and	CCONJ	O	O
cautious	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
titrated	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
ephedrine	NOUN	O	I-Entity
are	VERB	O	O
advised	VERB	O	O
.	PUNCT	O	O

To	PART	O	O
clarify	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
bromocriptine	NOUN	O	I-Entity
on	ADP	O	O
prolactinoma	NOUN	O	I-Entity
cells	NOUN	O	O
in	ADP	O	O
vivo	NOUN	O	O
,	PUNCT	O	O
immunohistochemical	ADJ	O	O
,	PUNCT	O	O
ultrastructural	ADJ	O	O
and	CCONJ	O	O
morphometrical	ADJ	O	O
analyses	NOUN	O	O
were	VERB	O	O
applied	VERB	O	O
to	ADP	O	O
estrogen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
rat	NOUN	O	O
prolactinoma	NOUN	O	I-Entity
cells	NOUN	O	O
1	NUM	O	O
h	NOUN	O	O
and	CCONJ	O	O
6	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
injection	NOUN	O	O
of	ADP	O	O
bromocriptine	NOUN	O	I-Entity
(	PUNCT	O	O
3	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
of	ADP	O	O
body	NOUN	O	O
weight	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Golgi	PROPN	O	O
cisternae	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prolactinoma	NOUN	O	I-Entity
cells	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (2265898)

Seizures	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
the	DET	O	O
cocaine	NOUN	O	I-Entity
metabolite	NOUN	O	O
benzoylecgonine	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
separate	ADJ	O	O
equimolar	ADJ	O	O
doses	NOUN	O	O
(	PUNCT	O	O
0.2	NUM	O	O
and	CCONJ	O	O
0.4	NUM	O	O
mumol	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
either	DET	O	O
cocaine	NOUN	O	I-Entity
or	CCONJ	O	O
BE	VERB	O	I-Entity
were	VERB	O	O
injected	VERB	O	O
ventricularly	ADV	O	O
in	ADP	O	O
unanesthetized	ADJ	O	O
juvenile	NOUN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Treated	VERB	O	O
rats	NOUN	O	O
were	VERB	O	O
then	ADV	O	O
evaluated	VERB	O	O
for	ADP	O	O
incidence	NOUN	O	O
,	PUNCT	O	O
latency	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
seizure	NOUN	O	I-Entity
pattern	NOUN	O	O
or	CCONJ	O	O
for	ADP	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
in	ADP	O	O
animals	NOUN	O	O
without	ADP	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

Whereas	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
were	VERB	O	O
best	ADV	O	O
characterized	VERB	O	O
as	ADP	O	O
brief	NOUN	O	O
,	PUNCT	O	O
generalized	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
tonic	NOUN	O	O
and	CCONJ	O	O
resulted	VERB	O	O
in	ADP	O	O
death	NOUN	O	I-Entity
,	PUNCT	O	O
those	DET	O	O
induced	VERB	O	O
by	ADP	O	O
BE	PROPN	O	I-Entity
were	VERB	O	O
prolonged	VERB	O	O
,	PUNCT	O	O
often	ADV	O	O
multiple	ADJ	O	O
and	CCONJ	O	O
mixed	ADJ	O	O
in	ADP	O	O
type	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
rarely	ADV	O	O
resulted	VERB	O	O
in	ADP	O	O
death	NOUN	O	I-Entity
.	PUNCT	O	O

Electrical	ADJ	O	O
recordings	NOUN	O	O
from	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
rhythmic	ADJ	O	O
progression	NOUN	O	O
in	ADP	O	O
EEG	PROPN	O	O
frequency	NOUN	O	O
and	CCONJ	O	O
voltage	NOUN	O	O
with	ADP	O	O
clinical	ADJ	O	O
seizure	NOUN	O	I-Entity
expression	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
finding	NOUN	O	O
that	ADJ	O	O
cocaine-	X	O	I-Entity
and	CCONJ	O	O
BE	VERB	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
differ	VERB	O	O
in	ADP	O	O
several	ADJ	O	O
respects	NOUN	O	O
suggests	VERB	O	O
more	ADJ	O	O
than	ADP	O	O
one	NUM	O	O
mechanism	NOUN	O	O
for	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
emphasizes	VERB	O	O
the	DET	O	O
importance	NOUN	O	O
of	ADP	O	O
a	DET	O	O
cocaine	NOUN	O	I-Entity
metabolite	NOUN	O	O
,	PUNCT	O	O
BE	VERB	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (1436384)

This	DET	O	O
prolonged	ADJ	O	O
depletion	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
was	VERB	O	O
antagonized	VERB	O	O
by	ADP	O	O
dizocilpine	NOUN	O	I-Entity
(	PUNCT	O	O
MK-801	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
non	ADV	O	O
-	PUNCT	O	O
competitive	ADJ	O	O
antagonist	NOUN	O	O
of	ADP	O	O
NMDA	PROPN	O	I-Entity
receptors	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
by	ADP	O	O
LY274614	PROPN	O	I-Entity
(	PUNCT	O	O
a	DET	O	O
competitive	ADJ	O	O
antagonist	NOUN	O	O
of	ADP	O	O
NMDA	PROPN	O	I-Entity
receptors	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	INTJ	O	O
dose	NOUN	O	O
of	ADP	O	O
LY274614	PROPN	O	I-Entity
was	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
antagonizing	VERB	O	O
the	DET	O	O
depletion	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
,	PUNCT	O	O
when	ADV	O	O
given	VERB	O	O
as	ADV	O	O
long	ADV	O	O
as	ADP	O	O
8	NUM	O	O
hr	PRON	O	O
prior	ADV	O	O
to	ADP	O	O
amphetamine	NOUN	O	I-Entity
but	CCONJ	O	O
not	ADV	O	O
when	ADV	O	O
given	VERB	O	O
24	NUM	O	O
hr	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
amphetamine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
strengthen	VERB	O	O
the	DET	O	O
evidence	NOUN	O	O
that	ADP	O	O
the	DET	O	O
neurotoxic	ADJ	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
amphetamine	NOUN	O	I-Entity
and	CCONJ	O	O
related	VERB	O	O
compounds	NOUN	O	O
toward	ADP	O	O
nigrostriatal	ADJ	O	O
dopamine	NOUN	O	I-Entity
neurons	NOUN	O	O
involves	VERB	O	O
NMDA	PROPN	O	I-Entity
receptors	NOUN	O	O
and	CCONJ	O	O
that	ADP	O	O
LY274614	ADV	O	I-Entity
is	VERB	O	O
an	DET	O	O
NMDA	PROPN	O	I-Entity
receptor	NOUN	O	O
antagonist	NOUN	O	O
with	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
lasting	VERB	O	O
in	ADP	O	O
vivo	ADJ	O	O
effects	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O


Reversal	NOUN	O	O
by	ADP	O	O
phenylephrine	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
nitroglycerin	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
myocardial	ADJ	O	I-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

Elevation	NOUN	O	O
of	ADP	O	O
ADAM10	PROPN	O	O
,	PUNCT	O	O
ADAM17	PROPN	O	O
,	PUNCT	O	O
MMP-2	PROPN	O	O
and	CCONJ	O	O
MMP-9	PROPN	O	O
expression	NOUN	O	O
with	ADP	O	O
media	NOUN	O	O
degeneration	NOUN	O	O
features	VERB	O	O
CaCl2-induced	PROPN	O	I-Entity
thoracic	ADP	O	B-Entity
aortic	ADJ	O	I-Entity
aneurysm	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
rat	NOUN	O	O
model	NOUN	O	O
.	PUNCT	O	O

MMP-2	NOUN	O	O
,	PUNCT	O	O
MMP-9	PROPN	O	O
,	PUNCT	O	O
ADAM-10	PROPN	O	O
and	CCONJ	O	O
ADAM-17	PROPN	O	O
mRNA	PROPN	O	O
levels	NOUN	O	O
were	VERB	O	O
increased	VERB	O	O
in	ADP	O	O
CaCl(2)-treated	VERB	O	I-Entity
segments	NOUN	O	O
(	PUNCT	O	O
all	DET	O	O
p<0.01	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
trends	NOUN	O	O
of	ADP	O	O
elevation	NOUN	O	O
in	ADP	O	O
CaCl(2)-untreated	VERB	O	I-Entity
segments	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
NaCl	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
segments	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19843802)


Forty	NUM	O	O
-	PUNCT	O	O
three	NUM	O	O
ovarian	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
were	VERB	O	O
available	ADJ	O	O
for	ADP	O	O
analysis	NOUN	O	O
following	VERB	O	O
six	NUM	O	O
cycles	NOUN	O	O
of	ADP	O	O
the	DET	O	O
same	ADJ	O	O
PAC	PROPN	O	I-Entity
-	PUNCT	O	O
containing	VERB	O	O
regimen	NOUN	O	O
:	PUNCT	O	O
23	NUM	O	O
had	VERB	O	O
been	VERB	O	O
supplemented	VERB	O	O
by	ADP	O	O
glutamate	NOUN	O	I-Entity
all	ADV	O	O
along	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
a	DET	O	O
daily	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
times	NOUN	O	O
500	NUM	O	O
mg	NUM	O	O
(	PUNCT	O	O
group	NOUN	O	O
G	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
20	NUM	O	O
had	VERB	O	O
received	VERB	O	O
a	DET	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
P	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O


-DOCSTART- (19387625)

Testosterone	NOUN	O	I-Entity
-	PUNCT	O	O
dependent	ADJ	O	O
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
upregulation	NOUN	O	O
of	ADP	O	O
intrarenal	ADJ	O	O
angiotensinogen	NOUN	O	O
in	ADP	O	O
Dahl	PROPN	O	O
salt	NOUN	O	I-Entity
-	PUNCT	O	O
sensitive	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
goal	NOUN	O	O
of	ADP	O	O
these	DET	O	O
studies	NOUN	O	O
was	VERB	O	O
to	PART	O	O
use	VERB	O	O
an	DET	O	O
animal	NOUN	O	O
model	NOUN	O	O
to	PART	O	O
examine	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
prenatal	ADJ	O	O
protein	NOUN	O	O
deprivation	NOUN	O	O
on	ADP	O	O
behaviors	NOUN	O	O
and	CCONJ	O	O
receptor	NOUN	O	O
binding	VERB	O	O
with	ADP	O	O
relevance	NOUN	O	O
to	ADP	O	O
schizophrenia	NOUN	O	I-Entity
.	PUNCT	O	O

PD	PROPN	O	O
female	ADJ	O	O
rats	NOUN	O	O
also	ADV	O	O
showed	VERB	O	O
increased	VERB	O	O
(	PUNCT	O	O
3)H	NUM	O	I-Entity
-	PUNCT	O	O
haloperidol	NOUN	O	I-Entity
binding	NOUN	O	O
and	CCONJ	O	O
decreased	VERB	O	O
dopamine	NOUN	O	I-Entity
transporter	NOUN	O	O
binding	VERB	O	O
in	ADP	O	O
striatum	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
animal	NOUN	O	O
model	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
useful	ADJ	O	O
to	PART	O	O
explore	VERB	O	O
the	DET	O	O
mechanisms	NOUN	O	O
by	ADP	O	O
which	ADJ	O	O
prenatal	ADJ	O	O
nutritional	ADJ	O	B-Entity
deficiency	NOUN	O	I-Entity
enhances	VERB	O	O
risk	NOUN	O	O
for	ADP	O	O
schizophrenia	NOUN	O	I-Entity
in	ADP	O	O
humans	NOUN	O	O
and	CCONJ	O	O
may	VERB	O	O
also	ADV	O	O
have	VERB	O	O
implications	NOUN	O	O
for	ADP	O	O
developmental	ADJ	O	O
processes	NOUN	O	O
leading	VERB	O	O
to	ADP	O	O
differential	ADJ	O	O
sensitivity	NOUN	O	O
to	ADP	O	O
drugs	NOUN	O	O
of	ADP	O	O
abuse	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (18631865)

We	PRON	O	O
discuss	VERB	O	O
herein	ADV	O	O
the	DET	O	O
possible	ADJ	O	O
mechanisms	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
significance	NOUN	O	O
of	ADP	O	O
mToR	PROPN	O	O
blockade	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
proteinuria	NOUN	O	I-Entity
.	PUNCT	O	O

Individuals	NOUN	O	O
with	ADP	O	O
HIV	PROPN	O	O
can	VERB	O	O
now	ADV	O	O
live	VERB	O	O
long	ADJ	O	O
lives	NOUN	O	O
with	ADP	O	O
drug	NOUN	O	O
therapy	NOUN	O	O
that	ADJ	O	O
often	ADV	O	O
includes	VERB	O	O
protease	NOUN	O	O
inhibitors	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
ritonavir	NOUN	O	I-Entity
.	PUNCT	O	O

Briefly	NOUN	O	O
,	PUNCT	O	O
cells	NOUN	O	O
were	VERB	O	O
differentiated	VERB	O	O
for	ADP	O	O
72	NUM	O	O
h	NOUN	O	O
with	ADP	O	O
100	NUM	O	O
nM	ADJ	O	O
PMA	PROPN	O	O
to	PART	O	O
obtain	VERB	O	O
a	DET	O	O
macrophage	NOUN	O	O
-	PUNCT	O	O
like	ADJ	O	O
phenotype	NOUN	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
or	CCONJ	O	O
absence	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
nM	NUM	O	O
17beta	NUM	O	B-Entity
-	PUNCT	O	I-Entity
estradiol	NOUN	O	I-Entity
(	PUNCT	O	O
E2	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
100	NUM	O	O
nM	ADJ	O	O
progesterone	NOUN	O	I-Entity
or	CCONJ	O	O
vehicle	NOUN	O	O
(	PUNCT	O	O
0.01%	NUM	O	O
ethanol	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
data	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
E2	PROPN	O	I-Entity
modifies	VERB	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
CD36	PROPN	O	O
at	ADP	O	O
the	DET	O	O
level	NOUN	O	O
of	ADP	O	O
protein	NOUN	O	O
expression	NOUN	O	O
in	ADP	O	O
monocyte	NOUN	O	O
-	PUNCT	O	O
derived	VERB	O	O
macrophages	NOUN	O	O
resulting	VERB	O	O
in	ADP	O	O
reduced	VERB	O	O
cholesteryl	NOUN	O	B-Entity
ester	NOUN	O	I-Entity
accumulation	NOUN	O	O
following	VERB	O	O
ritonavir	ADJ	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

Upregulation	NOUN	O	O
of	ADP	O	O
brain	NOUN	O	O
expression	NOUN	O	O
of	ADP	O	O
P	NOUN	O	O
-	PUNCT	O	O
glycoprotein	NOUN	O	O
in	ADP	O	O
MRP2-deficient	PROPN	O	O
TR(-	PROPN	O	O
)	PUNCT	O	O
rats	NOUN	O	O
resembles	VERB	O	O
seizure	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
up	PART	O	O
-	PUNCT	O	O
regulation	NOUN	O	O
of	ADP	O	O
this	DET	O	O
drug	NOUN	O	O
efflux	NOUN	O	O
transporter	NOUN	O	O
in	ADP	O	O
normal	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Experiments	NOUN	O	O
with	ADP	O	O
systemic	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Pgp	PROPN	O	O
substrate	NOUN	O	O
phenobarbital	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
selective	ADJ	O	O
Pgp	PROPN	O	O
inhibitor	NOUN	O	O
tariquidar	NOUN	O	I-Entity
in	ADP	O	O
TR(-	PROPN	O	O
)	PUNCT	O	O
rats	NOUN	O	O
substantiated	VERB	O	O
that	ADP	O	O
Pgp	PROPN	O	O
is	VERB	O	O
functional	ADJ	O	O
and	CCONJ	O	O
compensates	VERB	O	O
for	ADP	O	O
the	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
MRP2	PROPN	O	O
in	ADP	O	O
the	DET	O	O
BBB	PROPN	O	O
.	PUNCT	O	O

CSS	PROPN	O	O
panel	NOUN	O	O
to	PART	O	O
localize	VERB	O	O
genes	NOUN	O	O
involved	VERB	O	O
in	ADP	O	O
susceptibility	NOUN	O	O
to	ADP	O	O
pilocarpine	VERB	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
approach	NOUN	O	O
provides	VERB	O	O
a	DET	O	O
framework	NOUN	O	O
for	ADP	O	O
identifying	VERB	O	O
potentially	ADV	O	O
novel	ADJ	O	O
homologous	ADJ	O	O
candidate	NOUN	O	O
genes	NOUN	O	O
for	ADP	O	O
human	ADJ	O	O
temporal	ADJ	O	B-Entity
lobe	NOUN	O	I-Entity
epilepsy	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
investigated	VERB	O	O
whether	ADP	O	O
increased	VERB	O	O
generation	NOUN	O	O
of	ADP	O	O
FR	NOUN	O	O
during	ADP	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
would	VERB	O	O
be	VERB	O	O
sufficient	ADJ	O	O
to	PART	O	O
provoke	VERB	O	O
abnormalities	NOUN	O	O
in	ADP	O	O
mtDNA	PROPN	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
expression	NOUN	O	O
and	CCONJ	O	O
activity	NOUN	O	O
of	ADP	O	O
cytochrome	NOUN	O	O
c	NOUN	O	O
oxidase	NOUN	O	O
(	PUNCT	O	O
CCO	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
complex	ADJ	O	O
IV	PROPN	O	O
of	ADP	O	O
the	DET	O	O
respiratory	ADJ	O	O
chain	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
chronic	ADJ	O	O
phase	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pilocarpine	NOUN	O	I-Entity
model	NOUN	O	O
of	ADP	O	O
temporal	ADJ	O	B-Entity
lobe	NOUN	O	I-Entity
epilepsy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15859940)

In	ADP	O	O
postrenal	ADJ	O	O
transplantation	NOUN	O	O
,	PUNCT	O	O
thrombotic	ADJ	O	B-Entity
microangiopathy	NOUN	O	I-Entity
is	VERB	O	O
often	ADV	O	O
a	DET	O	O
reflection	NOUN	O	O
of	ADP	O	O
hemolytic	ADJ	O	B-Entity
uremic	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

Five	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
thrombotic	ADJ	O	B-Entity
microangiopathy	NOUN	O	I-Entity
were	VERB	O	O
found	VERB	O	O
.	PUNCT	O	O

Three	NUM	O	O
cases	NOUN	O	O
were	VERB	O	O
related	VERB	O	O
to	ADP	O	O
cyclosporine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
1	NUM	O	O
case	NOUN	O	O
was	VERB	O	O
secondary	ADJ	O	O
to	ADP	O	O
both	DET	O	O
cyclosporine	NOUN	O	I-Entity
and	CCONJ	O	O
tacrolimus	NOUN	O	I-Entity
.	PUNCT	O	O


In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
reports	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
acute	ADJ	O	O
iatrogenic	ADJ	O	O
overdose	NOUN	O	I-Entity
are	VERB	O	O
rare	ADJ	O	O
.	PUNCT	O	O

-DOCSTART- (15130900)

In	ADP	O	O
the	DET	O	O
cohort	NOUN	O	O
the	DET	O	O
cumulative	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
bladder	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
after	ADP	O	O
Wegener	PROPN	O	B-Entity
's	PART	O	I-Entity
granulomatosis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
relative	ADJ	O	O
prevalence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
bladder	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
Wegener	PROPN	O	B-Entity
's	PART	O	I-Entity
granulomatosis	NOUN	O	I-Entity
,	PUNCT	O	O
were	VERB	O	O
also	ADV	O	O
estimated	VERB	O	O
.	PUNCT	O	O

ie	CCONJ	O	O
,	PUNCT	O	O
that	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
arginine	ADJ	O	I-Entity
uptake	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
cortisol	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8701950)

In	ADP	O	O
one	NUM	O	O
patient	NOUN	O	O
,	PUNCT	O	O
reintroduction	NOUN	O	O
of	ADP	O	O
FK506	PROPN	O	I-Entity
led	VERB	O	O
to	ADP	O	O
rapid	ADJ	O	O
recurrence	NOUN	O	O
of	ADP	O	O
MAHA	PROPN	O	I-Entity
.	PUNCT	O	O


Variant	NOUN	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
in	ADP	O	O
desipramine	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Mouse	PROPN	O	O
strain	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
amantadine	NOUN	O	I-Entity
on	ADP	O	O
motility	NOUN	O	O
and	CCONJ	O	O
brain	NOUN	O	O
biogenic	ADJ	O	O
amines	NOUN	O	I-Entity
.	PUNCT	O	O

in	ADP	O	O
6	NUM	O	O
increments	NOUN	O	O
of	ADP	O	O
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
each	DET	O	O
over	ADP	O	O
30	NUM	O	O
hr	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
mouse	NOUN	O	O
motility	NOUN	O	O
and	CCONJ	O	O
whole	ADJ	O	O
brain	NOUN	O	O
content	NOUN	O	O
of	ADP	O	O
selected	VERB	O	O
biogenic	ADJ	O	O
amines	NOUN	O	I-Entity
and	CCONJ	O	O
major	ADJ	O	O
metabolites	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
4	NUM	O	O
strains	NOUN	O	O
of	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
initial	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
amantadine	NOUN	O	I-Entity
depressed	ADJ	O	I-Entity
locomotor	NOUN	O	O
activity	NOUN	O	O
in	ADP	O	O
all	DET	O	O
mouse	NOUN	O	O
strains	NOUN	O	O
studied	VERB	O	O
with	ADP	O	O
the	DET	O	O
BALB	PROPN	O	O
/	SYM	O	O
C	PROPN	O	O
mice	NOUN	O	O
being	VERB	O	O
the	DET	O	O
most	ADV	O	O
sensitive	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
was	VERB	O	O
decreased	VERB	O	O
from	ADP	O	O
corresponding	VERB	O	O
controls	NOUN	O	O
in	ADP	O	O
all	DET	O	O
strains	NOUN	O	O
studied	VERB	O	O
,	PUNCT	O	O
except	ADP	O	O
for	ADP	O	O
the	DET	O	O
ICR	PROPN	O	O
mice	NOUN	O	O
,	PUNCT	O	O
during	ADP	O	O
an	DET	O	O
overnight	ADJ	O	O
drug	NOUN	O	O
-	PUNCT	O	O
free	ADJ	O	O
period	NOUN	O	O
following	VERB	O	O
the	DET	O	O
fourth	ADJ	O	O
amantadine	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

Readministration	NOUN	O	O
of	ADP	O	O
amantadine	NOUN	O	I-Entity
,	PUNCT	O	O
after	ADP	O	O
a	DET	O	O
drug	NOUN	O	O
-	PUNCT	O	O
free	ADJ	O	O
overnight	ADJ	O	O
period	NOUN	O	O
,	PUNCT	O	O
increased	VERB	O	O
motility	NOUN	O	O
from	ADP	O	O
respective	ADJ	O	O
saline	ADJ	O	O
control	NOUN	O	O
in	ADP	O	O
all	DET	O	O
strains	NOUN	O	O
with	ADP	O	O
exception	NOUN	O	O
of	ADP	O	O
the	DET	O	O
BALB	PROPN	O	O
/	SYM	O	O
C	PROPN	O	O
mice	NOUN	O	O
where	ADV	O	O
suppression	NOUN	O	B-Entity
of	ADP	O	I-Entity
motility	NOUN	O	I-Entity
occurred	VERB	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
amantadine	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
alter	VERB	O	O
whole	ADJ	O	O
brain	NOUN	O	O
dopamine	NOUN	O	I-Entity
levels	NOUN	O	O
but	CCONJ	O	O
decreased	VERB	O	O
the	DET	O	O
amounts	NOUN	O	O
of	ADP	O	O
3,4-dihydroxyphenylacetic	NUM	O	B-Entity
acid	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
BALB	PROPN	O	O
/	SYM	O	O
C	PROPN	O	O
mice	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
saline	ADJ	O	O
control	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
enhancement	NOUN	O	O
by	ADP	O	O
phenobarbital	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
hepatocarcinogenicity	NOUN	O	O
of	ADP	O	O
a	DET	O	O
choline	NOUN	O	I-Entity
-	PUNCT	O	O
devoid	ADJ	O	O
diet	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
experiment	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
to	PART	O	O
test	VERB	O	O
whether	ADP	O	O
inclusion	NOUN	O	O
of	ADP	O	O
phenobarbital	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
choline	NOUN	O	I-Entity
-	PUNCT	O	O
devoid	ADJ	O	O
diet	NOUN	O	O
would	VERB	O	O
increase	VERB	O	O
the	DET	O	O
hepatocarcinogenicity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
diet	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
hepatic	ADJ	O	O
preneoplastic	NOUN	O	O
nodules	NOUN	O	O
or	CCONJ	O	O
hepatocellular	ADJ	O	B-Entity
carcinomas	NOUN	O	I-Entity
developed	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
fed	VERB	O	O
the	DET	O	O
plain	ADJ	O	O
choline	NOUN	O	I-Entity
-	PUNCT	O	O
supplemented	VERB	O	O
diet	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
one	NUM	O	O
preneoplastic	NOUN	O	O
nodule	NOUN	O	O
and	CCONJ	O	O
one	NUM	O	O
hepatocellular	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
developed	VERB	O	O
in	ADP	O	O
two	NUM	O	O
rats	NOUN	O	O
fed	VERB	O	O
the	DET	O	O
same	ADJ	O	O
diet	NOUN	O	O
containing	VERB	O	O
phenobarbital	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
intracoronary	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
methylergonovine	NOUN	O	I-Entity
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
21	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
variant	NOUN	O	B-Entity
angina	NOUN	O	I-Entity
and	CCONJ	O	O
22	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
atypical	ADJ	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
others	NOUN	O	O
without	ADP	O	O
angina	NOUN	O	B-Entity
pectoris	NOUN	O	I-Entity
(	PUNCT	O	O
control	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Methylergonovine	PROPN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
continuously	ADV	O	O
at	ADP	O	O
a	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
min	VERB	O	O
up	PART	O	O
to	PART	O	O
50	NUM	O	O
micrograms	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
variant	NOUN	O	B-Entity
angina	NOUN	O	I-Entity
,	PUNCT	O	O
coronary	ADJ	O	B-Entity
spasm	NOUN	O	I-Entity
was	VERB	O	O
provoked	VERB	O	O
at	ADP	O	O
a	DET	O	O
mean	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
28	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
spasm	NOUN	O	I-Entity
provocation	NOUN	O	O
tests	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
use	VERB	O	O
an	DET	O	O
intracoronary	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
a	DET	O	O
relatively	ADV	O	O
low	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
methylergonovine	NOUN	O	I-Entity
,	PUNCT	O	O
have	VERB	O	O
a	DET	O	O
high	ADJ	O	O
sensitivity	NOUN	O	O
in	ADP	O	O
variant	NOUN	O	B-Entity
angina	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
vasoreactivity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
right	ADJ	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
greater	ADJ	O	O
than	ADP	O	O
that	DET	O	O
of	ADP	O	O
the	DET	O	O
other	ADJ	O	O
coronary	ADJ	O	O
arteries	NOUN	O	O
.	PUNCT	O	O

5	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
treated	VERB	O	O
from	ADP	O	O
1.6	NUM	O	O
to	ADP	O	O
14.3	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
5.3	NUM	O	O
)	PUNCT	O	O
before	ADP	O	O
this	DET	O	O
study	NOUN	O	O
with	ADP	O	O
27	NUM	O	O
to	PART	O	O
532	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
mean	VERB	O	O
196	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
echocardiographic	ADJ	O	O
data	NOUN	O	O
from	ADP	O	O
12	NUM	O	O
normal	ADJ	O	O
age	NOUN	O	O
-	PUNCT	O	O
matched	VERB	O	O
control	NOUN	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

End	NOUN	O	O
-	PUNCT	O	O
systolic	NOUN	O	O
left	VERB	O	O
ventricular	ADJ	O	O
posterior	ADJ	O	O
wall	NOUN	O	O
dimension	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
for	ADP	O	O
the	DET	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
group	NOUN	O	O
was	VERB	O	O
11	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Cardiac	PROPN	O	B-Entity
arrhythmias	NOUN	O	I-Entity
have	VERB	O	O
frequently	ADV	O	O
been	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
association	NOUN	O	O
with	ADP	O	O
respiratory	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

When	ADV	O	O
respiratory	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
was	VERB	O	O
produced	VERB	O	O
by	ADP	O	O
hypoventilation	NOUN	O	I-Entity
(	PUNCT	O	O
pH	PROPN	O	O
7.05	NUM	O	O
to	ADP	O	O
7.25	NUM	O	O
;	PUNCT	O	O
PC02	PROPN	O	O
70	NUM	O	O
to	ADP	O	O
100	NUM	O	O
mm	PROPN	O	O

-DOCSTART- (16740173)

The	DET	O	O
mode	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
was	VERB	O	O
said	VERB	O	O
to	PART	O	O
be	VERB	O	O
comparable	ADJ	O	O
to	ADP	O	O
that	DET	O	O
of	ADP	O	O
the	DET	O	O
synthetic	ADJ	O	O
compound	NOUN	O	O
'	PUNCT	O	O
carbamylcholin	NOUN	O	I-Entity
'	PUNCT	O	O
;	PUNCT	O	O
that	DET	O	O
is	VERB	O	O
,	PUNCT	O	O
carbachol	NOUN	O	I-Entity
.	PUNCT	O	O

Respiratory	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
was	VERB	O	O
further	ADV	O	O
worsened	VERB	O	O
by	ADP	O	O
Proteus	PROPN	O	B-Entity
mirabilis	ADJ	O	I-Entity
infection	NOUN	O	I-Entity
and	CCONJ	O	O
severe	ADJ	O	O
bronchoconstriction	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
analysed	ADJ	O	O
carbachol	NOUN	O	I-Entity
concentration	NOUN	O	O
exceeded	VERB	O	O
the	DET	O	O
supposed	VERB	O	O
serum	NOUN	O	O
level	NOUN	O	O
resulting	VERB	O	O
from	ADP	O	O
a	DET	O	O
therapeutic	ADJ	O	O
dose	NOUN	O	O
by	ADP	O	O
a	DET	O	O
factor	NOUN	O	O
of	ADP	O	O
130	NUM	O	O
to	ADP	O	O
260	NUM	O	O
.	PUNCT	O	O

Especially	ADV	O	O
in	ADP	O	O
old	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
intensivists	NOUN	O	O
should	VERB	O	O
consider	VERB	O	O
intoxications	NOUN	O	O
(	PUNCT	O	O
with	ADP	O	O
cholinergics	NOUN	O	O
)	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
cardiovascular	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

Crossover	PROPN	O	O
comparison	NOUN	O	O
of	ADP	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
preference	NOUN	O	O
for	ADP	O	O
rizatriptan	NOUN	O	I-Entity
10	NUM	O	O
mg	NUM	O	O
versus	ADP	O	O
ergotamine	NOUN	O	I-Entity
/	SYM	O	O
caffeine	NOUN	O	I-Entity
in	ADP	O	O
migraine	NOUN	O	I-Entity
.	PUNCT	O	O

Rizatriptan	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
selective	ADJ	O	O
5-HT(1B/1D	NOUN	O	I-Entity
)	PUNCT	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
with	ADP	O	O
rapid	ADJ	O	O
oral	ADJ	O	O
absorption	NOUN	O	O
and	CCONJ	O	O
early	ADJ	O	O
onset	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
in	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
migraine	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
randomized	ADJ	O	O
double-	ADJ	O	O
blind	ADJ	O	O
crossover	ADJ	O	O
outpatient	NOUN	O	O
study	NOUN	O	O
assessed	VERB	O	O
the	DET	O	O
preference	NOUN	O	O
for	ADP	O	O
1	NUM	O	O
rizatriptan	NOUN	O	I-Entity
10	NUM	O	O
mg	NUM	O	O
tablet	NOUN	O	O
to	ADP	O	O
2	NUM	O	O
ergotamine	NOUN	O	I-Entity
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
caffeine	NOUN	O	I-Entity
100	NUM	O	O
mg	NUM	O	O
tablets	NOUN	O	O
in	ADP	O	O
439	NUM	O	O
patients	NOUN	O	O
treating	VERB	O	O
a	DET	O	O
single	ADJ	O	O
migraine	ADJ	O	I-Entity
attack	NOUN	O	O
with	ADP	O	O
each	DET	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

More	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
(	PUNCT	O	O
completely	ADV	O	O
,	PUNCT	O	O
very	ADV	O	O
or	CCONJ	O	O
somewhat	ADV	O	O
)	PUNCT	O	O
satisfied	ADJ	O	O
2	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
rizatriptan	NOUN	O	I-Entity
(	PUNCT	O	O
69.8%	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
at	ADP	O	O
2	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
ergotamine	NOUN	O	I-Entity
/	SYM	O	O
caffeine	NOUN	O	I-Entity
(	PUNCT	O	O
38.6%	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
or	CCONJ	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Salvage	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
nelarabine	NOUN	O	I-Entity
,	PUNCT	O	O
etoposide	ADV	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
cyclophosphamide	NOUN	O	I-Entity
in	ADP	O	O
relapsed	VERB	O	O
/	SYM	O	O
refractory	ADJ	O	O
paediatric	NOUN	O	O
T	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
cell	NOUN	O	I-Entity
lymphoblastic	ADJ	O	I-Entity
leukaemia	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
lymphoma	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
d	NOUN	O	O
of	ADP	O	O
nelarabine	NOUN	O	I-Entity
(	PUNCT	O	O
AraG	PROPN	O	I-Entity
)	PUNCT	O	O
with	ADP	O	O
5	NUM	O	O
d	NOUN	O	O
of	ADP	O	O
etoposide	NOUN	O	I-Entity
(	PUNCT	O	O
VP	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
cyclophosphamide	NOUN	O	I-Entity
(	PUNCT	O	O
CPM	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
prophylactic	ADJ	O	O
intrathecal	ADJ	O	O
chemotherapy	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
as	ADP	O	O
salvage	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
seven	NUM	O	O
children	NOUN	O	O
with	ADP	O	O
refractory	NOUN	O	O
or	CCONJ	O	O
relapsed	VERB	O	O
T	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
cell	NOUN	O	I-Entity
leukaemia	NOUN	O	I-Entity
or	CCONJ	O	I-Entity
lymphoma	NOUN	O	I-Entity
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
some	DET	O	O
response	NOUN	O	O
to	ADP	O	O
the	DET	O	O
combined	VERB	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
five	NUM	O	O
of	ADP	O	O
the	DET	O	O
seven	NUM	O	O
went	VERB	O	O
into	ADP	O	O
complete	ADJ	O	O
remission	NOUN	O	O
after	ADP	O	O
one	NUM	O	O
or	CCONJ	O	O
two	NUM	O	O
courses	NOUN	O	O
of	ADP	O	O
AraG	PROPN	O	I-Entity
/	SYM	O	O
VP	PROPN	O	I-Entity
/	SYM	O	O
CPM	PROPN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
week	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
fulminant	ADJ	O	O
drug	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
induced	VERB	O	I-Entity
hepatitis	NOUN	O	I-Entity
,	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
anti	ADJ	O	O
-	PUNCT	O	O
nuclear	ADJ	O	O
autoantibodies	NOUN	O	O
(	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
with	ADP	O	O
other	ADJ	O	O
markers	NOUN	O	O
of	ADP	O	O
autoimmunity	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
accompanied	VERB	O	O
by	ADP	O	O
multi	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
organ	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
and	CCONJ	O	O
sepsis	NOUN	O	I-Entity
,	PUNCT	O	O
supervened	VERB	O	O
.	PUNCT	O	O



-DOCSTART- (19300402)

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
this	DET	O	O
paper	NOUN	O	O
confirm	VERB	O	O
that	ADP	O	O
inhibition	NOUN	O	O
of	ADP	O	O
bradykinin	NOUN	O	I-Entity
receptors	NOUN	O	O
and	CCONJ	O	O
inducible	ADJ	O	O

NO	PROPN	O	I-Entity
synthase	NOUN	O	O
activity	NOUN	O	O
reduces	VERB	O	O
diabetic	ADJ	O	B-Entity
hyperalgesia	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
also	ADV	O	O
shown	VERB	O	O
that	ADP	O	O
both	DET	O	O
products	NOUN	O	O
of	ADP	O	O
inducible	ADJ	O	O
NO	NOUN	O	I-Entity
synthase	NOUN	O	O
and	CCONJ	O	O
neuronal	ADJ	O	O
NO	NOUN	O	I-Entity
synthase	NOUN	O	O
activation	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
bradykinin	NOUN	O	I-Entity
are	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
hyperalgesia	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
vincristine	NOUN	O	I-Entity
.	PUNCT	O	O


In	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
,	PUNCT	O	O
its	ADJ	O	O
nonhematological	ADJ	O	O
dose	NOUN	O	O
-	PUNCT	O	O
limiting	VERB	O	O
toxicity	NOUN	O	I-Entity
is	VERB	O	O
cardiomyopathy	ADJ	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
combined	VERB	O	O
paclitaxel	NOUN	O	I-Entity
,	PUNCT	O	O
melphalan	NOUN	O	I-Entity
and	CCONJ	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
cyclophosphamide	NOUN	O	I-Entity
,	PUNCT	O	O
thiotepa	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
carboplatin	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
triple	ADJ	O	O
sequential	ADJ	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
regimen	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
metastatic	ADJ	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

Routine	ADJ	O	O
EKG	PROPN	O	O
monitoring	NOUN	O	O
during	ADP	O	O
infusional	ADJ	O	O
cyclophosphamide	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
predict	VERB	O	O
CHF	PROPN	O	I-Entity
development	NOUN	O	O
.	PUNCT	O	O

Inappropriate	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
carbamazepine	NOUN	O	I-Entity
and	CCONJ	O	O
vigabatrin	NOUN	O	I-Entity
in	ADP	O	O
typical	ADJ	O	O
absence	NOUN	O	B-Entity
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

Absences	NOUN	O	O
were	VERB	O	O
aggravated	VERB	O	O
in	ADP	O	O
both	DET	O	O
cases	NOUN	O	O
where	ADV	O	O
vigabatrin	NOUN	O	I-Entity
was	VERB	O	O
added	VERB	O	O
on	ADP	O	O
to	ADP	O	O
concurrent	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
omeprazole	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
aimed	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
whether	ADP	O	O
there	ADV	O	O
is	VERB	O	O
a	DET	O	O
relation	NOUN	O	O
between	ADP	O	O
hemoglobin	NOUN	O	O
,	PUNCT	O	O
haptoglobin	NOUN	O	O
and	CCONJ	O	O
angiogenesis	NOUN	O	O
soluble	ADJ	O	O
markers	NOUN	O	O
which	ADJ	O	O
are	VERB	O	O
modifiable	ADJ	O	O
and	CCONJ	O	O
can	VERB	O	O
help	VERB	O	O
in	ADP	O	O
developing	VERB	O	O
strategies	NOUN	O	O
against	ADP	O	O
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

Cocaine	NOUN	O	I-Entity
causes	VERB	O	O
memory	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
learning	VERB	O	I-Entity
impairments	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
:	PUNCT	O	O
involvement	NOUN	O	O
of	ADP	O	O
nuclear	ADJ	O	O
factor	NOUN	O	O
kappa	NOUN	O	O
B	PROPN	O	O
and	CCONJ	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
prevention	NOUN	O	O
by	ADP	O	O
topiramate	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
provide	VERB	O	O
evidence	NOUN	O	O
for	ADP	O	O
a	DET	O	O
possible	ADJ	O	O
mechanistic	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
oxidative	ADJ	O	O
and	CCONJ	O	O
nitrosative	ADJ	O	O
stress	NOUN	O	O
and	CCONJ	O	O
NFkappaB	PROPN	O	O
in	ADP	O	O
the	DET	O	O
alterations	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
cocaine	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (9495837)

The	DET	O	O
antinociception	NOUN	O	O
produced	VERB	O	O
by	ADP	O	O
(	PUNCT	O	O
+	SYM	O	O
/-)-PG-9	PROPN	O	I-Entity
was	VERB	O	O
prevented	VERB	O	O
by	ADP	O	O
the	DET	O	O
unselective	ADJ	O	O
muscarinic	NOUN	O	O
antagonist	NOUN	O	O
atropine	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
M1-selective	ADJ	O	O
antagonists	NOUN	O	O
pirenzepine	VERB	O	I-Entity
and	CCONJ	O	O
dicyclomine	VERB	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
acetylcholine	NOUN	O	I-Entity
depletor	NOUN	O	O
hemicholinium-3	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
by	ADP	O	O
the	DET	O	O
opioid	ADJ	O	O
antagonist	NOUN	O	O
naloxone	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminobutyric	ADJ	O	I-Entity
acidB	PROPN	O	I-Entity
antagonist	NOUN	O	O
3-aminopropyl	NUM	O	B-Entity
-	PUNCT	O	I-Entity
diethoxy	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
phosphinic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
H3	PROPN	O	O
agonist	NOUN	O	O
R-(alpha)-methylhistamine	PROPN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
D2	PROPN	O	O
antagonist	NOUN	O	O
quinpirole	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
5-hydroxytryptamine4	ADJ	O	I-Entity
antagonist	NOUN	O	O
2-methoxy-4-amino-5-chlorobenzoic	NUM	O	B-Entity
acid	NOUN	O	I-Entity
2-(diethylamino)ethyl	NUM	O	I-Entity
ester	NOUN	O	I-Entity
hydrochloride	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
5-hydroxytryptamin1A	ADJ	O	I-Entity
antagonist	NOUN	O	O
1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine	NUM	O	I-Entity
hydrobromide	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
polyamines	NOUN	O	O
depletor	NOUN	O	O
reserpine	NOUN	O	I-Entity
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
these	DET	O	O
data	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
can	VERB	O	O
be	VERB	O	O
postulated	VERB	O	O
that	ADP	O	O
(	PUNCT	O	O
+	SYM	O	O
/-)-PG-9	PROPN	O	I-Entity
exerted	VERB	O	O
an	DET	O	O
antinociceptive	ADJ	O	O
effect	NOUN	O	O
mediated	VERB	O	O
by	ADP	O	O
a	DET	O	O
central	ADJ	O	O
potentiation	NOUN	O	O
of	ADP	O	O
cholinergic	ADJ	O	O
transmission	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
high	ADJ	O	O
percentage	NOUN	O	O
of	ADP	O	O
kanamycin	NOUN	O	I-Entity
-	PUNCT	O	O
colistin	NOUN	O	I-Entity
and	CCONJ	O	O
povidone	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
iodine	NOUN	O	I-Entity
irrigations	NOUN	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
erosive	ADJ	O	O
cystitis	NOUN	O	I-Entity
and	CCONJ	O	O
suggested	VERB	O	O
a	DET	O	O
possible	ADJ	O	O
complication	NOUN	O	O
with	ADP	O	O
human	ADJ	O	O
usage	NOUN	O	O
.	PUNCT	O	O

Curcumin	PROPN	O	I-Entity
ameliorates	VERB	O	O
cognitive	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
and	CCONJ	O	O
oxidative	ADJ	O	O
damage	NOUN	O	O
in	ADP	O	O
phenobarbitone	NOUN	O	I-Entity
and	CCONJ	O	O
carbamazepine	NOUN	O	I-Entity
administered	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	PART	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
curcumin	NOUN	O	I-Entity
administration	NOUN	O	O
on	ADP	O	O
phenobarbitone-	ADJ	O	I-Entity
and	CCONJ	O	O
carbamazepine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cognitive	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
and	CCONJ	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Pharmacokinetic	ADJ	O	O
interactions	NOUN	O	O
of	ADP	O	O
curcumin	NOUN	O	I-Entity
with	ADP	O	O
phenobarbitone	NOUN	O	I-Entity
and	CCONJ	O	O
carbamazepine	NOUN	O	I-Entity
were	VERB	O	O
also	ADV	O	O
studied	VERB	O	O
.	PUNCT	O	O

piriform	NOUN	O	O
cortex	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
fractionated	VERB	O	O
pilocarpine	NOUN	O	I-Entity
model	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
might	VERB	O	O
indicate	VERB	O	O
that	ADP	O	O
the	DET	O	O
generation	NOUN	O	O
of	ADP	O	O
reactive	ADJ	O	O
oxygen	NOUN	O	I-Entity
species	NOUN	O	O
and	CCONJ	O	O
activation	NOUN	O	O
of	ADP	O	O
NF	PROPN	O	O
-	PUNCT	O	O
kappaB	PROPN	O	O
plays	VERB	O	O
a	DET	O	O
more	ADV	O	O
central	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
seizure	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
neuronal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
temporal	ADJ	O	O
cortex	NOUN	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
hippocampal	ADJ	O	O
hilus	NOUN	O	O
.	PUNCT	O	O


Development	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
in	ADP	O	O
parkinsonian	ADJ	O	I-Entity
monkeys	NOUN	O	O
may	VERB	O	O
depend	VERB	O	O
upon	ADP	O	O
rate	NOUN	O	O
of	ADP	O	O
symptom	NOUN	O	O
onset	NOUN	O	O
and/or	CCONJ	O	O
duration	NOUN	O	O
of	ADP	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

Using	VERB	O	O
macaque	ADJ	O	O
monkeys	NOUN	O	O
with	ADP	O	O
different	ADJ	O	O
types	NOUN	O	O
of	ADP	O	O
MPTP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
parkinsonism	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
degree	NOUN	O	O
to	PART	O	O
which	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
symptom	NOUN	O	O
progression	NOUN	O	O
,	PUNCT	O	O
symptom	NOUN	O	O
severity	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
response	NOUN	O	O
to	ADP	O	O
and	CCONJ	O	O
duration	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
therapy	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
LIDs	NOUN	O	I-Entity
.	PUNCT	O	O

MPTP	PROPN	O	I-Entity
exposure	NOUN	O	O
,	PUNCT	O	O
rapid	ADJ	O	O
symptom	NOUN	O	O
onset	NOUN	O	O
and	CCONJ	O	O
short	ADJ	O	O
symptom	NOUN	O	O
duration	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
therapy	NOUN	O	O
developed	VERB	O	O
dyskinesia	NOUN	O	I-Entity
between	ADP	O	O
11	NUM	O	O
and	CCONJ	O	O
24	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
daily	ADJ	O	O
levodopa	NOUN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

Propylthiouracil	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
perinuclear	NOUN	O	O
-	PUNCT	O	O
staining	VERB	O	O
antineutrophil	NOUN	O	O
cytoplasmic	ADJ	O	O
autoantibody	NOUN	O	O
-	PUNCT	O	O
positive	ADJ	O	O
vasculitis	NOUN	O	I-Entity
in	ADP	O	O
conjunction	NOUN	O	O
with	ADP	O	O
pericarditis	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
present	VERB	O	O
the	DET	O	O
first	ADJ	O	O
case	NOUN	O	O
report	NOUN	O	O
of	ADP	O	O
a	DET	O	O
woman	NOUN	O	O
with	ADP	O	O
hyperthyroidism	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
propylthiouracil	NOUN	O	I-Entity
in	ADP	O	O
whom	NOUN	O	O
a	DET	O	O
syndrome	NOUN	O	O
of	ADP	O	O
pericarditis	NOUN	O	I-Entity
,	PUNCT	O	O
fever	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
glomerulonephritis	NOUN	O	I-Entity
developed	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
literature	NOUN	O	O
review	NOUN	O	O
revealed	VERB	O	O
no	DET	O	O
prior	ADJ	O	O
reports	NOUN	O	O
of	ADP	O	O
pericarditis	NOUN	O	I-Entity
in	ADP	O	O
anti	ADJ	O	O
-	PUNCT	O	O
MPO	PROPN	O	O
pANCA	PROPN	O	O
-	PUNCT	O	O
positive	ADJ	O	O
vasculitis	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
propylthio-	ADJ	O	B-Entity
uracil	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Results	NOUN	O	O
presented	VERB	O	O
here	ADV	O	O
show	VERB	O	O
that	ADP	O	O
the	DET	O	O
differential	ADJ	O	O
sensitivities	NOUN	O	O
of	ADP	O	O
BS	PROPN	O	O
and	CCONJ	O	O
BR	PROPN	O	O
lines	NOUN	O	O
to	ADP	O	O
beta	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
CCM	PROPN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
extended	VERB	O	O
to	ADP	O	O
diazepam	NOUN	O	I-Entity
,	PUNCT	O	O
picrotoxin	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
pentylenetetrazol	NOUN	O	I-Entity
,	PUNCT	O	O
suggesting	VERB	O	O
a	DET	O	O
genetic	ADJ	O	O
selection	NOUN	O	O
of	ADP	O	O
a	DET	O	O
general	ADJ	O	O
sensitivity	NOUN	O	O
and	CCONJ	O	O
resistance	NOUN	O	O
to	ADP	O	O
several	ADJ	O	O
ligands	NOUN	O	O
of	ADP	O	O
the	DET	O	O
GABA(A	PROPN	O	I-Entity
)	PUNCT	O	O
receptor	NOUN	O	O
.	PUNCT	O	O

Analgesic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
ketamine	NOUN	O	I-Entity
in	ADP	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
on	ADP	O	O
morphine	NOUN	O	I-Entity
therapy	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	VERB	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
,	PUNCT	O	O
crossover	ADJ	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Pain	PROPN	O	I-Entity
not	ADV	O	O
responsive	ADJ	O	O
to	ADP	O	O
morphine	NOUN	O	I-Entity
is	VERB	O	O
often	ADV	O	O
problematic	ADJ	O	O
.	PUNCT	O	O

Animal	PROPN	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
N	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
D	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
aspartate	NOUN	O	I-Entity
(	PUNCT	O	O
NMDA	PROPN	O	I-Entity
)	PUNCT	O	O
antagonists	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
ketamine	NOUN	O	I-Entity
,	PUNCT	O	O
may	VERB	O	O
be	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
improving	VERB	O	O
opioid	ADJ	O	O
analgesia	NOUN	O	O
in	ADP	O	O
difficult	ADJ	O	O
pain	NOUN	O	I-Entity
syndromes	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
neuropathic	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
slow	ADJ	O	O
bolus	NOUN	O	O
of	ADP	O	O
subhypnotic	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
(	PUNCT	O	O
0.25	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
or	CCONJ	O	O
0.50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
given	VERB	O	O
to	ADP	O	O
10	NUM	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
whose	ADJ	O	O
pain	NOUN	O	I-Entity
was	VERB	O	O
unrelieved	ADJ	O	O
by	ADP	O	O
morphine	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
,	PUNCT	O	O
crossover	ADJ	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

nausea	NOUN	O	I-Entity
and	CCONJ	O	O
vomiting	NOUN	O	I-Entity
,	PUNCT	O	O
drowsiness	NOUN	O	O
,	PUNCT	O	O
confusion	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
dry	ADJ	O	B-Entity
mouth	NOUN	O	I-Entity
,	PUNCT	O	O
using	VERB	O	O
a	DET	O	O
scale	NOUN	O	O
from	ADP	O	O
0	NUM	O	O
to	ADP	O	O
3	NUM	O	O
(	PUNCT	O	O
not	ADV	O	O
at	ADV	O	O
all	ADV	O	O
,	PUNCT	O	O
slight	ADJ	O	O
,	PUNCT	O	O
a	DET	O	O
lot	NOUN	O	O
,	PUNCT	O	O
awful	ADJ	O	O
)	PUNCT	O	O
;	PUNCT	O	O
Mini	PROPN	O	O
-	PUNCT	O	O
Mental	PROPN	O	O
State	PROPN	O	O
Examination	PROPN	O	O
(	PUNCT	O	O
MMSE	PROPN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
0	NUM	O	O
-	SYM	O	O
30	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
and	CCONJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
before	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
drugs	NOUN	O	O
(	PUNCT	O	O
T0	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
30	NUM	O	O
minutes	NOUN	O	O
(	PUNCT	O	O
T30	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
60	NUM	O	O
minutes	NOUN	O	O
(	PUNCT	O	O
T60	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
120	NUM	O	O
minutes	NOUN	O	O
(	PUNCT	O	O
T120	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
180	NUM	O	O
minutes	NOUN	O	O
(	PUNCT	O	O
T180	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Significant	ADJ	O	O
increases	NOUN	O	O
in	ADP	O	O
drowsiness	NOUN	O	O
were	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
ketamine	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
more	ADJ	O	O
marked	ADJ	O	O
with	ADP	O	O
ketamine	NOUN	O	I-Entity
0.50	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
MMSE	PROPN	O	O
was	VERB	O	O
observed	VERB	O	O
at	ADP	O	O
T30	PROPN	O	O
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
0.50	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
.	PUNCT	O	O


Endocrine	NOUN	O	O
screening	VERB	O	O
in	ADP	O	O
1,022	NUM	O	O
men	NOUN	O	O
with	ADP	O	O
erectile	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
:	PUNCT	O	O
clinical	ADJ	O	O
significance	NOUN	O	O
and	CCONJ	O	O
cost	NOUN	O	O
-	PUNCT	O	O
effective	ADJ	O	O
strategy	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
reviewed	VERB	O	O
the	DET	O	O
results	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
testosterone	NOUN	O	I-Entity
and	CCONJ	O	O
prolactin	NOUN	O	O
determination	NOUN	O	O
in	ADP	O	O
1,022	NUM	O	O
patients	NOUN	O	O
referred	VERB	O	O
because	ADP	O	O
of	ADP	O	O
erectile	NOUN	O	B-Entity
dysfunction	NOUN	O	I-Entity
and	CCONJ	O	O
compared	VERB	O	O
the	DET	O	O
data	NOUN	O	O
with	ADP	O	O
history	NOUN	O	O
,	PUNCT	O	O
results	NOUN	O	O
of	ADP	O	O
physical	ADJ	O	O
examination	NOUN	O	O
,	PUNCT	O	O
other	ADJ	O	O
etiological	ADJ	O	O
investigations	NOUN	O	O
and	CCONJ	O	O
effects	NOUN	O	O
of	ADP	O	O
endocrine	NOUN	O	O
therapy	NOUN	O	O
to	PART	O	O
refine	VERB	O	O
the	DET	O	O
rules	NOUN	O	O
of	ADP	O	O
cost	NOUN	O	O
-	PUNCT	O	O
effective	ADJ	O	O
endocrine	NOUN	O	O
screening	VERB	O	O
and	CCONJ	O	O
to	PART	O	O
pinpoint	VERB	O	O
actual	ADJ	O	O
responsibility	NOUN	O	O
for	ADP	O	O
hormonal	ADJ	O	O
abnormalities	NOUN	O	O
.	PUNCT	O	O

Most	ADJ	O	O
of	ADP	O	O
the	DET	O	O
other	ADJ	O	O
low	ADJ	O	O
testosterone	NOUN	O	I-Entity
levels	NOUN	O	O
seemed	VERB	O	O
to	ADP	O	O
result	VERB	O	O
from	ADP	O	O
nonorganic	ADJ	O	O
hypothalamic	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
because	ADP	O	O
of	ADP	O	O
normal	ADJ	O	O
serum	NOUN	O	O
luteinizing	VERB	O	O
hormone	NOUN	O	O
and	CCONJ	O	O
prolactin	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
have	VERB	O	O
only	ADV	O	O
a	DET	O	O
small	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
erectile	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
(	PUNCT	O	O
definite	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
only	ADV	O	O
16	NUM	O	O
of	ADP	O	O
44	NUM	O	O
[	PUNCT	O	O
36%	NUM	O	O
]	PUNCT	O	O
after	ADP	O	O
androgen	NOUN	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
normal	ADJ	O	O
morning	NOUN	O	O
or	CCONJ	O	O
nocturnal	ADJ	O	O
erections	NOUN	O	O
in	ADP	O	O
30%	NUM	O	O
and	CCONJ	O	O
definite	ADJ	O	O
vasculogenic	ADJ	O	O
contributions	NOUN	O	O
in	ADP	O	O
42%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Determining	VERB	O	O
testosterone	NOUN	O	I-Entity
only	ADV	O	O
in	ADP	O	O
cases	NOUN	O	O
of	ADP	O	O
low	ADJ	O	B-Entity
sexual	ADJ	O	I-Entity
desire	NOUN	O	I-Entity
or	CCONJ	O	O
abnormal	ADJ	O	O
physical	ADJ	O	O
examination	NOUN	O	O
would	VERB	O	O
have	VERB	O	O
missed	VERB	O	O
40%	NUM	O	O
of	ADP	O	O
the	DET	O	O
cases	NOUN	O	O
with	ADP	O	O
low	ADJ	O	O
testosterone	NOUN	O	I-Entity
,	PUNCT	O	O
including	VERB	O	O
37%	NUM	O	O
of	ADP	O	O
those	DET	O	O
subsequently	ADV	O	O
improved	VERB	O	O
by	ADP	O	O
androgen	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
investigated	VERB	O	O
propofol	NOUN	O	I-Entity
injection	NOUN	O	O
pain	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
ambulatory	ADJ	O	O
anaesthesia	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
glycopyrrolate	NOUN	O	I-Entity
5	NUM	O	O
and	CCONJ	O	O
10	NUM	O	O
micrograms	NOUN	O	O
kg-1	NOUN	O	O
and	CCONJ	O	O
atropine	NOUN	O	I-Entity
10	NUM	O	O
and	CCONJ	O	O
20	NUM	O	O
micrograms	NOUN	O	O
kg-1	ADJ	O	O

immediately	ADV	O	O
before	ADP	O	O
the	DET	O	O
induction	NOUN	O	O
of	ADP	O	O
anaesthesia	NOUN	O	O
,	PUNCT	O	O
to	PART	O	O
prevent	VERB	O	O
arrhythmia	NOUN	O	I-Entity
and	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
following	VERB	O	O
repeated	VERB	O	O
doses	NOUN	O	O
of	ADP	O	O
suxamethonium	NOUN	O	I-Entity
in	ADP	O	O
children	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
studied	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
bradycardia	NOUN	O	I-Entity
of	ADP	O	O
50%	NUM	O	O
was	VERB	O	O
noted	VERB	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
this	DET	O	O
was	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
from	ADP	O	O
the	DET	O	O
frequency	NOUN	O	O
with	ADP	O	O
the	DET	O	O
active	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Acetaminophen	PROPN	O	I-Entity
(	PUNCT	O	O
up	ADV	O	O
to	ADP	O	O
150	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
mL	PROPN	O	O
)	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
retard	VERB	O	O
the	DET	O	O
incorporation	NOUN	O	O
of	ADP	O	O
radioactive	ADJ	O	O
adenosine	NOUN	O	I-Entity
into	ADP	O	O
ATP	PROPN	O	I-Entity
in	ADP	O	O
slices	NOUN	O	O
of	ADP	O	O
rat	NOUN	O	O
cerebral	ADJ	O	O
cortex	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
infusion	NOUN	O	O
studies	NOUN	O	O
,	PUNCT	O	O
flestolol	NOUN	O	I-Entity
was	VERB	O	O
well	ADV	O	O
tolerated	VERB	O	O
at	ADP	O	O
the	DET	O	O
effective	ADJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blocking	VERB	O	O
dose	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
up	ADP	O	O
to	PART	O	O
seven	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Flestolol	PROPN	O	I-Entity
effectively	ADV	O	O
reduced	VERB	O	O
heart	NOUN	O	O
rate	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
supraventricular	ADJ	O	B-Entity
tachyarrhythmia	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
unstable	ADJ	O	B-Entity
angina	NOUN	O	I-Entity
,	PUNCT	O	O
flestolol	ADJ	O	I-Entity
infusion	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
safe	ADJ	O	O
and	CCONJ	O	O
effective	ADJ	O	O
in	ADP	O	O
controlling	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (1639466)

This	DET	O	O
paper	NOUN	O	O
presents	VERB	O	O
the	DET	O	O
results	NOUN	O	O
of	ADP	O	O
treating	VERB	O	O
IST	NOUN	O	I-Entity
by	ADP	O	O
intratympanic	ADJ	O	O
instillation	NOUN	O	O
of	ADP	O	O
lignocaine	NOUN	O	I-Entity
(	PUNCT	O	O
lidocaine	NOUN	O	I-Entity
)	PUNCT	O	O
2	NUM	O	O
per	ADP	O	O
cent	NOUN	O	O
through	ADP	O	O
a	DET	O	O
grommet	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
five	NUM	O	O
weekly	ADJ	O	O
courses	NOUN	O	O
.	PUNCT	O	O

Fifty	NUM	O	O
-	PUNCT	O	O
two	NUM	O	O
patients	NOUN	O	O
suffering	VERB	O	O
from	ADP	O	O
intractable	ADJ	O	O
tinnitus	NOUN	O	I-Entity
entered	VERB	O	O
this	DET	O	O
therapeutic	ADJ	O	O
trial	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
only	ADV	O	O
nine	NUM	O	O
finished	VERB	O	O
all	DET	O	O
five	NUM	O	O
courses	NOUN	O	O
.	PUNCT	O	O

Perhexiline	NOUN	O	B-Entity
maleate	NOUN	O	I-Entity
and	CCONJ	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Peripheral	PROPN	O	B-Entity
neuropathy	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
noted	VERB	O	O
as	ADP	O	O
a	DET	O	O
complication	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
with	ADP	O	O
perhexiline	NOUN	O	B-Entity
maleate	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
drug	NOUN	O	O
widely	ADV	O	O
used	VERB	O	O
in	ADP	O	O
France	PROPN	O	O
(	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
in	ADP	O	O
the	DET	O	O
United	PROPN	O	O
States	PROPN	O	O
)	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
prophylactic	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
angina	NOUN	O	B-Entity
pectoris	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
24	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
this	DET	O	O
complication	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
marked	ADJ	O	O
slowing	NOUN	O	O
of	ADP	O	O
motor	NOUN	O	O
nerve	NOUN	O	O
conduction	NOUN	O	O
velocity	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
electromyographic	ADJ	O	O
changes	NOUN	O	O
imply	VERB	O	O
mainly	ADV	O	O
a	DET	O	O
demyelinating	VERB	O	B-Entity
disorder	NOUN	O	I-Entity
.	PUNCT	O	O

,	PUNCT	O	O
one	NUM	O	O
hour	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
tyrosine	NOUN	O	I-Entity
hydroxylase	NOUN	O	O
,	PUNCT	O	O
significantly	ADV	O	O
decreased	VERB	O	O
the	DET	O	O
activity	NOUN	O	O
-	PUNCT	O	O
increasing	VERB	O	O
effects	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
.	PUNCT	O	O

And	CCONJ	O	O
the	DET	O	O
results	NOUN	O	O
are	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
morphine	NOUN	O	I-Entity
acts	VERB	O	O
by	ADP	O	O
retarding	VERB	O	O
the	DET	O	O
release	NOUN	O	O
of	ADP	O	O
acetylcholine	NOUN	O	I-Entity
at	ADP	O	O
some	DET	O	O
central	ADJ	O	O
cholinergic	ADJ	O	O
synapses	NOUN	O	O
.	PUNCT	O	O

Mechanisms	PROPN	O	O
of	ADP	O	O
FK	PROPN	O	B-Entity
506-induced	NUM	O	I-Entity
hypertension	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	O
utility	NOUN	O	O
of	ADP	O	O
FK	PROPN	O	B-Entity
506	NUM	O	I-Entity
is	VERB	O	O
complicated	VERB	O	O
by	ADP	O	O
substantial	ADJ	O	O
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

To	PART	O	O
clarify	VERB	O	O
the	DET	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
FK	PROPN	O	B-Entity
506-induced	NUM	O	I-Entity
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
studied	VERB	O	O
the	DET	O	O
chronic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
FK	PROPN	O	B-Entity
506	NUM	O	I-Entity
on	ADP	O	O
the	DET	O	O
synthesis	NOUN	O	O
of	ADP	O	O
endothelin-1	PROPN	O	O
(	PUNCT	O	O
ET-1	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
mRNA	PROPN	O	O
of	ADP	O	O
ET-1	PROPN	O	O
and	CCONJ	O	O
endothelin	ADV	O	O
-	PUNCT	O	O
converting	VERB	O	O
enzyme-1	NOUN	O	O
(	PUNCT	O	O
ECE-1	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
endothelial	ADJ	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
synthase	NOUN	O	O
(	PUNCT	O	O
eNOS	PROPN	O	O
)	PUNCT	O	O
activity	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
mRNA	PROPN	O	O
of	ADP	O	O
eNOS	PROPN	O	O
and	CCONJ	O	O
C	PROPN	O	O
-	PUNCT	O	O
type	NOUN	O	O
natriuretic	ADJ	O	O
peptide	NOUN	O	O
(	PUNCT	O	O
CNP	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
rat	NOUN	O	O
blood	NOUN	O	O
vessels	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (20633755)

Suxamethonium	PROPN	O	I-Entity
induced	VERB	O	O
prolonged	ADJ	O	O
apnea	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
receiving	VERB	O	O
electroconvulsive	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
randomized	ADJ	O	O
sample	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
234	NUM	O	O
euthymic	ADJ	O	O
men	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
receiving	VERB	O	O
some	DET	O	O
type	NOUN	O	O
of	ADP	O	O
SSRI	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
men	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
bupropion	NOUN	O	I-Entity
SR	PROPN	O	O
(	PUNCT	O	O
150	NUM	O	O
mg	NUM	O	O
twice	ADV	O	O
daily	ADV	O	O
,	PUNCT	O	O
117	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
twice	ADV	O	O
daily	ADV	O	O
,	PUNCT	O	O
117	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Efficacy	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
using	VERB	O	O
the	DET	O	O
Clinical	PROPN	O	O
Global	ADJ	O	O
Impression	NOUN	O	O
-	PUNCT	O	O
Sexual	ADJ	O	O
Function	PROPN	O	O
(	PUNCT	O	O
CGI	PROPN	O	O
-	PUNCT	O	O
SF	PROPN	O	O
;	PUNCT	O	O
the	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
measure	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
International	PROPN	O	O
Index	PROPN	O	O
of	ADP	O	O
Erectile	PROPN	O	O
Function	PROPN	O	O
(	PUNCT	O	O
IIEF	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
Arizona	PROPN	O	O
Sexual	PROPN	O	O
Experience	PROPN	O	O
Scale	PROPN	O	O
(	PUNCT	O	O
ASEX	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Erectile	PROPN	O	B-Entity
Dysfunction	PROPN	O	I-Entity
Inventory	PROPN	O	O
of	ADP	O	O
Treatment	PROPN	O	O
Satisfaction	PROPN	O	O
(	PUNCT	O	O
EDITS	PROPN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
secondary	ADJ	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Bupropion	NOUN	O	I-Entity
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
male	NOUN	O	O
SD	PROPN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
SSRIs	NOUN	O	I-Entity
.	PUNCT	O	O


Cancer	NOUN	O	I-Entity
patients	NOUN	O	O
who	NOUN	O	O
are	VERB	O	O
chronic	ADJ	O	O
carriers	NOUN	O	O
of	ADP	O	O
HBV	PROPN	O	O
have	VERB	O	O
a	DET	O	O
higher	ADJ	O	O
hepatic	ADJ	O	B-Entity
complication	NOUN	O	I-Entity
rate	NOUN	O	O
while	ADP	O	O
receiving	VERB	O	O
cytotoxic	NOUN	O	O
chemotherapy	NOUN	O	O
(	PUNCT	O	O
CT	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
this	DET	O	O
has	VERB	O	O
mainly	ADV	O	O
been	VERB	O	O
attributed	VERB	O	O
to	ADP	O	O
HBV	PROPN	O	O
reactivation	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
who	NOUN	O	O
have	VERB	O	O
solid	ADJ	O	O
and	CCONJ	O	O
hematological	ADJ	O	B-Entity
malignancies	NOUN	O	I-Entity
with	ADP	O	O
chronic	ADJ	O	O
HBV	PROPN	O	B-Entity
infection	NOUN	O	I-Entity
received	VERB	O	O
the	DET	O	O
antiviral	ADJ	O	O
agent	NOUN	O	O
lamivudine	NOUN	O	I-Entity
prior	ADV	O	O

and	CCONJ	O	O
during	ADP	O	O
CT	PROPN	O	O
compared	VERB	O	O
with	ADP	O	O
historical	ADJ	O	O
control	NOUN	O	O
group	NOUN	O	O
who	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
receive	VERB	O	O
lamivudine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
historical	ADJ	O	O
controls	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
50	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
who	NOUN	O	O
underwent	VERB	O	O
CT	PROPN	O	O
without	ADP	O	O
prophylactic	ADJ	O	O
lamivudine	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
prophylactic	ADJ	O	O
lamivudine	NOUN	O	I-Entity
group	NOUN	O	O
severe	ADJ	O	O
hepatitis	NOUN	O	I-Entity
were	VERB	O	O
observed	VERB	O	O
only	ADV	O	O
in	ADP	O	O
1	NUM	O	O
patient	NOUN	O	O
(	PUNCT	O	O
2.7%	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
37	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.006	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Our	ADJ	O	O
study	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
prophylactic	ADJ	O	O
lamivudine	NOUN	O	I-Entity
significantly	ADV	O	O
decreases	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
HBV	PROPN	O	O
reactivation	NOUN	O	O
and	CCONJ	O	O
overall	ADJ	O	O
morbidity	NOUN	O	O
in	ADP	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
during	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
immunosuppressive	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Ginsenoside	PROPN	O	B-Entity
Rg1	PROPN	O	I-Entity
restores	VERB	O	O
the	DET	O	O
impairment	NOUN	O	B-Entity
of	ADP	O	I-Entity
learning	VERB	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
chronic	ADJ	O	O
morphine	NOUN	O	I-Entity
administration	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Rg1	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
ginsenoside	NOUN	O	I-Entity
extracted	VERB	O	O
from	ADP	O	O
Panax	PROPN	O	O
ginseng	NOUN	O	O
,	PUNCT	O	O
could	VERB	O	O
ameliorate	VERB	O	O
spatial	ADJ	O	O
learning	VERB	O	B-Entity
impairment	NOUN	O	I-Entity
.	PUNCT	O	O

Previous	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
demonstrated	VERB	O	O
that	ADP	O	O
Rg1	PROPN	O	I-Entity
might	VERB	O	O
be	VERB	O	O
a	DET	O	O
useful	ADJ	O	O
agent	NOUN	O	O
for	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
Rg1	NOUN	O	I-Entity
on	ADP	O	O
learning	VERB	O	B-Entity
impairment	NOUN	O	I-Entity
by	ADP	O	O
chronic	ADJ	O	O
morphine	NOUN	O	I-Entity
administration	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
mechanism	NOUN	O	O
responsible	ADJ	O	O
for	ADP	O	O
this	DET	O	O
effect	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
sample	NOUN	O	O
for	ADP	O	O
the	DET	O	O
study	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
50	NUM	O	O
patients	NOUN	O	O
to	PART	O	O
whom	NOUN	O	O
subcutaneous	ADJ	O	O
heparin	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
bruising	VERB	O	I-Entity
occurrence	NOUN	O	O
was	VERB	O	O
64%	NUM	O	O
with	ADP	O	O
the	DET	O	O
injection	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
seconds	NOUN	O	O
duration	NOUN	O	O
and	CCONJ	O	O
42%	NUM	O	O
in	ADP	O	O
the	DET	O	O
30-second	NOUN	O	O
injection	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
determined	VERB	O	O
that	ADP	O	O
the	DET	O	O
size	NOUN	O	O
of	ADP	O	O
the	DET	O	O
bruising	NOUN	O	I-Entity
was	VERB	O	O
smaller	ADJ	O	O
in	ADP	O	O
the	DET	O	O
30-second	NOUN	O	O
injection	NOUN	O	O
.	PUNCT	O	O

PRACTICE	NOUN	O	O
:	PUNCT	O	O
When	ADV	O	O
administering	VERB	O	O
subcutaneous	ADJ	O	O
heparin	NOUN	O	I-Entity
injections	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
important	ADJ	O	O
to	PART	O	O
extend	VERB	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
injection	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
the	DET	O	O
treatments	NOUN	O	O
and	CCONJ	O	O
behavioral	ADJ	O	O
observation	NOUN	O	O
,	PUNCT	O	O
glutamate	NOUN	O	I-Entity
uptake	NOUN	O	O
by	ADP	O	O
segments	NOUN	O	O
of	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
was	VERB	O	O
analyzed	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
the	DET	O	O
psychotic	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
that	ADJ	O	O
occur	VERB	O	O
following	VERB	O	O
phenytoin	NOUN	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
some	DET	O	O
epileptic	ADJ	O	I-Entity
patients	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
the	DET	O	O
direct	ADJ	O	O
result	NOUN	O	O
of	ADP	O	O
medication	NOUN	O	O
,	PUNCT	O	O
unrelated	ADJ	O	O
to	ADP	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O


kg	NOUN	O	O
of	ADP	O	O
distilled	VERB	O	O
water	NOUN	O	O
and	CCONJ	O	O
5%	NUM	O	O
w	PROPN	O	O
/	SYM	O	O
v	ADP	O	O
cellulose	NOUN	O	O
,	PUNCT	O	O
10	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
gum	NOUN	O	B-Entity
Arabic	PROPN	O	I-Entity
(	PUNCT	O	O
2	NUM	O	O
mL	PROPN	O	O
/	SYM	O	O

The	DET	O	O
only	ADJ	O	O
recent	ADJ	O	O
change	NOUN	O	O
in	ADP	O	O
their	ADJ	O	O
treatment	NOUN	O	O
was	VERB	O	O
the	DET	O	O
introduction	NOUN	O	O
or	CCONJ	O	O
increased	VERB	O	O
dosage	NOUN	O	O
of	ADP	O	O
zonisamide	NOUN	O	I-Entity
.	PUNCT	O	O

Glomerular	ADJ	O	O
epithelial	ADJ	O	O
protein	NOUN	O	O
1	NUM	O	O
(	PUNCT	O	O
GLEPP1	PROPN	O	O
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
podocyte	NOUN	O	O
receptor	NOUN	O	O
membrane	NOUN	O	O
protein	NOUN	O	O
tyrosine	NOUN	O	I-Entity
phosphatase	NOUN	O	O
located	VERB	O	O
on	ADP	O	O
the	DET	O	O
apical	ADJ	O	O
cell	NOUN	O	O
membrane	NOUN	O	O
of	ADP	O	O
visceral	ADJ	O	O
glomerular	ADJ	O	O
epithelial	ADJ	O	O
cell	NOUN	O	O
and	CCONJ	O	O
foot	NOUN	O	O
processes	NOUN	O	O
.	PUNCT	O	O

Puromycin	PROPN	O	B-Entity
aminonucleoside	ADV	O	I-Entity
nephrosis	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
single	ADJ	O	O
intraperitoneal	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
(	PUNCT	O	O
PAN	PROPN	O	I-Entity
,	PUNCT	O	O
20	NUM	O	O
mg/100	NOUN	O	O
g	NOUN	O	O
BW	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Tissues	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
at	ADP	O	O
0	NUM	O	O
,	PUNCT	O	O
5	NUM	O	O
,	PUNCT	O	O
7	NUM	O	O
,	PUNCT	O	O
11	NUM	O	O
,	PUNCT	O	O
21	NUM	O	O
,	PUNCT	O	O
45	NUM	O	O
,	PUNCT	O	O
80	NUM	O	O
and	CCONJ	O	O
126	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
PAN	PROPN	O	I-Entity
injection	NOUN	O	O
so	ADP	O	O
as	ADP	O	O
to	PART	O	O
include	VERB	O	O
both	CCONJ	O	O
the	DET	O	O
acute	ADJ	O	O
phase	NOUN	O	O
of	ADP	O	O
proteinuria	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
foot	NOUN	O	O
process	NOUN	O	O
effacement	NOUN	O	O
(	PUNCT	O	O
days	NOUN	O	O
5	NUM	O	O
-	SYM	O	O
11	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
chronic	ADJ	O	O
phase	NOUN	O	O
of	ADP	O	O
proteinuria	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
glomerulosclerosis	NOUN	O	I-Entity
(	PUNCT	O	O
days	NOUN	O	O
45	NUM	O	O
-	SYM	O	O
126	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	ADV	O	O
seemed	VERB	O	O
to	PART	O	O
be	VERB	O	O
no	DET	O	O
direct	ADJ	O	O
correlation	NOUN	O	O
between	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
or	CCONJ	O	O
duration	NOUN	O	O
used	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
bone	NOUN	O	B-Entity
marrow	NOUN	O	I-Entity
suppression	NOUN	O	I-Entity
.	PUNCT	O	O

Facilitation	NOUN	O	O
of	ADP	O	O
memory	NOUN	O	O
retrieval	NOUN	O	O
by	ADP	O	O
pre	NOUN	O	O
-	PUNCT	O	O
test	NOUN	O	O
morphine	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
state	NOUN	O	O
dependency	NOUN	O	O
in	ADP	O	O
the	DET	O	O
step	NOUN	O	O
-	PUNCT	O	O
through	ADP	O	O
type	NOUN	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
learning	VERB	O	O
test	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
facilitation	NOUN	O	O
of	ADP	O	O
memory	NOUN	O	O
retrieval	NOUN	O	O
by	ADP	O	O
pre	NOUN	O	O
-	PUNCT	O	O
test	NOUN	O	O
morphine	NOUN	O	I-Entity
might	VERB	O	O
be	VERB	O	O
the	DET	O	O
direct	ADJ	O	O
action	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
rather	ADV	O	O
than	ADP	O	O
a	DET	O	O
state	NOUN	O	O
dependent	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
rats	NOUN	O	O
,	PUNCT	O	O
detection	NOUN	O	O
of	ADP	O	O
apomorphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
was	VERB	O	O
facilitated	VERB	O	O
by	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
acclimatization	NOUN	O	O
to	ADP	O	O
the	DET	O	O
test	NOUN	O	O
conditions	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
apomorphine	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
reductions	NOUN	O	O
in	ADP	O	O
striatal	ADJ	O	O
dopamine	NOUN	O	I-Entity
turnover	NOUN	O	O
were	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
both	DET	O	O
novel	NOUN	O	O
and	CCONJ	O	O
home	NOUN	O	O
cage	NOUN	O	O
environments	NOUN	O	O
.	PUNCT	O	O

